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1. Species differences in elements of the peroxisome proliferator domain (PPD), 
including the cytochrome P450 4A subfamily of fatty acid hydroxylases and 
peroxisomal fatty acid B-oxidation have been examined.
2. Microsomal preparations from a panel of human livers showed cross-reactivity
with a sheep anti-sera to rat cytochrome P450 4A1 and gave a single band on 
Western blot analysis with a relative Mj. of approximately 51kDa (compared to
approximately 51.5kDa for the rat). Spectral analysis of ferrous-CO complexes 
revealed peak maxima between 450-452nm with the total cytochrome P450 specific 
content and NADPH-cytochrome P450 reductase activity displaying about three and 
two-fold variations, respectively. Immunoquantification of the cytochrome P450 
4A1 human orthologue by an ELISA protocol gave between 4-12% of total 
cytochrome P450 content. NADPH-fortified human liver microsomal preparations 
from all the samples used both laurate and arachidonate as substrate and formed the 
(JÙ- and (w-l)- metabolites at varying rates. Moreover, anti-rat P450 4Al-enriched 
IgG fraction inhibited the human w-lauiate hydroxylase activity to greater than 55% 
(20% in the rat) at a concentration of 5mg/nmol total cytochrome P450. Taken 
collectively, the information thus presented is strongly suggestive of the expression 
of a member(s) of the cytochrome P450 4A subfamily in the panel of human liver 
tissues examined.
3. To further elucidate the mechanism of cytochrome P450 4A1 induction and 
peroxisome proliferation by a diversity of peroxisome proliferators, I also examined 
the stereochemical specificity in the induction of members of the peroxisome 
proliferation domain by optically active enantiomers of a clofibrate-analogue. In all 
the parameters examined, the R(-)- enantiomer was identified as the eutomer and its 
corresponding S(+)-antipode as the distomer, with the racemic mixture intermediate 
in inducing these enzyme activities.
4. The effect of a relatively newly described peroxisome proliferator, perfluoro-n- 
decanoic acid (PFDA), on the peroxisome proliferation domain in a responsive (rat) 
and a non-responsive (guinea pig) species was also investigated. At the dose level 
investigated (20 mg/ kg), PFDA administration did not appear to impair food intake 
nor weight gain but resulted in distinct differences in the hepatic and renal response 
between the two species examined. In the rat, hepatomegaly was observed with the 
coordinate induction of total cytochrome P450 levels (1.5 fold), NADPH- 
cytochrome P450 reductase (1.5-fold), palmitoyl CoA oxidase (6-fold), carnitine 
acetyl transferase (peroxisomal and mitochondrial, 15-fold) and preferential 
cytochrome P450 4A1-mediated w-laurate hydroxylase activity (5-fold). In addition, 
a substantial inhibition in the activity of cytochrome P450 lAl-associated enzyme 
activity as measured by ethoxyresorufin-O-deethylase (EROD) activity was observed 
in the rat liver (74%) and kidney (39%). Western blotting analysis of hepatic and 
renal microsomes for cytochromes P450 4A1 and lA l isozymes reflected the above 
changes. A similar analysis showed significant induction of the trifunctional protein 
of the rat hepatic peroxisomal B-oxidation spiral. Generally, the guinea pig 
appeared to be non-responsive at this dose level. However, a significant inhibition 
of the EROD activity was detected in both the liver (35%) and kidney (31%). A 
similar pattern of results was obtained for the PROD activity in both tissues. 
Generally, the rat kidney was less responsive than the liver.
5. The ligand-binding site for peroxisome proliferators in the peroxisome 
proliferator-activated receptor (PPAR) has been computer-modelled and used as a 
basis to discuss the structural diversity of peroxisome proliferators.
6. Species differences in response to peroxisome proliferators have been discussed 
in terms of lipid homoeostasis and/or regulatory elements of the relevant genes.
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CHAPTER ONE 
Genera/ /ntroduction
General Introduction
1.1 Nomenclature and Multiplicity of Ctytochrome P450 Gene 
Superfamily
What is now known as the cytochrome P450 gene superfamily (EC 1.14.14.1) 
encodes numerous enzymes that are remarkable in the variety of chemical reactions 
catalysed and the number of substrates handled [Guengerich, 1991]. They comprise 
a family of b-type haemoproteins with an identical prosthetic group and mechanism 
of catalysis, but different apoprotein structures which are responsible for the 
different substrate specificities. Cytochrome P450 evolution is believed to have 
begun 2-3 billion years ago, with only a few genes coding P450 forms that were 
engaged in the metabohsm of endogenous substrates such as steroids, fatty acids and 
eicosanoids [Nebert et al., 1991]. Humans and rats are believed to have diverged 
from common ancestors some 80 million years ago, with one of the consequences of 
the human cytochrome P450 gene evolution being the polymorphism of drug 
metabolism, leading to marked differences in the response of individuals to the toxic 
and carcinogenic effects of drugs and other environmental chemicals [Guengerich, 
1989; Nebert etal., 1991].
Indeed no exaggeration is made in stating that cytochrome P450 is the most 
versatile and abundant biological catalyst known, considering the rapid progress that 
has been made in recent years in the characterisation of over 150 isoforms. There 
are presently 154 P450 genes and seven putative pseudogenes that have been 
described in 23 eukaryotes (including nine mammalian and one plant species) and in 
six prokaryotes [Nebert et al., 1991]. Of at least 27 gene families described so far, 
10 exist in all mammals comprising 18 subfamilies or clusters of genes, of which 16 
have been mapped on the human gene.
Most of the cytochrome P450's were discovered primarily through protein 
purification research, which meant many of them demonstrated broad and 
overlapping substrate specificities which precluded establishing a nomenclature 
system based upon distinct catalytic functions. However, within the last decade the 
isolation and sequencing of P450 proteins, genes and cDNAs have facilitated the 
development of a P450 classification system based on primary amino acid sequence 
alignment data [Nebert and Gonzalez, 1987].
Since many of the individual cytochrome P450’s catalyse multiple reactions, the 
incompatibility of individual designation and symbols for identical forms resulted in 
a joint effort to devise a more systematic nomenclature based on structural 
homology [Nebert et ah, 1991]. This system of nomenclature is constantly 
evolving as more P450's are isolated and characterised. According to this 
classification scheme, those cytochrome P450 proteins with 40% or greater 
sequence homology are included in the same family (designated by an Arabic 
number), and those with greater than 55% identity are included in the same 
subfamily (designated by a Capital letter). The individual genes are arbitrarily 
assigned numbers in order of their discovery. However, even two very similar rat 
forms CYPs 2B1 and 2B2, with less than 3% difference in sequence homology, 
have distinct genes. The main advantage of the unified nomenclature is that 
structurally identical or highly similar P450's are easily recognisable, regardless of 
the source (species, tissue, or organelle), the inducer, or the catalytic activity 
examined.
Our knowledge of the scope of cytochrome P450 catalysed reactions is still 
incomplete as these haemoproteins are widespread in nature and many isoforms 
have yet to be fully characterised or even identified. Mammalian cytochromes P450 
can be roughly divided into two major groups based on their intracellular location 
and the enzyme from which they receive electrons [Gonzalez, 1990]. On the one 
hand, the mitochondrial P450s, such as the side-chain cleavage enzyme (cytochrome
P450 see) and steroid 11 6-hydroxylase (cytochrome P450 116) synthesised by 
membrane-free polyribosomes [Nabi et al., 1983] are found in the adrenal cortex 
and are involved in steroid hormone biosynthesis, whereas the second group found 
primarily in the endoplasmic reticulum (i.e membrane bound) are synthesised by 
membrane-bound polyribosomes [Gonzalez and Kasper, 1980].
The orientation of eukaryotic cytochromes P450 with respect to the membrane 
of the endoplasmic reticulum has also been investigated [Edwards et al., 1991] and 
results from such studies suggest that cytochrome P450 is most likely oriented such 
that the haem is not fixed horizontally to the plane of the membrane. This may be 
relevant to the intramolecular movements of cytochrome P450 during its catalytic 
cycle and the partitioning of substrates for cytochrome P450 between the cytosol 
and membrane.
1.2 Cytochrome P450 4 Family Proteins
An unusual aspect of some forms of cytochrome P450 is their capacity to 
preferentially oxidise primary rather than secondary or tertiary carbon-hydrogen 
bonds. This is particularly evident for fatty acid substrates such as lauric acid, 
arachidonic acid and the eicosanoids where the hydroxylation of the terminal carbon 
is referred to as w—hydroxylation [Kupfer, 1980]. The a>—hydroxylated fatty acids 
are subsequently oxidised further to dicarboxylic acids [Bjokhem, 1976], which are 
elevated in several species during ketotic states such as starvation or diabetes [Horie 
et al., 1981]. These lipid substrates are additionally hydroxylated by several 
members of other cytochrome P450 isoenzymes at various positions in the alkyl 
chain, and it appears that hydroxylation at the terminal carbon atom is most 
characteristic of the cytochrome P450 4A subfamily.
The cytochrome P450 enzymes that catalyse w—hydroxylation reactions appear 
to comprise a distinct family of haemoproteins belonging to the cytochrome P450 4 
family, in the uniform system of nomenclature [Nebert et al., 1991; Gibson and
Lake, 1991]. The complementary DNAs of this family of proteins have been 
isolated from cDNA libraries from liver, kidney, prostate and lung of various 
species including the rat, mouse, rabbit and human [Gibson and Lake, 1991]. Some 
of these P450 gene/ protein designates are shown in Table 1.1. The cytochrome 
P450 4A subfamily consists of eleven members to date arranged in three subfamilies 
and all eleven of the corresponding genes have been sequenced and their amino acid 
sequences predicted. Of these eleven gene designates, nine are cDNAs and only 
two (P450 4A1 and 4A2) are derived from genomic libraries. As such, these 
contain introns and 5' upstream flanking regions, the latter containing putative 
regulatory sites that may interact with its inducer.
A cDNA corresponding to a rat hver lauric acid w—hydroxylase, P450 4A1, has 
been cloned and characterised in the livers of clofibrate-treated rats [Hardwick et 
al., 1987; Eamshaw et al., 1988]. In addition, two genomic clones for P450 4A2 
and 4A3 have been isolated [Kimura et al., 1989a; 1989b]. The mRNAs for these 
three forms were also induced in the kidney by clofibiate. Moreover, cytochrome 
P450 4A2 was constitutively expressed at a higher level in the kidney and was only 
slightly induced by clofibrate treatment in this tissue [Kimura et al., 1989b].
A rabbit lung isozyme, which is involved in the w—hydroxylation of 
prostaglandins and induced during pregnancy or after progesterone treatment, 
showed close similarities to the derived amino acid sequence of the rat cytochrome 
P450 4A1 and was designated cytochrome P450 4A4 [Matsubara et al., 1987; 
Nebert et al., 1989]. However, preparations of cytochrome P450 4A4 exhibit 
negligible lauric acid co—hydroxylase activity [Yamamoto et al., 1984], suggesting 
that members of the cytochrome P450 4A subfamily, distinct from cytochrome 
P450 4A4, may be expressed in the rabbit. This led to the isolation of cDNAs for 
three rabbit kidney lauric acid o)—hydroxylases denoted cytochromes P450 4A5, 
4A6 and 4A7 [Johnson et ah, 1990]. A similar or possibly identical protein to 
cytochrome P450 4A4 has been isolated from livers of pregnant rabbits [Kikuta et
Table 1.1 Identified genes/ protein designates of some members of the 
cytochrome P450 4 family
P450 Genes/ 
protein designation
Species Tissue References ^
CYP 4A 1 rat liver, kidney Hardwick etal., 1987; 
Eamshaw et al., 1988
4A2 rat liver, kidney Kimura etal., 1989a
4A3 rat liver, kidney Kimura ef a/., 1989b 
Aoyamaefa/., 1990
4A4 rabbit lung, kidney, liver, 
uterus, placenta
Matsubara ef a /., 1987; 
Kikuta et al., 1989
4A5 rabbit liver, kidney, 
small intestine
Johnson et al., 1990
4A6 rabbit kidney, liver
4A7 rabbit kidney
4A8 rat prostate, kidney Stromstedt ef a7., 1990
4A9 human liver Hardwick, J.P., 1991 
[personal communication]
4B 1 rat, human 
rabbit
lung, kidney, 
intestine
Nhamburo er aA, 1989; 
Gasser and Philpot, 1989
4C1 cockroach fat body Bradfield et al., 1991
^ Reference with complete cDNA and amino acid sequence, regulation of gene 
expression stated.
ai, 1989]. Another member of the cytochrome P450 4A subfamily has been very 
recently tentatively identified in human liver [Hardwick et a l, 1991, personal 
communication] and designated cytochrome P450 4A9.
Based on structural information derived from a nucleotide sequence, a
cytochrome P450 designated isozyme 5, remarkably similar to the rabbit 
cytochrome P450p_2 [Gasser and Philpot, 1989], is also expressed in the rat and
placed in a previously unrecognised cytochrome P450 4B gene subfamily. Indeed , 
the conservation of primary structure seen with the cytochrome P450 4B members 
was estimated at 5 to 15% greater than between other pairs of cytochrome P450 
isozymes from rat and rabbit that have been assigned to the same gene subfamilies 
[Matsubara et ah, 1987]. More recently, a human form was isolated from a lung 
cDNA library using the rat CYP 4A1 cDNA as a probe [Nhamburo et al., 1989]. 
The cDNA-deduced amino acid sequence of this P450, designated 4B1, consisted of 
511 amino acids and coded for a protein of relative M^ 59.5 kDa with 51%, 53%,
and 52% amino acid homologies to CYP 4A1, 4A2, and rabbit P450p_2,
respectively. However, the protein was shown only to be constitutively expressed 
in the lung but could not be identified in the livers of test patients.
The finding that the sequence derived for a human pulmonary cytochrome P450 
4B isozyme [Nhamburo et al., 1989; Gonzalez, 1989, personal communication] is 
81 % identical to the sequence of rabbit isozyme 5, provides additional evidence of 
extensive conservation of structure within the cytochrome P450 4B subfamily 
[Vanderslice et al., 1987]. Cytochrome P450 4B subfamily proteins mainly 
mediate the pulmonary N-oxidation of aromatic amines such as the promutagen 2- 
aminofiuorene. Unlike the rabbit orthologous form, human cytochrome P450 4B1 
was unable to metabohse this compound despite the presence of cytochrome P450 
4B1 mRNA in three out of four lungs analysed [Nhamburo et al., 1989]. In 
contrast to its expression in lung, cytochrome P450 4B1 mRNA was undetectable in 
livers obtained from 14 individuals (including those from which the lungs were
derived). Similarly, cytochrome P450 4B1-related mRNA was also expressed in rat 
lung but was undetected in untreated rat liver. Expression of cytochrome P450 4B1 
in rabbit but not rat or human liver suggests an interesting species difference in 
tissue-specific expression of this gene. Yet another newly identified member of the 
cytochrome P450 4 family has been reported in the cockroach (Blaberus discoidalis) 
and the gene represented by the cloned cDNA has been named CYP4C1 [Bradfield 
et a l, 1991]. The sequence of this cDNA is 32-36% identical to mammalian family 
4A and 4B enzymes and contains a 13-residue sequence characteristic of the 
cytochrome P450 4 family suggesting that substrates for these enzymes might be 
closely related. It is mainly present in the fat bodies and the physiological role for 
cytochrome P450 4C1 is highly speculative but the mRNA level is known to be 
elevated by both the hypertrehalosemic hormone (HTH) and starvation. A principal 
function of HTH is stimulation of fat body glycogenolysis, thus providing 
precursors for the formation of trehalose, the main circulating carbohydrate in 
insects. Bradfield and co-workers concluded from their studies that cytochrome 
P450 4C1 may be hormonally regulated in association with energy substrate 
mobilization. However, its protein catalytic activity and regulation of the 
corresponding gene by HTH still remains to be ascertained.
A model for the positioning of lauric acid in the active site of cytochrome P450 
4A1 has been proposed [CaJacob et ah, 1988] and is depicted in Figure 1.1. It has 
been suggested that the active site of lauric acid w—hydroxylase is highly structured 
in the vicinity of the activated oxygen and sterically suppresses (w—1)- 
hydroxylation in order to deliver oxygen to the thermodynamically disfavoured 
terminal carbon of the methyl group. This is probably achieved by the active site 
cleft allowing the terminal methyl group to reach the haem's activated oxygen. 
Furthermore, tolerance of varying lengths of fatty acids suggests that the terminal 
methyl specificity is not governed by specific interactions of the protein with the 
acid's carboxyl group, but by steric constraints within the catalytic site.
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1.3 Cytochrome P450 Catalysed Reactions
The cytochrome P450-mediated mixed-function monooxygenases of liver 
microsomal membranes are of central importance in the metabolism of a variety of 
xenobiotics, including substances that occur biologically but are foreign to animals, 
such as antibiotics and unusual compounds in plants, vitamins as well as many 
drugs, carcinogens, synthetic organic chemicals, environmental pollutants and a 
variety of steroids and physiologically occurring lipids [Cheng and Schenkman, 
1983, 1984; Ryan et a l, 1982; Ryan and Levin, 1990; Boddupalli et a l, 1990; 
Guengerich, 1991]. These enzyme systems are also present in many other tissues 
and in a wide range of organisms including animals, plants and microorganisms 
[Kato, 1979; Nebert e /a /., 1991].
The principal role of cytochromes P450 in the metabolism of xenobiotics is to 
introduce a polar hydroxyl group into the xenobiotic molecule, thus providing a 
"handle" for the phase II or conjugating reactions which introduce additional polar 
groups, usually of endogenous origin. This then facilitates the elimination of such 
unwanted metabolites from the body which otherwise would be retained in the body 
thereby causing deleterious effects. Hence because of the existence of multiple 
forms of cytochromes P450 in any single organism, they may afford quite a strong 
physiological and defensive ability to handle a wide range of substrates. Some of 
the cytochromes P450, such as those involved in steroid and fatty acid 
biotransformations are fairly selective in their choice of substrates with substantial 
regio- and stereo- selectivity, whereas others particularly those in liver microsomes, 
have unusually broad and overlapping substrate specificity.
Most of the cytochrome P450 catalysed reactions begin with the transfer of
electrons fi'om NAD(P)H to either NADPH-cytochrome P450 reductase and in 
some cases cytochrome b^ in the microsomal system (or a ferredoxin reductase and
a non-haem iron protein in the mitochondrial and bacterial systems), and then to 
cytochrome P450, thus leading to the reductive activation of molecular oxygen
followed by the insertion of one oxygen atom into the substrate. The scheme 
presented (Figure 1.2) is in accord with the established stoichiometry of the 
cytochrome P450 catalysed hydroxylation reaction, where RH represents the 
substrate.
RH + O2 + NADPH + H+ ROH+ H^O + NAD? +
The scheme begins with the binding of the substrate (RH), which perturbs the spin
state equilibrium of the cytochrome P450, thereby facilitating the uptake of the first
electron. It is suggested that substrates that undergo reduction rather than
oxygenation, such as epoxides, accept two electrons in a stepwise fashion to yield 
RH(H)2 [Porter and Coon, 1991].
To initiate the oxidative reactions, O2 is bound to the ferrous cytochrome P450 to 
form an intermediate, Fe^4-(02“), with the substrate still attached. Transfer of the 
second electron then occurs, with the possible involvement of cytochrome 65 as an
additional electron donor in mammalian microsomal systems [Schenkman et al., 
1976]. The next step involves splitting of the oxygen-oxygen bond with the uptake 
of two protons (2H"*") and the formation of an "activated oxygen" species and 
simultaneous release of water. It has been suggested that oxygen insertion into the 
substrate involves hydrogen abstraction from the substrate and recombination of the 
resulting transient hydroxy and carbon radicals to give the product [Groves et al., 
1978] but this is still debatable as the identity of the powerful oxidant that is 
necessary for oxygen insertion into the substrates is still not known. The cycle is 
completed with the dissociation of the product (ROH), which restores the 
cytochrome P450 to the starting ferric state ready to handle yet another substrate 
molecule.
10
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Figure 1.2 Microsomal cytochrome P450-mediating electron transport cycle.
Fe^*  ^ represents oxidised cytochrome P450; RH, substrate; RH(H)2, a reduction product; ROH, a 
monooxygenation product, and XQGH, a peroxy compound that can serve as an alternative oxygen 
donor, (ifeprcx/i/ced/?om Porter and Coon, 1991).
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1.4 Pleiotropic Response to the Administration of Peroxisome 
Proliferators
Administration of several groups of structurally diverse compounds including 
hypolipidaemic agents such as clofibrate, do cause different characteristic changes in 
the morphology and biochemistry of the liver in susceptible species such as the 
rodents and more particularly the mouse and rat [Reddy et al., 1982a]. These 
hypolipidaemic agents among other classes of compounds such as the phthalate 
esters, fatty acid analogues and high fat diets, especially those rich in very-long 
chain fatty acids (VLCFA), are termed peroxisome proliferators (PPs) as they lead 
to the proliferation of this organelle. Examples of some peroxisome proliferators 
are listed in Table 1.2. and generally, the prolonged use of some of these 
compounds as lipid-lowering drugs has been associated with occasional side-effects 
of varying magnitude in humans (Table 1.3). Some of the proliferative effects of 
these compounds are summarised below.
1.4,1 Hepatomegaly
The pleioptropic responses observed following the administration of peroxisome 
proliferators may either be hypertrophic i.e associated with organelle proliferation 
or hyperplastic due to increase in cell number and size which may all be dependent 
on the dose and duration of treatment [Beckett et al., 1972]. Usually the first 
response visible is hepatomegaly and is reflected in a significant increase in the 
liver to body weight ratio [Hess et al., 1965]. Also associated with such response, 
is mid-zonal and periportal accumulation of lipid droplets and an increase in 
phospholipid and total protein levels in the liver [Azamoff et al., 1965, Mann et 
al., 1985]. It would appear that administration of hypolipidaemic agents 
characteristically results in hepatomegaly of a hypertrophic and hyperplastic nature. 
Hypertrophy may be associated with a combined proliferation of the smooth
12
Table 1.2 Uses of some compounds that are peroxisomal proliferators
Peroxisome proliferator Use Reference
Drugs
Clofibrate } 
Ciprofibrate } 
Bezafibrate}
Hypolipidaemic Hawkins et al., 1987
Aspirin Anti-inflammatory Oesch and Schladt, 1987
POCA Hypoglycaemic Bone etal., 1982 
Buiyan et al., 1988
Chlorpromazine Tranquillizer Vamecq eta l, 1987
1 -Benzylimidazole Anti-fungal
Valproic acid Anti-epileptic Horie and Suga, 1985
Industrial Chemicals
Isooctane Industrial solvent Lock etal., 1987
Pnidhoe Bay crude oil Crude petroleum mix Khan et al., 1989
Perfluorinated fatty acids Surfactants, flame retardants Ikeda et al., 1986
Pesticides
Tridipane, 2,4-D, 2,4,5-T Herbicide Lundgren et al., 1987
Lactofen herbicide Butler et al, 1988
Dimethrin Insecticide Hruban et al., 1974
Miscellaneous
DEHP, DEHA Plasticizers Sharmae/aA, 1988b 
Canning etal., 1987
Citral, Linolol Food flavouring Roffey etal, 1990 
Jackson et al., 1987
Abbreviations used: POCA, 2-[5-(4-chlorophenyl) pentyl] oxirane-2-carboxylate; DEHP, di-(2- 
ethylhexyl) phthalate; DEHA, di-(2-ethylhexyl) adipate.
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endoplasmic reticulum and a contributory increase in mitochondrial numbers [Hess 
etal., 1965].
Liver enlargement occurs rapidly in response to administration of peroxisome 
proliferators (such as clofibrate, Wy-14643, methylclofenepate and ciprofibrate), 
reaching a steady state level within two weeks, and is maintained throughout 
treatment, returning to pretreatment levels within a similar period of time [Reddy 
and Lalwani, 1983; Rao and Reddy, 1987]. Following clofibrate pretreatment in 
the rat, the relative liver weight increased rapidly during the first week and fell to 
pretreatment levels after withdrawal of the drug at three to four weeks [Lake et a/., 
1975].
1.4.2 Peroxisomal and Mitochondrial Changes
Treatment of rats with peroxisome proliferators results in several observable 
changes in hepatic peroxisomes and mitochondria, which include an increase in both 
peroxisome numbers and volume, proliferation of the mitochondria, structural 
changes, enlargement and induction of certain enzymes [Reddy and Lalwani, 1983; 
Gibson et al., 1982; Svoboda and Azamoff, 1966]. These proteins, including 
among others the cytochrome P450 4A subfamily of fatty acid hydroxylases, 
members of the peroxisomal fi-oxidation spiral as well as the cytosolic fatty acid 
binding protein, have been classified as belonging to a distinct class, termed the 
peroxisome proliferator domain (PPD) [Watanabe et al., 1985]. The peroxisome 
may account for up to 25% of the hepatocyte cytoplasmic volume in the livers of 
rats and mice treated with potent peroxisome proliferators such as ciprofibrate [Rao 
and Reddy, 1987]. This represents a 10-20 fold increase which is also reflected in 
the induction of some enzymes of the peroxisomal B-oxidation system [Reddy et ai., 
1986].
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Catalase activity is only slightly induced, often not more than 2-fold and the 
activity of carnitine acetyl transferase, a peroxisomal enzyme which is also located 
in the mitochondrial membrane, may be induced to a much greater extent (which 
could be several hundred fold), than that of peroxisomal 6-oxidation under similar 
experimental conditions [Stott, 1988]. Likewise, carnitine octanoyltransferase, a 
purely peroxisomal enzyme, can be induced over 40- fold by DEHP [Miyazawa et 
al, 1983].
Increases in the activity of acyl-CoA synthetase, carnitine acetyltransferase, 
carnitine palmitoyltransferase and acyl-CoA hydrolase have been observed in 
hepatic mitochondria isolated ft’om rats treated with peroxisome proliferators 
[Leighton eta l, 1982; Berge et a l, 1983]. A slight induction in the mitochondrial 
6-oxidation of short-chain acyl-camitines has been demonstrated in clofibrate-treated 
rats [Christiansen et a l, 1978]. Clofibrate administration has also been shown to 
inhibit branched-chain amino acid metabolism in the mitochondria [Wagenmakers et 
a l, 1985].
Several other hepatic peroxisomal and mitochondrial enzymes are also affected 
in varying degrees and are well documented [Hess et a l, 1965; Cohen and Grasso, 
1981; Antonenkov et a l, 1983]. Similarly, cytosolic changes have been reported. 
For instance, inhibition of cytosolic glutathione peroxidase, glutathione transferase 
and superoxide dismutase have been observed when rats have been treated with a 
number of peroxisome proliferators for a period of 30 days or more [Lake et a l, 
1987, 1989]. The administration of peroxisome proliferators to rats also induces 
certain cytosolic proteins, namely palmitoyl-CoA hydrolase, cytosolic epoxide 
hydrolase and fatty-acid binding protein [Berge et a l, 1987; Moody et a l, 1985, 
1991]. The proportion of catalase in rat liver cytosol is also increased and may 
reflect an altered fluidity of the peroxisomal membrane [Crane et a l, 1985].
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1.5 Perfluorocarboxylic Acid Derivatives and Peroxisome 
Proliferation.
Interest in the toxicity of the perfluorocaibons and their carboxylic acid 
derivatives began when a non-ionic form of fluoride consistent with the presence of 
a fluorocarbon was found in the serum of humans [Taves, 1968]. Subsequent 
studies led to its isolation and identification as perfluorooctanoic acid (PFOA), [Guy 
et a l, 1976]. Generally, perfluorocarbons are considered metabolically inert and 
relatively non-toxic compounds [Sargent and Seffl, 1970]. Recently, however, 
perfluorinated compounds such as perfluorooctanoic acid (PFOA), 
perfluorodecanoic acid (PFDA), and ammonium perfluorooctanoate have been 
shown to be peroxisome proliferators [Ikeda et al., 1985; Pastoor et al., 1987; 
Harrison et al., 1988; Borges et al., 1992]. Hence, these compounds like the other 
well characterised peroxisome proliferators, such as the hypolipidaemic drugs 
(clofibrate, fenofibrate and structurally-related analogues) [Hawkins et al., 1987, 
Milton et al., 1990; Chinje and Gibson, 1991], plasticizers (phthalate derivatives), 
[Sharma et al., 1988b] and chlorophenoxy acid herbicides [Bacher and Gibson, 
1988], do induce hepatomegaly, endoplasmic reticulum, and peroxisomal 
proliferation as well as peroxisomal and mitochondrial metabolism of fatty acids. 
Collectively, these chemicals are classified as peroxisome proliferators and concern 
has been expressed about their safety because they are non-genotoxic carcinogens in 
susceptible species, particularly rodents [Reddy et al., 1980; Reddy and Lalwani, 
1983; Rao and Reddy, 1987], probably as a result of indirect DNA damage caused 
by oxidative stress mechanisms [Elliot et al., 1986; Takagi et al., 1990].
Studies on the induction of peroxisome proliferation by perfluorinated fatty acids 
and their analogues (Figure 1.3 ) has also shown the importance of chain length and 
the presence of a carboxylic acid group in the molecule [Ikeda et al., 1985]. 
Because of their general metabolic inertness, they are considered as ideal for 
structure activity relationship (SAR) studies. For instance following a single i.p.
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CF3(CF2)8C00H Perfluoro-n-decanoic acid 
(PFDA)
CF3(CF2)6C00H Perfluoro-n-octanoic acid 
(PFOA)
CF3(CF2)2C00H Perfluoro-n-butyric acid 
(PFBA)
CF3(CF2)6CH20H 1 -H, 1 -H-Pentadecafluorooctanol 
(PFOL)
CF3(CF2)ioCF3 Perfluorododecane
(PFD)
CF3(CF2)6CF3 Perfluorooctane
(PFO)
Figure 1.3 Structures of some perfluoro fatty acids and their derivatives.
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dose, PFDA, PFOA and l-H,l-H-pentadecafluoro-n-octanoI (PFOL) were shown to 
be inducers of the peroxisome proliferation-associated polypeptide (PPA-80) and 
lauric acid w—hydroxylase, whereas perfluoro-n-butyric acid (PFBA) and the 
perfluorinated paraffins, perfluorododecane (PFD) and perfluorooctane (PFO) did 
not induce these enzymes. Similarly, several chain length perfluorinated fatty acids 
have been examined for their ability to inhibit mitochondrial acyl-CoA synthetase 
(ACS) [Vanden Heuvel e ta l, 1991]. ACS is an enzyme essential for both oxidation 
and estérification of fatty acids. Short-chain perfluorinated fatty acids 
(perfluoropropionic and perfluorobutyric acids) did not inhibit ACS activity, 
whereas medium-chain perfluorinated acids, such as perfluorooctanoic and 
perfluorodecanoic acids, were found to be potent inhibitors of ACS in isolated 
mitochondria. However, these workers did not establish whether ACS inhibition 
was causally related to PFDA-induced peroxisome proliferation and altered lipid 
metabolism seen in vivo.
The biological effects of the perfluoro-fatty acids appear to be of a persistent 
nature [Van Rafelghen et a l, 1987; George and Andersen, 1986] and exposure to 
rodents have been demonstrated to give rise to a peculiar "wasting syndrome" 
resulting in severe weight loss and hypothermia [Langley, 1990]. It has been 
reported that the body weights of rats provided with a diet containing PFDA ceased 
to increase, even though these animals consumed as much food as their control 
counterparts [Borges et a l, 1990]. More recent studies carried out by Borges et a l 
[1992], showed that rats treated with cumulative doses of PFDA <  12 mg/kg did 
not differ from their pair-fed control counterparts, in growth or feed intake, while 
those which received cumulative doses of >  40 mg/kg lost weight and decreased 
their feed intake. Similarly, total peroxisomal B-oxidation was decreased in a dose- 
related manner, whereas the liver to body weight ratio and activities of the 
individual enzymes comprising the peroxisomal B-oxidation system, namely fatty
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acyl-CoA oxidase, enoyl-CoA hydratase, 3-hydroxyacyl-CoA dehydrogenase, and 
thiolase were increased.
It has also been reported that rats treated with doses of PFDA between 40 and 
150 mg/ kg exhibit delayed lethalities occurring 2-3 weeks after treatment with the 
xenobiotic [Oslon and Andersen, 1983]. The target organ of PFDA-induced 
toxicity is the liver, although thymic atrophy, fatty changes in the proximal tubular 
epithelium of the kidney and testicular seminiferous tubular degeneration have also 
been reported [Van Rafelghem et al., 1982, Ikeda et al., 1985; George and 
Andersen, 1986; Harrison et al., 1988]
Comparative toxicity of PFOA with its 10-carbon analogue PFDA, revealed that 
the latter was more toxic having a 30-day LD50 of approximately 41 mg/ kg, which
was considerably less than that for PFOA (189 mg/ kg) [Oslon and Andersen,
1983]. Moreover, delayed lethalities occurring 2-3 weeks following PFDA 
administration at doses between 40 and 150 mg/kg were not seen with PFOA 
administration. PFDA is poorly metabolized by rats and is excreted at the rate of 
about 0.5% of the administered dose per day [Vanden Heuvel et al., 1991; Ylinen 
and Auriola, 1990], the urinary elimination being a minor route of elimination. In 
an experiment carried out by Vanden Heuvel and co-workers, in which the 
percentage dose of PFDA-derived ^^C per gram tissue was estimated after a single 
intraperitoneal dose of 9.4 mmol [l-^^C] PFDA/ kg, it was observed that 24h after 
administration, the liver (5.9%) contained 10-fold that of the kidney (0.62%). A 
similar distribution pattern was maintained for up to 4 weeks with the liver still 
having the highest distribution (3%), followed by the plasma (0.32%), kidney 
(0.25%), heart (0.2%), epididymal fat pad (0.1%) and testis (0.05%).
A single i.p dose of PFDA (50 mg/kg) administered to Sprague-Dawley rats 
caused disruption of the endoplasmic reticulum, mitochondrial swelling and 
increases in intracellular lipid droplets in hepatocytes [Harrison et al., 1988]. These
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effects were quite similar to those reported for 2,3,7,7-tetrachlorodibenzo-p-dioxin, 
(TCDD), however, dioxin does not cause peroxisome proliferation. PFDA 
administration to rats has also been shown to rather increase the plasma triglyceride 
levels while causing a decrease in plasma cholesterol levels. This finding was in 
contrast to that observed for other classical peroxisome proliferators, such as the 
hypolipidaemic agent, clofibrate and has led to the classification of PFDA as a 
"non-hypotriglyceridaemic" peroxisome proliferator [Borges e ta l, 1990].
One of the current hypothesis concerning the signal for peroxisome proliferation 
is based on the formation of a thioester between the proliferator and coenzyme A 
[Lock et ah, 1989]. However, it remains to be demonstrated if PFDA and other 
analogues, such as perfluorooctanoic acid (PFOA), are also linked to this 
mechanism. Perfluorooctane and perfluorodecane do not appear to cause 
peroxisome proliferation in rat liver [Ikeda et ah, 1985], suggesting that the 
carboxylate group may be essential in triggering peroxisome proliferation. PFDA 
and PFOA may both act in a similar manner, as an uncoupler of oxidative 
phosphorylation and as an inhibitor of the electron transport chain, as observed in 
rats [Langley, 1990].
1.6 Role of Peroxisomes and Mitochondria in B-Oxidation of 
Fatty Acids
Peroxisomes often occur in close association with elements of the endoplasmic 
reticulum [Zaar et al., 1987], highlighting the earlier belief that peroxisomes were 
formed by budding from the endoplasmic reticulum [De Duve and Baudhuin, 1966]. 
However, the polypeptide composition of the peroxisomal membrane and the 
endoplasmic reticulum have been shown to be markedly dissimilar [Fujiki et al., 
1982]. The current model of peroxisome biogenesis suggests that peroxisomes are 
formed by fission from pre-existing organelles [Yamamoto and Fahimi, 1987;
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Fujiki et al., 1984]. Unlike the enzymatic complement of many other organelles, 
the enzymology of the peroxisome may vary considerably from one tissue to another 
and between species.
Generally peroxisomes provide a compartment for alternative pathways in the 
metabolism of fatty acids [Lock et al., 1989]. In several tissues examined so far, 
three main functional cellular compartments that are responsible for fatty acid 
oxidation, have been well distinguished. These include (i) the extra-mitochondrial 
compartment comprising the endoplasmic reticulum, the cytosol and the outer 
mitochondrial membrane, (ii) the peroxisomes, and (iii) the mitochondrial matrix. 
The metabolic function of these different compartments varies depending on the 
fatty acid chain length as depicted in Figure 1.4. Peroxisomes participate in a 
number of specific metabolic pathways that lead to energy production and oxidative 
metabolism [De Duve and Baudhuin, 1966].
Although the reactions involved during peroxisomal B-oxidation are identical to
those of mitochondrial B-oxidation, the enzymes are quite distinct from their
mitochondrial counterparts. One outstanding difference is that fatty acids are
incompletely oxidised by peroxisomes and long chain acyl-CoA has been found to
undergo 2-5 cycles of B-oxidation [Lazarow and De Duve, 1976; Osmundsen, 
1982]. Since C22 fatty acids are poor substrates for mitochondria, chain shortening
of these fatty acids leads to fatty acids which are more easily oxidised by the 
mitochondria. Peroxisomal B-oxidation of these fatty acids therefore becomes a 
mechanism by which poorly oxidisable fatty acids are converted to metabolically 
more degradable products. As this is achieved by chain shortening, rather than 
complete oxidation, a minimum of metabolic energy is wasted. It has also been 
suggested that B-oxidation in peroxisomes may be a chain-shortening mechanism for 
long-chain dicarboxylic acids formed during fatty acid w—oxidation [Hemmelgam 
etal., 1977].
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C e l l  membrane M i t o c h o n d r  i on
B - OH - bu t
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AcAc--------
Perox  i some
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Acyl -CoA
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Acyl -CoA Acyl -CoA
Glyc.P-
T r i  a c y l g l y c .
FFA
Figure 1.4 Compartmentation of fatty acid metabolism in the liver.
Abbreviations used: FFA, free fatty acids; Glyc.P, glycero-3-phosphate; P-lip., phospholipids; 
Ac-CoA, acetyl-CoA; AcAc, acetoacetate; B-ox., B-oxidation. The circles across the mitochondrial 
membrane represent the carnitine-dependent transport of acetyl and long-chain acyl groups from 
extramitochondrial to intramitochondrial CoA. {Derived ûom Bremer and Osmundsen, 1984).
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In terms of capacity; to generate acetyl groups, the capacity of the peroxisomes is
relatively low, being argi^nd 10% of the mitochondrial capacity in rats treated with
clofibrate [Osmundsen, ^82; Neat et a l, 1981]. However, if chain-shortening of
fatty acids is considered a,major function of peroxisomal B-oxidation, then it is the 
peroxisomal capacity to chain shorten e.g a C22:l fatty acid which is significant.
The peroxisomal capacity to chain shorten a C22:l fatty acid may be as much as
100-300% of the mitochondrial capacity to oxidise this fatty acid [Bremer and
Osmundsen, 1984]. Hence, there appears to be a peroxisomal capacity which
would be of significant physiological value. It has been reported that patients
suffering from the inheritable disease adrenoleukodystrophy show accumulation of 
very long-chain fatty acids (C25 and C26) in adrenals as well as in the central
nervous system, probably due to a defect in peroxisomal B-oxidation [Singh et al.,
1981].
Subsequent identification o f additional peroxisomal enzymes led to further 
speculation on the metabolic role of these organelles. A number of enzymes such as 
oxidases, dehydrogenases, catalase, acyl-transferases and those of the fatty acid 
oxidation cycle have been identified in peroxisomes isolated from a variety of plants 
and animals. Beta-oxidation of both mono- and di-carboxylic fatty acids [Lazarow,
1982] are due to the presence of four main enzymes namely: acyl CoA oxidase, 
enoyl-CoA hydratase, 3-hydroxyacyl-CoA dehydrogenase and 3-ketoacyl-CoA 
thiolase (Figure 1.5). The last three are found on the so called trifunctional protein 
[Goel et al., 1986] or the peroxisome proliferator-associated protein 80,000 daltons 
(PPA-80) [Osumi and Hashimoto, 1979].
The enzymes of peroxisomal B-oxidation differ from mitochondrial enzymes 
with respect to their catalytic and molecular properties. For instance, it has been 
shown that, unlike the carnitine-dependent cyanide-sensitive mitochondrial system, 
peroxisomal B-oxidation enzymes are cyanide-insensitive in vitro and do not require 
carnitine [Lazarow, 1982]. The discovery of carnitine acetyltransferase in
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Figure 1.5 B-Oxidation sequence in peroxisomes.
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peroxisomes was of special interest because this enzyme was considered to be 
primarily located in the mitochondria. Various chain lengths of the acyl transferase 
have been described ranging from short- through medium- to long- chain 
acyltransferases. These acyltransferases and in particular, the short- and medium- 
chain lengths have seen their barely detectable levels of activity in livers of 
untreated rats and mice, increase between 30 - 160 fold in animals following 
treatment with peroxisome proliferators [Moody and Reddy, 1974; 1978]. It has 
been suggested that these transferases may play a role in the removal of end 
products of metabolism in the peroxisomes [Lazarow, 1982].
Peroxisome proliferation appears to be a tissue and species specific 
phenomenon. The liver is the most susceptible organ, though the kidney, heart, 
intestinal mucosa and skeletal muscle all respond depending on the dose and 
duration of exposure to peroxisome proliferators [Stott, 1988]. The induction of 
mitochondrial and peroxisomal enzymes involved in the B-oxidation of fatty acids, 
in conjunction with other known cellular responses, points to a common mechanism 
involved in their hypolipidaemic effect.
1.7 Induction of Qiochwme P450 4A Subfamily Pmieins 
and Their Role in the Metabolism of En(k}genous Substrates.
The cytochromes P450 associated with the microsomal fraction of the liver and 
other organs such as the kidney and lung, catalyse the NADPH- and oxygen- 
dependent metabolism of a variety of lipophilic foreign and endogenous compounds. 
Many of these cytochromes P450 are present at very low but measurable 
constitutive levels in untreated rats and may be under hormonal regulation 
[Schenkman et al., 1989]. They may also be induced several fold by a variety of 
structurally diverse foreign compounds [Guengerich, 1991; Boobis and Davies,
1984].
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Associated with smooth endoplasmic reticulum proliferation is the induction of 
one of the most active cytochrome P450 fatty acid-metabolising haemoproteins, 
designated cytochrome P450 4A1 [Hardwick et al., 1987; Tamburini et al., 1984; 
Gibson et al., 1982]. The metabolism of lauric acid, as substrate, to its w— and 
(co—l)-hydroxyl metabolites has been attributed to the activity of this isozyme 
[Gibson, 1989; Sharma et al., 1989]. Consideration of the fact that the 
concentration of both free and esterified laurate is low in the hepatic endoplasmic 
reticulum membrane was indicative of the presence of other endogenous substrates. 
The involvement of cytochromes P450 in the metabolism of arachidonic acid to a 
wide variety of oxygenated products, has been well documented [Sharma et al., 
1989; Oliw and Oates, 1981; Capdevila etal., 1985; Chacos eta l, 1983].
Arachidonic acid is an important constituent of biological membranes and is
almost invariably found esterified to the 2-position of various cellular 
glycerophospholipids. Phospholipases of the A2~type are responsible for
hydrolysing this fatty acid thereby releasing it into the cell medium. The actions of 
lipooxygenases, cyclooxygenases, lead to the production of intermediates that serve 
as precursors of a variety of compounds with potent physiological and 
pharmacological properties. Such by-products include the prostaglandins, 
thromboxanes, prostacyclins, hydroxyeicosatetraenoates and leukotrienes.
Arachidonic acid also serves as an excellent substrate for the clofibrate-induced 
cytochrome P450 4Al hydroxylase system in the rat [Bains et al., 1985; Sharma et 
al., 1989]. Pretreatment of rats with ciprofibrate resulted in an 8-fold stimulation 
of w— and (co—l)-oxidation of arachidonic acid with a simultaneous net decrease in 
the formation of the other oxygenated metabolites [Capdevila et al., 1985]. 
Recently, it was reported that co— and (co—l)-hydroxyarachidonates had potent 
biological activities [Schwartzman et al., 1989]. Whereas co—hydroxy arachidonic 
acid shows properties of a vasoœnstrictor, the (co — l)-product, has been 
demonstrated as a stimulator of Na+/ K+- ATPase.
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It would seem plausible that members of the cytochrome P450 4A subfamily
proteins with co—/ (co—1)-hydroxylase activities, are capable on the basis of broad
substrate specificity to metabolise other substrates containing co— and (co—l)-carbon 
atoms. Interestingly, this is not the case with the leukotrienes (e.g leukotriene B4,
found in polymorphonuclear leukocytes), which serve as important mediators of the
inflammatory process [Samuelsson, 1983]. Studies on the metabolism of 
leukotriene B4 (LTB4) suggest that this is a relatively poor substrate for both the
renal and hepatic cytochrome P450 4Al-dependent enzyme system as it was 
demonstrated that both the co— and (co—1)-LTB4 hydroxylase activities were
decreased in both tissues following pretreatment of rats with clofibrate [Sharma et
al., 1989]. Such findings prompted these workers to suggest that the induction or
specific gene "switch on" of laurate hydroxylase by clofibrate appeared to result in a 
specific gene "switch o f f  of LTB4 hydroxylase.
LTB4 hydroxylases are present in rat liver and kidney as constitutive isozymes 
of cytochrome P450 but are distinct from those which mediate the hydroxylation of 
laurate and possibly, prostaglandins [Romano et al., 1987]. Similarly, it has been
suggested that prostaglandin hydroxylases are distinct from laurate hydroxylases and 
possibly LTB4 hydroxylases [Matsubara eta l, 1987]. The isolation and sequencing
of a prostaglandin oj-hydroxylase from rabbit lung (cytochrome P450 p_2) 4A4,
showing about 74% amino acid sequence homology with that of laurate cj— 
hydroxylase (cytochrome P450 4A1), prompted its classification into a new 
cytochrome P450 gene subfamily, CYP 4B1 [Nhamburo et ah, 1989].
As one would expect because of the multiplicity of cytochrome P450, there is 
considerable diversity in the mechanisms of regulation of these enzymes. 
Transcriptional regulation is the most common means of gene regulation and has 
been reported for a number of mammalian cytochrome P450 isozymes, the most 
extensively characterised being cytochrome P450 lA l [Nebert and Jones, 1989]. 
This is the only cytochrome P450 for which a receptor- mediated mechanism of
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induction has been clearly demonstrated via an Ah or TCDD receptor [Poland et 
ai., 1976; Fujisawa-Sehara et al., 1987]. Another form of regulation may be post- 
translational. The relative proportion of a particular form of P450 and its associated 
enzyme activities are determined by multiple steps ranging from gene transcription, 
through mRNA stabilisation to enzyme stabilisation via translation. In contrast to 
P450 lA l, which is primarily regulated by transcriptional control, 1A2, a closely 
related isoform is regulated for the most part [Kimura et al., 1986], apparently 
through enhanced stability and intranuclear processing of the 1A2 mRNA precursor 
[Silver and Krauter, 1990].
There is considerable documentation of mRNA stabilisation as a mechanism of 
induction for several other cytochromes P450, as exemplified by the ethanol- 
inducible cytochrome P450 2E1. This isozyme is induced by other small molecules 
such as acetol, acetone, pyrazole and is thought to be via specific protein 
stabilisation effects of these molecules [Eliasson et al., 1990; Song et al., 1989]. 
Other factors such as diabetes and fasting have each been reported to produce up to 
a 10-fold elevation in cytochrome P450 2E1 mRNA, the increase with diabetes 
being as a result of mRNA stabilisation [Song et al., 1987] and that by fasting, due 
to gene transcription [Johansson et al., 1990].
1.8 Pewxisome Pmliferators and Hepatocaranogenesis
A good correlation exists between the incidence of liver cancer and the 
effectiveness of the administered dose in inducing peroxisomes [Reddy and Lalwani,
1983]. These workers were able to show that the genesis of tumours in rats and 
mice by peroxisome proliferators requires continuous exposure for 60 to greater 
than 500 days depending upon the potency of the carcinogen and that once tumour 
formation has begun, its progression is not inhibited by cessation of exposure to the 
carcinogen. Numerous studies indicate that these agents are not mutagenic and do
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not interact directly with nor damage DNA fButterworth et al., 1984; Glauert etal., 
1984; Warren et al., 1980]. More recently, Schiestl, [1989], has developed a 
system for chromosomal recombination in yeast which is inducible by a number of 
non-genotoxic carcinogens and a number of hypolipidaemic peroxisome 
proliferators tested in this system, were without effect [Schiestl and Reddy, 1990], 
thus supporting the notion that peroxisome proliferators are truly non-mutagenic 
carcinogens. Subchronic treatment of rodents with a variety of structurally diverse 
compounds leads to hepatic peroxisome proliferation, whilst life-time feeding with 
such compounds is associated with an elevated incidence of hepatocellular 
carcinomas [Reddy et al., 1980], a finding which prompted these latter workers to 
suggest that peroxisome proliferators form a novel class of carcinogens.
In view of the heterogeneous nature of agents which induce peroxisome 
proliferation and their widespread and varied use, human exposure to such 
compounds is inevitable. In general, peroxisome proliferators are not considered 
genotoxic i.e they are not thought to interact directly with cellular DNA. This is 
borne out by the fact that several such agents did not induce DNA-repair in cultured 
human lymphocytes [Warren et al., 1980] nor could covalent binding to 
hepatocellular DNA be demonstrated [Goel et al., 1985]. It was due to such 
considerations that led to the postulation that peroxisome proliferators may induce 
DNA damage by indirect mechanisms [Reddy et al., 1980]. Furthermore, no 
carcinogenic peroxisome proliferators, including the hypolipidaemic drugs and 
phthalate plasticizers displayed any capacity to covalently modify or damage cellular 
DNA either in vivo or in vitro [Glauert et al., 1984; Linnainman, 1984]. The 
carcinogenicity of these non-mutagenic and non-DNA adduct-forming peroxisome 
proliferators appears to be related to biologically active products of the proliferated 
peroxisomes rather than a direct chemical effect.
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1.8.1 The Cellular Oxidative Stress Hypothesis
The oxidative stress hypothesis was advanced to explain how peroxisome 
proliferation may result in hepatocellular carcinomas. Long-term administration of 
peroxisome proliferators to rats and mice is often associated with increased 
incidences of hepatocellular carcinomas [Reddy et al., 1980; Rao and Reddy,
1987]. To date, all peroxisome proliferators that have been tested have been shown 
to produce hepatic tumours in responsive species such as the rat and mouse. In the 
proposed model (Figure 1.6), the enhanced production of hydrogen peroxide (via 
the peroxisomal fatty acid B-oxidation system, see earlier) overcomes the ability of 
peroxisomal catalase, or other hydrogen peroxide degrading enzymes and results in 
a slow accumulation of oxidative damage to the genome. Evidence for this model 
has gained support from a number of laboratories which have demonstrated in vitro 
damage to DNA associated with proliferated peroxisomes [Fahl et al., 1984], 
increased production of hydroxy radical by proliferated peroxisomes [Elliot et ah,
1986] and a close association between lipofuscin accumulation and carcinogenesis of 
peroxisome proliferators [Conway etal., 1989; Reddy etal., 1982a].
Persistent increase in the formation of 8-hydroxydeoxyguanosine was observed 
in rats continuously fed a diet containing the peroxisome proliferator, ciprofibrate, 
for 16 to 20 weeks [Kasai et al., 1989]. Strikingly this could not be found within 3 
to 4 hours after a single dose of the same peroxisome proliferator, suggesting that 
persistent peroxisome proliferation is required for the formation of oxidative 
damage to DNA. Similar response in the formation of 8-hydroxydeoxyguanosine 
was observed in rat liver and not the kidney when treated with both DEHP and 
DEHA for 1 and 2 weeks, respectively [Takagi et al., 1990].
The oxidative stress is related to the tissue/ cell specific increase in mRNAs of 
the B-oxidation system and this cell specificity is attributed to specific recognition 
factors in responsive cells. This provides compelling evidence that hepatocellular 
carcinoma formation in laboratory animals treated with peroxisome proliferators is
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Figure 1.6 The oxidative stress hypothesis for peroxisome proliferator-induced 
hepatocarcinogenicity. ( D e r / V e J Reddy and Lalwani, 1983; Kasai et al., 1989).
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directly linked to the persistent increase in peroxisomes. At the present time, there 
is no conclusive evidence of a causal link between peroxisome proliferation 
associated oxidative stress and hepatocarcinogenicity. There is, however, good 
evidence of a strong association between these processes. The findings by some 
workers using hepatocytes, have indicated that induction of peroxisomal B-oxidation 
and stimulation of DNA synthesis do not always go hand-in-hand [Bieri et al.,
1988]. This observation is supported by further findings that cast doubt on the 
correlation between peroxisome proliferation and neoplasia [Marsman et al., 1988]. 
The studies carried out by these researchers was based on a previous report that rats 
fed with DEHP at 1.2% in the diet produced a 10% incidence of hepatocellular 
carcinoma after two years, whereas Wy-14,643 at 0.1% in the diet resulted in a 
100% incidence after 15 months [Kluwe et al., 1982; Lalwani et al., 1981]. The 
lack of a quantitative correlation between the degree of peroxisome proliferation to 
hepatocarcinogenicity in such study, despite little differences in the magnitude of 
peroxisomal enzyme induction between the two compounds, suggests that 
measurements of peroxisome proliferation by such class of xenobiotics are not 
reliable predictors of the carcinogenic potential of these chemicals. Consequently, 
in any study of the species differences on the effect of peroxisome proliferators, the 
induction of hepatocellular DNA synthesis should also be taken into account.
1,8.2 Peroxisome Proliferators as Tumour Promoters
The requirement for long-term continuous feeding of peroxisome proliferators to 
produce tumours and their non-genotoxic nature suggest that non-tiaditional 
mechanisms may be involved in the mechanism of carcinogenesis. Peroxisome 
proliferators have been tested for their promotion effects in a number of studies 
[Conway et al., 1989; Cattley and Popp, 1989; Kraup-Grasl etal., 1990, 1991]. In 
general, they act as positive promoters when studies were carried out to sufficient 
length for tumour formation to be used as the end-point, but gave variable results in
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short-term studies which only measured altered cell foci formation. The eventual 
neoplasia is a result of selection and clonal expansion of these pre-initiated focii in 
older rodents which are generally more susceptible to hepatocarcinogenesis by 
peroxisome proliferators (Kraup-Grasl et al., 1991). However, such reports have to 
be rationalised with work indicating that some of these tumour promoters can act as 
inhibitors [Staubli et al., 1984; Numoto et al., 1984; Popp et al., 1985]. Increased 
levels of oncogene products have been observed within 28 days of rat treatment with 
nafenopin and have been implicated in the process of tumour formation [Bentley et 
al., 1988], although the precise details and molecular mechanisms of regulation 
remains to be established.
Peroxisome proliferators as tumour promoters provide an alternative proposal to 
explain how peroxisome proliferation may result in hepatocellular carcinomas. In 
this model, it is proposed that peroxisome proliferators may act through promotion 
of spontaneously initiated foci in the liver [Cattley and Popp, 1989; Glauert et al., 
1986; Schulte-Hermann et al., 1983; Ward et al., 1986]. Quite recently, the 
promotional activities of the peroxisome proliferators have been associated with 
their ability to stimulate foci or tumour growth through localised increases in cell 
replication [Marsman et al., 1988]. This proposal merits further study and may be 
valid, offering a unique form of initiation-promotion.
The use of initiation-promotion protocols is providing greater insight into the 
carcinogenic action of peroxisome proliferators [Garvey et al., 1987; Ward et al., 
1986; Cattley et al., 1989, 1991; Glauert and Clark, 1989]. To date, the results of 
initiation-promotion and hepatocyte replication studies suggest that peroxisomal 
proliferating chemicals may be causing promotion of spontaneously initiated sites 
rather than initiating the hepatocarcinogenic response in rodents. Therefore, there is 
need for further clarification as to the involvement of peroxisome proliferators in 
the rodent model before clear health assessment issues for humans can be 
established.
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The importance of cell signalling in peroxisome proliferation is only just 
beginning to emerge [Bronfman et a i. 1986, 1989; Itoga et a l , 1990; Watanabe et 
al, 1991]. Protein kinase C (Ca^+-activated, phospholipid-dependent protein 
kinase; pkc) has been implicated in tumorigenesis by the observation that this 
protein represents the major cellular receptor for tumour-promoting phorbol esters 
[Nishizuka, 1984]. It has been suggested that the carcinogenic effects of many 
peroxisome proliferators are activated to their corresponding CoA thioesters and that 
the latter (but not the free acids) were able to stimulate protein kinase C, which 
may result in the phosphorylation of regulatory proteins [Bronfman et al., 1986,
1989]. However, the significance of this process is not known.
It is well established that protein kinase C activity depends on the presence of 
Ca^*^ and it has recently been shown that the Ca^*  ^ antagonist, nicardipine, 
suppresses peroxisome proliferation and cytochrome P450 4A1 induction [Itoga et 
al., 1990, Watanabe et al., 1991]. It is highly likely that this suppression may be 
due to a decreased activity of protein kinase C. Furthermore, rats treated with 
clofibrate, and other hypolipidaemic drugs, show an increased liver concentration of 
natural long chain acyl-CoAs [Berge and Aarsland, 1985], which would also help to 
stimulate protein kinase C activity.
1.8.3 Proposed Mechanisms for the Induction of Peroxisome 
Proliferation
The exact underlying cellular mechanism responsible for the induction of 
peroxisome proliferation and associated enzyme activities, remains to be fully 
ascertained. A number of theories have been put forward which remain to be fully 
explored.
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i) Receptor-mediated hypothesis for carcinogenesis
The mechanism by which structurally diverse peroxisome proliferators produce a 
similar pleiotropic response is not known but the tissue specific biological response 
and rapid rate of transcription of peroxisomal fatty acid B-oxidation enzyme genes 
support the hypothesis that these agents act by binding to a specific recognition 
molecule. The diverse nature of the chemical structures of the agents known to 
produce essentially the same pleiotropic response makes it difficult to explain how 
they interact with a single type of binding protein having a single recognition site. 
If more than one type of receptor molecule exists, then these must converge on a 
common final pathway to induce similar biological and biochemical effects in 
hepatocytes. The demonstration of a reversible, specific, albeit weak binding of 
nafenopin, a peroxisome proliferator, to a cytosolic protein in rat liver [Lalwani et 
al., 1983] led to the proposal that peroxisome proliferators evoke their action 
possibly by a receptor-mediated mechanism [Reddy and Lalwani, 1983; Rao and 
Reddy, 1987].
Circumstantial evidence supporting the existence of a specific receptor for the 
xenobiotic peroxisome proliferator have been previously reported [Foumel et al., 
1985; Lundgren et al., 1987, 1988]. It was also suggested that the peroxisome 
proliferator binding protein (PPbp), purified fi-om rat liver cytosol by affinity and 
ion-exchange chromatographys [Lalwani et al., 1987], acts in a similar manner to 
that proposed for the Ah receptor [Nebert, 1979]. In such a scheme, it is postulated 
that the peroxisome proliferators enter the cell by passive diffusion through the 
plasma membrane and then bind to the receptor inside the cell. The binding of the 
ligand activates the receptor and this ligand-receptor complex then binds with 
increased affinity to selective site(s) in cellular DNA, thereby possibly triggering 
the transcription of the genes of the peroxisome proliferator domain. However, 
extensive studies by other research groups in exploiting the above observation about 
a peroxisome proliferator receptor were unsuccessful and the identity and nature of
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this postulated receptor remain unknown with a number of questions being raised 
about the existence of such a receptor [Milton et al., 1988; Siest et al., 1988].
More research has since been devoted to further characterising the postulated 
cytosolic receptor [Alvares et al., 1990]. These workers were able to show that this 
protein is homologous with the 'Heat shock' protein HS P70 family by analysis of 
amino acid sequences of isolated peptides from tiypsin-treated clofibric acid binding 
protein and by cross-reactivity with a monoclonal antibody raised against the 
conserved region of the 70 kDa heat shock protein. Furthermore, the clofibric acid- 
sepharose column could bind HS P70 protein isolated ft-om various species, which 
could then be eluted with either clofibric acid or ATP, suggesting that clofibric acid 
preferentially interacts with P72 (a constitutively expressed member of the HS P70 
family) at or near the ATP binding site. It remains to be shown whether these 
interactions are directly linked to the events that lead to peroxisome proliferator- 
induced liver pathophysiology. Nevertheless, the isolation of a single protein with 
high affinity for three fibric acid analogues favourably argues for a specific binding 
protein. Additional work is required to ascertain if binding occurs in vivo and if 
this plays a role in transcriptional activation.
The presence of a peroxisome proliferator binding protein and the ability of 
peroxisome proliferators to activate gene transcription suggested that the mechanism 
by which these chemicals act could be similar to that of steroid hormone action 
[Reddy and Rao, 1986]. Quite recently, there have been more convincing reports 
on the existence of a receptor which could be activated by the presence of some of 
the well known peroxisome proliferators, which should by and large explain the 
mechanism by which peroxisome proliferators regulate gene expression and induce 
liver tumours in rodents [Green, 1992]. The identification of such a putative 
transcription factor specifically activated by peroxisome proliferators suggest that 
this receptor directly mediates the effects of this class of chemical [Issemann and 
Green, 1990, 1991]. These workers, by screening a mouse liver cDNA library
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using a concensus probe derived from the combined nucleotide sequences of several 
nuclear hormone receptors, were able to identify four new members of the hormone 
receptor family. The nuclear hormone receptor superfamily comprises at least 25 
mammalian genes that encode receptors for the classical steroid and thyroid 
hormones [Carson-Jurica, 1990; Evans, 1988]. It further demonstrated that one of 
the four newly identified members of the hormone receptor family could be 
activated by the addition of a variety of peroxisome proliferators and therefore 
termed Peroxisome Proliferator-Activated Receptor (PPAR) [Issemarm and Green, 
1991]. A possible role in the regulation of responsive genes by this receptor 
subsequent to the administration of a peroxisome proliferator is depicted in Figure 
1.7. According to this scheme, the receptor-ligand complex is thought to switch-on 
acyl-CoA oxidase gene expression by the interaction with putative regulatory 
elements in the 5' flanking region of the gene. The precise molecular details of this 
gene regulation are only now beginning to emerge and it is theoretically possible 
that the peroxisome proliferator-PPAR complex or a lipid-PPAR complex regulates 
the corresponding responsive genes.
There is tissue specific expression of PPAR and the highest reported levels of 
expression are observed in the liver and to a lesser extent in brown adipose tissue, 
kidney, heart, brain and testis. It will be important to determine whether all of the 
effects of peroxisome proliferators are receptor-mediated. If they are, then learning 
more about the role and function of PPAR presents an exciting and unique 
opportunity to understand more about the role of peroxisome proliferators in 
hypolipidaemia, peroxisome proliferation and etiology of cancer. Furthermore, 
examination of the expression and function of PPAR in humans could have 
important implications in assessing the hazard that peroxisome proliferators may 
represent to the human population.
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Figure 1.7 A possible mechanism of action of the peroxisome proliferator- 
activated receptor (PPAR) in hepatic pleiotropic responses to peroxisome 
proliferators.
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H) The "Cascade” or Substrate Overload Theory
Early suggestions indicated that an influx of fatty acids into the liver as a result 
of treatment leads to a lipid excess, therefore triggering peroxisomal 6-oxidation 
[Reddy and Lalwani, 1983]. Fatty acids serve as substrates for the microsomal 
cytochrome P450 hydroxylase system as well as for peroxisomal 6-oxidation, and 
both activities undergo substantial induction in hypolipidaemic-treated animals.
The close relationship between the induction of cytochrome P450 4A1 and the 
endoplasmic reticulum on the one hand, and peroxisomal and mitochondrial enzyme 
induction on the other, led to an alternative proposed mechanism for the co­
induction of hepatic microsomal cytochrome P450 4A1 and peroxisomal 6-oxidation 
enzymes by hypolipidaemic agents [Sharma et al., 1988b; Lock et. al., 1989]. In 
this scheme (Figure 1.8), the hypolipidaemic agent or peroxisome proliferator is 
taken up by the hepatocyte followed by initially inhibition of fatty acid oxidation by 
the dual mechanism of inhibition of carnitine acyl transferase in the mitochondrion 
[Lock et. al., 1989] or sequestration of essential Co A by the peroxisome 
proliferator itself [Bronfman et. ah, 1989]. Induction of cytochrome P450 4A1 
synthesis then occurs as an early event, possibly via a receptor as discussed above. 
This is supported by the observation that there is an increase in the rate of 
cytochrome P450 4A1 gene transcription as early as Ihr after the administration of 
clofibrate [Hardwick et al., 1987]. This increase was then followed by an elevation 
of cytochrome P450 4A1 mRNA immunochemically detectable protein, and its 
associated catalytic activity [Hardwick et al., 1987; Eamshaw et al., 1988; Milton 
et al., 1990]. This specific sequence of events has also bee demonstrated in vitro in 
rat hepatocyte primary culture [Bieri et. al., 1991].
Subsequent to the induction of cytochrome P450 4A1 by these hypolipidaemic 
agents, there is an enhanced oj— and (w— l)-hydroxylation of medium- and long- 
chain monocarboxylic fatty acids, such as lauric acid and arachidonic acid. Further
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metabolism of these hydroxy monocarboxylic acids into their keto-derivatives and 
dicarboxylic acids, is catalysed by cytosolic alcohol and aldehyde dehydrogenases 
[Mitz and Heinrikson, 1961; Robbins, 1968]. It is then proposed that these 
dicarboxylic acids are then taken up by the peroxisome, thus presenting the 
organelle with a substrate overload of one of its preferred substrates [Singh et ah,
1984], because the mitochondrion cannot readily metabolise long chain fatty acids 
[Alexson and Cannon, 1984]
The hypolipidaemic drug induction of peroxisomal 6-oxidation enzymes may be 
considered as a secondary adaptive cellular response by the hepatocyte in an attempt 
to clear long chain dicarboxylic fatty acids for subsequent chain shortening by the 
mitochondrion [Alexson and Cannon, 1984], thereby maintaining lipid 
homoeostasis. This theory is supported by the observation that dicarboxylic acids 
are substrates for peroxisomal 6-oxidation enzymes [Mortensen, 1986; Vamecq and 
Draye, 1987]. In addition, an elevated level of dicarboxylic acids has been 
suggested as a possible mechanism of stimulation of peroxisomal 6-oxidation in 
hepatocyte cultures [Mitchell and Elcombe, 1986]. Evidence for the dicarboxylic 
acid-mediated induction of peroxisomes may well explain a number of other 
physiological factors that have been found to induce peroxisome proliferation, such 
as high fat diets [Osmundsen, 1982; Nilsson et ah, 1984], cold adaptation, 
starvation and diabetes [Ishii et ah, 1980; Horie et ah, 1984].
It may well be possible that the above sequential mechanism put forward by 
Sharma and co-workers for peroxisomal 6-oxidation, may not be dependent on 
cytochrome P450 4A1 induction, thus suggesting a casual relationship between the 
two phenomena. An alternative mechanism is possible whereby the commonality is 
related to structurally similar regulatory elements in the 5' upstream flanking 
regions of the cytochrome P450 4A1 and acyl-CoA oxidase genes. This would 
imply the peroxisome proliferator may directly interact with the common regulatory 
sequences or indirectly modulate gene expression by lipids derived as a direct result
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of inhibition of mitochondrial fatty acid 6-oxidation described above or from lipids 
displaced from fatty acid binding proteins [Cannon and Eacho, 1991]. If this 
alternative mechanism is plausible, then this commonality of gene expression may 
also rationalise why many proteins are induced by peroxisome proliferators and the 
so-called peroxisome proliferator domain may simply reflect the existence of 
common regulatory elements in what would appear to be functionally unconnected 
proteins. This alternative mechanism may also provide an explanation as to why 
several structurally diverse inducers of cytochrome P450 4A1 and acyl-CoA oxidase 
exist, in that the peroxisome proliferators may not all directly interact with the 
inducible genes but indirectly act by influencing lipid disposition or a common 
perturbation of lipid biotransformation.
1.9 Species Differences in Response to Peroxisonæ 
Proliferators
There exists pronounced species difference in xenobiotic-induced peroxisome 
proliferation and this has rendered the extrapolation of data from other species to 
human, in assessing risk involvement rather difficult. Extrapolation of rodent 
toxicity data to assess potential human risk, following exposure to peroxisome 
proliferators requires certain pre-conditions. Amongst such conditions, is the need 
to consider whether such changes occurring in rodents represent a rodent specific 
phenomenon or a species common response.
Some of the species that have been examined for their response after challenge 
by various peroxisome proliferators, include various rat strains, hamster, dog, 
rhesus monkey, guinea pig, mice, ferret, rabbit, marmoset and humans [De La 
Iglesia et al., 1982; Gray and De La Iglesia, 1984; Orton et al., 1984; Reddy et 
al., 1984; Gariot et al., 1983; Makowska et al., 1991]. The results obtained have 
so far revealed that higher mammalian species are considerably less sensitive than 
rats, or totally insensitive to the effects of known peroxisome proliferative agents at
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tolerated or therapeutic doses. Thus, compounds such as cloburazit, gemfibrozil, 
fenofibrate, which cause as much as a 10-20 fold increase in rats, cause only slight 
increases, or no change in dogs and non human primates at much higher dose 
levels. Similar differences between rats, mice and higher mammalian species have 
been reported for DEHP and trichloroacetic acid [Elcombe et al., 1985; Elcombe 
and Mitchell, 1986] and this was also reflected in both laurate oj—hydroxylase and 
peroxisomal B-oxidation activities [Lhuguenot, 1988]. Caution must be shown 
when categorising rodents as sensitive species to peroxisome proliferators [Stott,
1988] since this may be misleading because, guinea pigs which are non-responsive, 
hamsters which are weakly responsive, and rats and mice which are highly 
responsive species, all belong to the order rodentia.
The induction of peroxisome proliferation in humans resulting from therapy with 
several hypolipidaemic agents appear to be questionable and it may be speculated 
that peroxisome proliferation is either a species-dependent or a dose-dependent 
phenomenon. With respect to non-human primate toxicity studies, dubious, if not 
misleading information may be generated when using excessively high doses in 
comparison to the relatively low levels employed in human therapy. It should be 
noted that peroxisome populations in human liver vary considerably in number and 
volume densities, hence complicating the evaluation of peroxisome numbers.
The only substantiated report of a chemically induced increase in the number of 
peroxisomes in humans was made by Hanefeld et al. [1983]. A morphological 
analysis of liver biopsy tissue obtained from hyperlipidaemic patients receiving a 
therapeutic dose level of clofibrate (20-40 mg/kg/day) revealed a 1.5-fold increase 
in the peroxisome number. Likewise, a 23% increase in the number of 
hepatocellular peroxisomes in hypolipidaemic patients receiving therapeutic dose 
levels of gemfibrozil or fenofibrate have also been reported [Gariot et al., 1983,
1987]. Liver peroxisomal proliferation ascribed to chronic cumulative leakage of 
phthalate ester plasticizers from dialysis tubing and haemodialysis transfusion
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containers was also reported in patients treated by haemodialysis for more than one 
year [Ganing et al., 1984]. Similarly, prolonged use of clofibrate in the treatment 
of patients with myocardial infarction was investigated in a 5-year US Coronary 
Drug Project in 1975, but the results were inconclusive and have since restricted the 
use of clofibrate reflecting doubts about the effectiveness of its therapeutic action 
and the possibility of latent side-effects
Interspecies differences in the response to peroxisome proliferators demonstrated 
in vivo, have likewise been reproducible in vitro, using cultured hepatocytes 
[Mitchell et ah, 1985; Allen et al., 1987; Hertz et al., 1987]. This was in contrast 
to earlier suggestion that phylogenetic differences in the responses could be 
attributed simply to interspecies differences in the pharmacokinetics in handling 
these compounds [Berge et al., 1984]. Thus rat and mouse hepatocyte cultures 
were found to respond to peroxisome proliferators, whereas guinea pig, marmoset 
monkey, cynomologus monkey and human hepatocyte cultures were not responsive.
In general, the sensitivity of species to peroxisome proliferators followed the 
trends: rats, mice > > hamster > guinea pig > rabbit > dog, primates including 
man. On the basis of limited studies in humans, it has been argued by some 
researchers that humans are at limited risk from the carcinogenic effects of 
peroxisome proliferators. This may be a reasonable argument, but to be convincing 
peroxisome proliferation must be proven as the cause of the carcinogenic response.
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1.10 Objectives of Thesis
In recent years, growing concern has arisen with respect to the long term 
exposure of man to hypolipidaemic agents and many industrial chemicals that have 
been shown to induce peroxisome proliferation. Such concern is largely based on 
the ever increasing evidence that these compounds constitute a class of hepatic 
carcinogens, at least in rodents. The phenomenon of peroxisome proliferation has 
invariably been associated with induction of member(s) of the cytochrome P450 4A 
subfamily proteins, a relationship which at present is still not well defined. 
Accordingly, the main objectives of this thesis are three-fold:
1- To further substantiate the mechanistic interrelationship between peroxisome 
proliferation and co-induction of cytochrome P450 4A1 by employing stereoisomers 
of a clofibrate analogue.
2- To characterise the expression of the human orthologous form(s) of 
cytochrome P450 4A subfamily in human liver with structural comparison to the 
well-characterised rat form. This, I hope, will serve as a preliminary step to better 
understanding of the implications of extrapolating animal data to humans.
3- A recently proposed alternative mechanism of co-regulation of cytochrome 
P450 4A1 and acyl-CoA genes of the peroxisome proliferator domain suggests it 
may be mediated through the recently described peroxisome proliferator activated 
receptor (PPAR). It may well be that fatty acids are natural ligands to this receptor. 
Accordingly, I have therefore explored the use of perfluoro-fatty acids which are 
also peroxisome proliferators and may mimic the natural ligands in vivo, a 
combination of characteristics which make them highly useful in studies designed to 
reveal the mechanism of peroxisome proliferation.
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CHAPTER TWO
Isolation, Purification and Characterisation of Clo fibrete- 
Indu cible Cyh  ch rame P450 4AI (452) In Ihe Male Rat and 
Characterisation of a Corresponding Antibody
Isolation, Purification and Characterisation of 
Clofibrate-lndücible Cytochrome P4S0 4A1 (P452) in 
the Male Rat and Characterisation of a Corresponding 
Antibotfy
2.1 Introduction
The cytochrome P450-mediated mixed-function monooxygenases of mammalian 
liver microsomal membranes are of central importance in the metabolism of a wide 
range of xenobiotics and steroid hormones, including many drugs, environmental 
pollutants and carcinogens [Hietanen eta l., 1982; Murray and Reidy, 1990]. These 
enzyme systems are also present in many other tissues and in a wide variety of 
organisms [Lu and West, 1980; Nebert and Negishi, 1982]. Much progress has 
been made in recent years in understanding the importance of such enzymes with 
the advent of methodologies for purification and resolution of these isozymes from 
hepatic and extra-hepatic tissues of a number of species.
One of these isozymes, cytochrome P450 4A1 (formerly termed P452), is 
induced following pretreatment of animals with the hypolipidaemic agent, 
clofibrate, (ethyl 2-(p-chloro-phenoxy)isobutyrate [Gibson ef af., 1982]. Induction 
resulted in significant and selected increases in cytochrome P450 levels with the 
cytochrome P450 4A1 having a high activity towards the w— and (w—1)- 
hydroxylation of fatty acids such as lauric acid [Tamburini et al., 1984; Bains et 
al., 1985; Lake etal., 1984b; Sharma eta l., 1989].
The initial methodology employed to purify this isozyme was described by
Tamburini et al., [1984] and subsequently by Hardwick et al., [1987]. The
nomenclature of cytochrome P452 was originally based on the wavelength
absorption maxima of the ferrous-carbon monoxide adduct of the haemoprotein and 
was alternatively designated as P450 LA^  ^ by Hardwick and co-workers, to reflect
the catalytic activity of the isozyme. More recently, a nomenclature based on
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divergent evolution has been proposed [Nebert et al., 1987; 1991] and the above 
enzyme redesignated cytochrome P450 4A1. Highly purified cytochrome P450 4A1 
isolated from the hepatic microsomes of clofibrate-pretreated rats has been 
compared to the major isozymes isolated from hepatic microsomes derived from 
phénobarbital- and fi-naphthoflavone-treated rats [Tamburini et al., 1984]. This 
comparison indicated marked structural, immunological, catalytical and 
spectrophotometric differences between the three forms, indicating the uniqueness 
of the cytochrome P450 4A1 haemoprotein.
Several of the cytochrome P450 isozymes are present in detectable constitutive 
levels which are readily modulated by xenobiotics. To study the basal and induced 
levels of the cytochrome P450 4A1 in tissues of various species such as those from 
the rat (Chapters 3 and 4), guinea pig (Chapter 4) and human (Chapter 5), a 
sensitive and quantitative assay system was required. Accordingly, this study was 
initiated with a view to isolating and purifying to electrophoretic homogeneity the 
major clofibrate-inducible cytochrome P450 isozyme. The procedure described in 
this chapter is the most up-to-date methodology applied in our laboratories to obtain 
cytochrome P450 4A1 in a highly electrophoretic homogeneous form and of greatly 
improved yield. As such the purified protein was then used to reboost a previously 
immunised sheep and the polyclonal antibody obtained further characterised for use 
in immunological studies. It is worth mentioning here that such an antibody has 
been previously used to isolate a full length cDNA coding for cytochrome P450 
4A1 [Hardwick ef 1987; Eamshaw etal., 1988].
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2.2 Materials and Methods
2.2.1 Chemicals
The chemicals and materials used in these studies are listed below under the 
various suppliers. Analytical grade solvents were either supplied by the British 
Drug Houses Ltd (Poole, Dorset, UK) or Fisons (Loughborough, Leicestershire, 
UK).
Amersham Radiochemicals (Buckinghamshire, UK): [l-^^C] Lauric acid.
British Drug Houses Ltd (Poole, Dorset, UK):
Ammonium persulphate, ammonium sulphate, citric acid, cyanogen bromide, 
EDTA, glycine, sodium dodecyl sulphate, sodium cholate, potassium chloride, 
potassium cyanide, potassium phosphate, sodium carbonate, sodium dithionite 
sodium potassium tartrate, sodium hydrogen carbonate, sodium succinate, sodium 
azide, sucrose, sodium sulphate, magnesium chloride.
Fisons (Loughborough, Leicestershire, UK):
Glacial acetic acid, acetone, diethylether, absolute ethanol, glycerol, hydrochloric 
acid, hexane, methanol, trichloroacetic acid, acetonitrile, ethylacetate, sodium 
hydroxide.
Pharmacia Fine Chemicals Ltd. (Milton Keynes, UK):
DEAE-sephacel, hydroxylapatite, sepharose 4B.
Sigma Chemical Co. Ltd (Poole, Dorset, UK):
2-mercaptoethanol, bromophenol blue, coomassie brilliant blue R-250, N,N- 
tetramethylethylenediamine (TEMED), Triton X-100, diaminobenzidine chloride, 
Tween 20, bovine cytochrome oxidase, bovine serum albumin, L-a-dilauroyl 
phosphatidylcholine (DPLC), clofibric acid, cytochrome c, dithiothreitol (DTT), 
lauric acid, NADH, NADPH, trizma base, 30% (v/v) hydrogen peroxide solution, 
cyanogen bromide-activated sepharose 4B, phénobarbital, 3- methylcholanthrene.
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Other suppliers:
Nitrocellulose filters (Anderman and Co Ltd. Kingston-upon-Thames, UK); Dialysis 
tubing (FSA Supplies, Loughborough, Leicestershire, UK); acrylagel and 
bisacrylagel (National Diagnostics, Aylesbury, UK); emulgen 911 (KAO Atlas 
Company, Tokyo, Japan); 3MM blotting paper and DEAE cellulose (Whatman, 
Maidstone, Kent, UK); slab gel apparatus (Hoefer Scientific Instruments, 
Newcastle, Staffs. UK); power packs (BioRad, Watford, Herts. UK); amicon 
ultrafiltration cell, model 8400 (Amicon Corp. Danvers, USA); flat well supreme 
series microplates (Alpha Laboratories, Eastleigh, Hampshire, UK).
2.2.2 Animals and drug pretreatment
Male wistar albino rats (150-2(X)g body weight. University of Surrey Breeders) 
were housed in cages with sawdust bedding and allowed food (Spratts Animal Diet 
No. 1) and water ad libitum. A twelve-hour light/ dark cycle was maintained at 
22°C and 50% relative humidity. The animals were dosed with sodium clofibrate 
(250 mg/kg i.p in 0.9% (w/v) saline) once daily for three days and sacrificed on the 
fourth day, i.e one day after the last injection.
2.2.3 Isolation o f hepatic microsomes
Rats were sacrificed by cervical dislocation and the livers were quickly removed 
perfused with 0.9% (w/v) ice-cold saline, blotted dry and weighed. Livers from 
thirty rats were pooled together, scissor-minced and homogenised in ice-cold 0.25M 
sucrose using a Potter-Elvehjem glass-teflon homogeniser and adjusted to 25-33% 
(w/v) with the same sucrose solution. At this s t^e , aliquots of whole liver 
homogenate were fi'ozen at -8CPC for subsequent analyses. All subsequent stages 
were carried out at 4®C.
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The homogenate was centrifuged in a JA-17 rotor in a Beckman J2-21 centrifuge 
at 12,600g for 30 min to remove cell debris and mitochondrial fractions. The 
resulting supernatant was subjected to a further ultra-spin at 105,000g for Ih in a 
Beckman preparative ultracentrifuge, model L7-65 (Beckman Co., USA), using a 
60-Ti rotor. Aliquots of the cytosol were also frozen at -80®C in case it was 
required. The microsomal pellet was resuspended in ice-cold 50mM potassium 
phosphate buffer, pH 7.25, containing 20% (v/v) glycerol and aliquoted out in 0.5- 
1ml volumes in eppendorfs and stored at -80®C until required. Under these storage 
conditions, enzyme activities remained stable for several months.
2.2.4 Solubilisation o f hepatic microsomes
Although the solubilisation of functional membrane proteins is a central task in 
modem membrane biochemistry, systematic experimentation directed at achieving 
this goal has not been successful. However in the present work, sodium cholate 
was employed because of its physico-chemical properties (Table 2.1).
In the initial solubilisation reaction medium, 21% (w/v) sodium cholate stock 
was used to achieve a final concentration of 1.8% (w/v). Solubilisation was carried 
out under an atmosphere of nitrogen at 4®C and at a microsomal protein 
concentration of 10 mgml"^. The appropriate volume of the 21% (w/v) sodium 
cholate stock solution was added under these conditions dropwise with stirring over 
20 min and then left for a further period of 40 min. The mixture was then 
centrifuged at 35,0(X) rpm for Ih in a 50 Ti-rotor head in the Beckman centrifuge. 
The pale pellet was discarded and the reddish supernatant diluted with the 
appropriate buffer to give a suspension having a final cholate concentration of 0.6% 
(w/v). An aliquot from this pool was taken out for total cytochrome P450 and 
protein determinations. The remaining material was processed immediately on a 
previously prepared 8- aminooctyl sepharose 4B affinity chromatography column.
51
Table 2.1 Properties of sodium cholate as detergent
Property Data
Monomer molecular weight 431
Micelle molecular weight 1700
Critical micelle concentration (mM) 8.0
Critical micelle concentration [ % (w/v)] 0.36
Dialysability Yes
Suitability for ' ’ charge fractionation’ ’ No
Binds divalent cations Yes
Significant absorbance at 280 nm No
Interference with protein assays No
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2.2 .5  General column chromatography procedures
a) CoJunm oourina and équilibration
A small volume of column equilibration buffer (l-5ml) was poured into the 
bottom of an assembled chromatography column of the desired dimensions. The 
buffer was partially allowed to run through the outlet tap to displace any air trapped 
under the column bed. With the outflow fully closed, and the reservoir assembled 
in the pouring mode, the chromatography medium was carefully poured into the 
column as a 20% (v/v) suspension.
After allowing the medium to settle for 12h in the column, adequate packing 
was achieved under a constant pressure head at the flow rate required during 
chromatography. All chromatography columns were equilibrated with at least 3 
column volumes of equilibration buffer, during which time the pH of the eluting 
buffer was regularly monitored.
b) Samide loadiae and elution
About 5000-6(XX) nmol of cytochrome P450 were loaded per packed column 
(2.6x38 cm). While loading, the columns and reservoirs were covered in 
aluminium foil to minimise light-dependent haem degradation. The flow rate was 
adjusted to 20-30ml h"  ^ and the loading eluate was retained to check if the 
cytochrome P450 was indeed retained by the column.
c) UHraGItiation o f pooled fractions
An Amicon PM-30 membrane of molecular weight exclusion of 30 kDa, was 
routinely used and was placed in an Amicon ultrafiltration cell of 350ml capacity 
(Amicon Corp., Danvers, U.S.A.). Prior to ultrafiltration, the assembled chamber 
was filled with distilled water and attached via a high pressure tubing to a nitrogen 
cylinder. A constant pressure of 20psi was then applied to force water through the 
amicon membrane. This procedure was repeated twice before introducing the 
protein-containing pooled fractions. Ultrafiltration was accomplished using 30psi
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pressure. The eluate was checked to ensure the membrane wasn’t flawed or the 
chamber incorrectly assembled. The chamber was maintained throughout at 4®C by 
placing it on a tray of ice on a magnetic stirrer to prevent the membrane pores from 
clogging up.
The resulting concentrate was poured into prepared dialysis tubings of 
appropriate lengths as described below and dialysis carried out at 4°C. A minimum 
of three changes of the dialysis buffer (3L each) was found adequate, with 12h 
period between changes. On each occasion the dialysis container was wrapped up 
in tin foil to minimise degradation of the cytochrome P450.
d) Préparation o f dialysis tubins
The dialysis tubing was cut into pieces of convenient length (usually 10-20 cm) 
and boiled for 10 min in a large volume of 2% (w/v) sodium bicarbonate and ImM 
EDTA, pH 8. The tubing was then rinsed thoroughly in distilled water and boiled 
for another 10 min in ImM EDTA, pH 8. After allowing the tubing to cool to 
room temperature, it was then stored at 4®C until required. From this point onward 
it was important not to handle the tubing without gloves and each time before use, 
both the inside and outside of the tubing was washed with distilled water.
2,2 .6  8 ■'Aminooctyl Sepharose 4B Affinity Chromatography
a) Meibod o f synthesis
Diaminooctane was coupled to sepharose 4B utilising cyanogen bromide 
activation as described by Cuatrecasas [1970]. Finely divided cyanogen bromide 
(lOOg) was added with stirring to 4(X) ml (packed volume) of sepharose 4B present 
as a 1:1 suspension in distilled water. The pH and temperature were maintained at 
11 and 20®C respectively by either using a ION sodium hydroxide solution or by 
adding ice. When the pH of the solution no longer showed a tendency to drop, 
large amounts of ice were added, followed by rapid washing under suction with 3L
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of 50mM sodium carbonate/bicarbonate buffer, pH 10, on a sintered glass funnel. 
The activated sepharose 4B was then transferred into a beaker containing 400ml of 
25% (w/v) diaminooctane adjusted to pH 10, and gently stirred at 4^C for 20h. 
The derivatised sepharose 4B was washed on a sintered glass funnel consecutively 
with 3L of the above buffer, followed by distilled water and lOOmM potassium 
phosphate buffer, pH 7.25, containing 20% (v/v) glycerol, 0.7% (w/v) sodium 
cholate, ImM dithiothreitol, ImM EDTA, 2^M FMN, and was stored in the last 
buffer containing 0.02 % (w/v) sodium azide at 4 ®C.
b) Method o f column neeeaeration
To achieve a successful regeneration, it was important to elute NADPH 
cytochrome P450 reductase and cytochrome b$ whilst packed in a column by using
the appropriate buffers. Following column chromatography, the media was 
transferred to a sintered glass funnel and washed consecutively under suction (with 
occasional stirring) by utilising 2L of each of the following: KXlmM potassium 
phosphate buffer, pH 7.25, containing 0.4% (v/v) emulgen 911; the same buffer 
containing 0.4% sodium deoxcholate; distilled water; 10% (v/v) aqueous dioxane; 
distilled water again and finally 500mM potassium phosphate buffer, pH 7.25, 
containing 0.7% (w/v) sodium cholate, ImM dithiothreitol, ImM EDTA and 2/xM 
FMN.
c) Column Loadine and Elution
The solubilised microsomal supernatant derived above, was applied to two 
columns of 8-aminooctyl sepharose 4B (2.6x38 cm) previously equilibrated with 3 
column volumes of buffer A (lOOmM potassium phosphate buffer, pH 7.25, 
containing 20% (v/v) glycerol, ImM EDTA, ImM dithiothreitol, 2pM FMN, 0.6% 
(w/v) sodium cholate). Upon loading, a dark red band (cytochrome P450) was seen 
to form at the top of the column. Loading was terminated when the band had 
increased to occupy a third to half the column. The columns were then washed with 
at least 3 column volumes of buffer A in which the sodium cholate concentration
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had been decreased to 0.42% (w/v) to remove unadsorbed protein. Cytochrome 
P420 and membrane lipids were also eluted at this stage.
Elution of cytochrome P450 was achieved by washing the columns with buffer B 
(lOOmM potassium phosphate buffer, pH 7.25, containing 20% (w/v) glycerol, 
0.33% (w/v) sodium cholate, ImM dithiothreitol, ImM EDTA, 2pM FMN and 
0.08% (v/v) emulgen 911), whereupon the dark red band was seen to migrate 
slowly and sharpen upon descending the column. The cytochrome P450 content of 
eluted fractions was routinely monitored spectrophotometrically at 417nm. 
Fractions displaying an absorbance greater than a third of the elution peak value 
were pooled and dialysed against two successive 3.5L volumes of buffer C (20mM 
potassium phosphate buffer, pH 7.25, containing 20% (v/v) glycerol, 0.2% (v/v) 
emulgen 911), for 12-15 h period. The high absorbance of emulgen 911 at 280nm 
present in subsequent buffers prevented the rapid estimation of the purity of 
cytochrome P450 by utilising the 417/ 280 nm absorbance ratio.
2 .2 .7  DEAE Sephacel Anionic Exchange Chromatography
a) Preparation o f media
The required amount of the medium was transferred to a sintered glass funnel 
and washed under gravity with distilled water to remove the storage solution. The 
chloride counter ion was exchanged with phosphate and the medium set to the 
correct pH by transferring an excess volume of 400mM potassium phosphate, pH 
7.25. This was left standing for 24h before replacing the buffer with the 
equilibration buffer and packing the column.
b) Reseneration o f column watenal
DEAE sephacel was regenerated by standing the media in an excess volume of 
400 mM potassium phosphate, pH 7.25, overnight, followed by extensive washing 
with 5(X)mM sodium chloride and distilled water. The medium was stored in
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400mM potassium phosphate buffer, pH 7.25, containing 20% (v/v) methanol, at
40c.
c) Loadine and Elution
Pooled and dialysed cytochrome P450 concentrate from 8-aminooctyl sepharose 
4B column chromatography was applied onto a DEAE sephacel column (30x2.6 cm) 
previously equilibrated with the last dialysis buffer and the flow rate adjusted to 30- 
40 ml/h. Upon loading, a tight red band developed at the top of the column. 
However, some of the cytochrome P450 did not stick to the column but passed 
straight through. When loading was completed, the column was washed with at 
least four column volumes of 5mM potassium phosphate buffer, pH 7.25, 
containing 20% (v/v) glycerol, 0.2% (v/v) emulgen 911. This process eliminates 
some hydrophobic molecules that are still present on the column. Elution of 
cytochrome P450 was then achieved by washing with the same buffer in which the 
ionic strength had been increased stepwise from 5mM to 50mM in increments of 
5mM. Cytochrome P450 in the eluate was detected and pooled as judged by their 
purity on calibrated 10% (w/v) SDS-PAGE gels. Aliquots from each pool was 
assayed for total cytochrome P450 and protein contents.
2.2.8 Hydroxylapatite (Biogel H I)
a) Preparation o f media
The required amount of hydroxylapatite was transferred into a beaker containing 
an excess of the equilibration buffer and gently swirled into suspension. The gel 
was allowed to settle, leaving a cloudy buffer volume above, containing slowly 
sedimenting ’fines’, which were decanted. Fresh buffer was added, and the 
procedure repeated 4 times. The medium was discarded after use.
b) Loadine and Elution
The pooled and dialysed cytochrome P450 concentrate obtained from the DEAE
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sephacel column was applied onto a prepared hydroxylapatite column (2.6x15 cm). 
The column was washed with 2 volumes of buffer D (5mM potassium phosphate 
buffer, pH 7.25, containing 20% (v/v) glycerol and 0.2% (v/v) emulgen 911). 
Cytochrome P450 was eluted with a linear gradient of the same buffer ranging from 
5-150 mM concentrations. Fractions eluted were monitored at 417nm and an 
aliquot from every second tube was used to check the purity on calibrated 10% 
(w/v) SDS-PAGE gels and pools were made based on the information obtained. 
Pooled fractions were dialysed against two successive 3L volumes of buffer D for 
12h period.
2.2.9 Total CO-Discemible Cytochrome P450 Determination
Cytochrome P450 was routinely determined as the reduced carbon monoxide 
adduct [Omura and Sato, 1964]. Microsomes were diluted with 50mM potassium 
phosphate buffer, pH 7.25, containing 20% (v/v) glycerol to give a protein 
concentration of 1-2 mg/ml. Reduction to the ferrous form of the haemoprotein 
was achieved by the addition of a few milligrams of sodium dithionite. The sample 
was then split between two quartz cuvettes and a baseline recorded using a Kontron- 
Uvikon 860 spectrophotometer (Kontron Instruments Ltd, Switzerland). Carbon 
monoxide (30 bubbles at approximately one per second) was gassed through the 
sample cuvette only and the contents of the cuvettes were rescanned between 4(X)- 
500nm. The concentration of cytochrome P450 was calculated using the difference 
extinction coefficient (450-490 nm) of 91 mM"^cm-l.
2.2.10 Determination o f Cytochrome
Cytochrome b^ was determined from the difference spectrum between NADH-
reduced and air-saturated microsomes (under aerobic conditions), essentially
according to the method of Omura and Sato [1964]. In NADH-reduced microsomes 
cytochrome P450 was mostly in the oxidised form whereas cytochrome 65 was in
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the reduced form. The increment of the molar extinction between 424 and 409nm 
in the difference spectrum was assumed to be 185 mM'^cm'L
The microsomal suspension contained approximately 2mg of protein per ml in 
50mM phosphate buffer, pH 7.25, containing 20% (v/v) glycerol. The mixture was 
saturated with air and split between two cuvettes for baseline recording between 400 
and 5(X)nm, prior to the addition of 25fA of 2% (w/v) NADH in 1% (w/v) sodium 
bicarbonate to the sample cuvette. The sample was rescanned until there was no 
further spectral development at 424nm.
2.2.11 Determination of NADPH-Cytochrome P450 Reductase 
Activity
The activity of the flavoprotein cytochrome P450 reductase was determined by 
the method of French and Coon [1979], according to its ability to reduce 
cytochrome c.
The microsomal sample was diluted with KXlmM Tris-HCl buffer, pH 7.5, to 2 
mg/ml and 200^1 of this together with 1.0ml of cytochrome c (0.46 mg/ml) were 
added to each cuvette. The final volume was 3.0ml after addition of all the other 
components. The reaction was followed at 550nm until a baseline was established 
and then lOO/xl of 40mM NADPH in 1% (w/v) sodium bicarbonate solution (ImM, 
final concentration) was added to the sample cuvette and the initial reaction rate 
was measured. The activity was calculated using the extinction coefficient for 
reduced cytochrome c of 18.5 mM'^cm'^.
2.2.12 Protein Determination
Protein concentration was determined by the method of Lowry et al. [1951] 
using bovine serum albumin (Fraction V , Sigma Co.) as standard.
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2.2.13 Reconstitution Methodology for Assaying Cytochrome P450 
4A1
The metabolism of a model substrate by purified preparation of cytochrome 
P450 was routinely determined using the standard reconstituted system of Haugen et 
al., [1975].
The components of the reconstitution system for lauric acid metabolism were 
added sequentially to achieve the following final concentration or amounts: L-a- 
dilauroyl phosphatidylcholine (30/xg), cytochrome P450 (0.1-0.3^M), purified 
NADPH-cytochrome c reductase (0.5-0.9 U/ml), sodium deoxycholate (50^g/ml), 
50mM potassium phosphate buffer, pH 7.25, magnesium chloride (15mM), 
saturating amounts of lauric acid as substrate (200nmol), and distilled water added 
to the required volume of 1ml.
The system was pre-incubated for 5 min, on a shaking water bath set at 37®C, 
prior to the initiation of the reaction by the addition of NADPH to a final 
concentration of ImM. The reaction was then allowed to proceed for 10 min after 
which it was terminated by the addition of 300/tl of 3M HCl.
2.2.14 Analysis o f Lauric Acid Metabolism byh.p.l.c.
The metabolism of [1-^^C] lauric acid to w— and (w—l)-hydroxylated products 
was evaluated essentially as described by Parker and Orton [1980].
2 ml incubation volume contained [1-^^C] lauric acid (0.1/iCi in 10/d methanol) 
and O.lmM [1-^^C] lauric acid (2(X)mM stock solution in methanol diluted to ImM 
in 0.5M Tris-HCl buffer, pH 7.4). Img of protein was used per assay. The tubes 
were pre-incubated for 5 min at 37®C prior to the addition of 40/d of 40mM 
NADPH to initiate the reaction. Microsomal blanks contained distilled water 
instead of NADPH. Control and treated samples were incubated at 37®C for 10
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min. The reaction was terminated by the addition of 300/d of 3M HCl. 
Incubations were carried out in polypropylene stoppered tubes.
10ml of diethylether was then added to the incubation mixture followed by 
mixing on a rotary shaker for 20 min. The tubes were then spun at lOOOg for 2-3 
min to separate the phases after which the upper (ether) layer was transferred to a 
test tube and evaporated to dryness under a stream of nitrogen. The test tubes were 
sealed with parafilm and stored at -80 ^C until analysed.
The dried ether extracts were reconstituted in 150/d of the eluting solvent (water 
: methanol : glacial acetic acid. 45: 55: 0.05 by volume) of which l(X)/d was then 
injected onto a reverse phase Microbondapak MCH-10 column (30x4.4 cm, Varian 
Associates Ltd, Walton-on-Thames, UK.). The metabolites were resolved using a 
linear gradient of water : methanol (45: 55 containing 0.1% acetic acid) to 100% 
methanol over a 45 min period at a flow rate of 1 ml/min.
The eluate was passed through a Berthold LB 506 C-1 Radioactivity Monitor 
(Lab-Impex, Twickenham, UK), containing a 200/il flow cell and interfaced with a 
microprocessor (Motorola 68B09 CPU). This was linked to a PC IV 286 AT- 
Compact computer (Opus Technology pic, Redhill, UK), enabling quantitative 
analysis of lauric acid metabolism. The (co — 1)- and co—hydroxylated products were 
successively eluted followed by the unchanged lauric acid. The rates of 
hydroxylation were calculated from the fractional conversion of substrate to w— and 
(w— l)-hydroxyl products obviating the need for the estimation of recovery of 
radioactive products. The fractional conversions of the substrate were obtained on 
data print-outs which gave relative percentages after correction for background 
counts. The rate of formation (R) of individual metabolites was quantified using the 
following formula:
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s  (nmol) X m (%)
R  = ----------------------
t (min) X p (mg)
S = amount of original substrate in incubation mixture (nmol) 
m = percentage of substrate converted to metabolite 
t = incubation time in minutes 
p = amount of protein per incubate (mg)
R is then expressed as: nmol product formed/ min/ mg protein.
Alternatively, the rate of product formation may be expressed per nmol cytochrome 
P450 and given by the formula:
E = R/Q where, Q = cytochrome P450 content (nmol/ mg protein); 
R as defined above and E = nmol product formed/ min/ nmol P450.
2,2.15 Antiserum Production, Immunopurification and 
Characterisation
a) Cytochwwe P450 4A1 antibody production
Production of a sheep polyclonal antisera was achieved with a single hepatic 
protein purified as above (cytochrome P450 4A1). The sheep used in this study had 
been previously primed and boosted with this same antigen which resulted in the 
production of a high titre antibody with specificity and avidity [Sharma, 1988; Ph.D 
Thesis, University of Surrey].
In the second boosting experiment (after the monitored antibody level had 
returned to basal levels, approximately 24 months later), 100fig of the highly 
homogeneous antigen (cytochrome P450 4A1) was added to an equal volume of 
non-ulcerative Freunds complete adjuvant containing heat-killed BCG mycobacteria. 
The use of Freund’s complete adjuvant results in a far greater antibody response 
than is stimulated by antigen in a simple water-in-oil emulsion because of the 
greater persistence of the antigenic complex within the tissues of the test animal.
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thus delaying absorption. Similarly the presence of the heat-killed mycobacteria 
serve to stimulate the entire reticuloendothelial system of the animal with the 
droplets slowly removed by the macrophages of this system.
The antigen-adjuvant emulsion is obtained by the double-hubbed needle method. 
This involves repeated aspiration and expulsion from an all-glass syringe fitted with 
an all-metal needle which makes the possibility of attacks by components of the 
adjuvant very remote. The stability of the emulsion was always ascertained by 
placing a single drop in a beaker of cold water and this was not expected to break 
up. Once satisfied as to the above, immunisation was achieved and the levels of 
antibody to cytochrome P450 4A1 were monitored every two weeks from serum 
prepared from large bleeds (approximately 300ml) by the ELISA technique. Serum 
is often preferred to plasma because it is less likely to form cryoprecipitates and was 
stored with 0.1% (w/v) sodium azide as preservative at 2-4®C. Under these 
conditions the serum was stable for at least six months.
b) litre and avidity determinations
An antiserum displacement curve was constructed as an indirect means of 
determining the avidity of the anti-cytochrome P450 4A1 antiserum to its specific 
antigen, in this case cytochrome P450 4A1. Essentially a microtitre plate was 
coated with a fixed amount of the antigen (0.02pmol in 200/il volumes) and 
incubated overnight at 4®C in a humid environment. Following incubation, the 
wells were washed with Phosphate Buffered Saline, pH 7.4, containing 0.1% (w/v) 
gelatin and 0.05% Tween 20, (PBSGT). Various dilutions of the antiserum were 
then prepared in PBSGT ranging from 1:500 - 1:256000 and 200/cl of each was then 
added in triplicates to a section of the wells either alone or with added free antigen 
(0.02pmol), the latter ensuring there was competition between the fixed and free 
antigens fo the antibody binding sites.
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After further incubation of the plate at room temperature for 2h, it was re­
washed with PBSGT and the donkey anti-sheep enzyme-labelled conjugate, 
horseradish peroxidase (200/d/well) was applied at a dilution of 1:5000. After a 
further 2h incubation at 37®C and a PBSGT wash, the substrate (75ml of 0.025M 
citric acid, 0.05M disodium hydrogen phosphate buffer, pH 5.6, containing 30mg 
orthophenylenediamine (OPD) tablet and 30ml of 30% (v/v) hydrogen peroxide was 
added to the plate (150/il/well). Following incubation for 10 min at 37®C, the 
reaction was terminated by the addition of 2.5M sulphuric acid (50/xl/well).
The absorbance of the wells was read at 492nm using a Titertek plate reader 
(Flow Laboratories, UK) and were plotted (after adjustments of the absorbances for 
non-specific binding i.e pre-immune sera values) against the serial dilutions of the 
antiserum on a logarithmic scale yielding two sigmoid curves. The extent of 
displacement of the antiserum dilution curve to the left was used as an indication of 
the avidity of the antiserum to its specific antigen. Likewise, the reciprocal of the 
antiserum dilution producing 50% of the maximum absorbance reading was 
described as the titre.
c) ImmunopunGcation o f cjiocbwme P450 4A1 pofyclonal antibody
Approximately 100/tg of purified cytochrome P450 4A1 was immobilised on 
100fig (300/d) of activated porous silica. It was then reacted with 1ml of antiserum 
diluted with 1ml lOOmM citrate/phosphate buffer, pH 7.0, in a 7ml disposable 
chromatography column. No D823 (Lab M, Bury, Lancs. England). This was left 
on a roller-mixer for 15 min after which the column was washed off with 2.5ml of 
the same citrate/ phosphate buffer, pH 7.0. The adsorbed antibody was eluted by 
reducing the pH in a step-wise manner with 4.5ml of lOOmM citrate/phosphate 
buffer pH’s of 5.5, 4.0 and finally 2.5. Pooled antibody fractions from the various 
pH elutions were equilibrated to pH 5.5 by the addition of 0.5ml of 2.5M acetate 
buffer, pH 5.5.
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Protein concentration of the samples were estimated by measuring the optical 
density at 280nm. Calculations were made based on the information that serum 
contains about 40mg albumin per ml and that at 280nm, Img IgG/ml solution has 
an absorbance of approximately 0.6 units whereas, immune serum contains between 
10-40 mg IgG/ml and at 280nm, a solution of Img IgG/ml has an absorbance of 1.4 
units.
d) Preparation o f IgG -enriched fractions
Immunoglobulin fractions from normal sheep and immunised sera were isolated 
by a modification of the method of Walker and Mayer [1976].
Essentially, 25ml of saturated solution of ammonium sulphate was added 
dropwise from a burette into 25ml of serum in a conical flask, while stirring on ice, 
to achieve a 50% saturation solution. Following this step, the precipitate formed 
was pelleted down at 12,600g for 20 min in a J2-21 Beckman centrifuge. The 
precipitate was then washed three times with ice-cold 1.75M ammoniun sulphate to 
achieve a clean whitish pellet. This ensured albumin, transferrin and Zç proteins, 
including haptoglobin and haemoglobin which may be present, were eliminated. 
The final white pellet was dissolved in 5ml of lOmM potassium phosphate buffer, 
pH 7.0, and dialysed overnight against 5L of water. Dialysis was then repeated 
against 2 x 3L of lOmM potassium phosphate buffer, pH 7.4, over a 16h period. 
The preparation was then loaded onto a DEAE cellulose Whatman DE 52 column 
(5x12 cm), previously equilibrated with the same buffer. The column was washed 
with the same buffer until all the IgG was eluted. Eluted fractions were monitored 
spectrophotometricaUy at an absorbance wavelength of 280nm. The fractions were 
then aliquoted and freeze-dried in quantities of 50-100 mg/vial for each of the pre- 
immune and immune IgG preparations.
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2.2.16 Enzyme-Jinked immunosorl)ent assay (ELISA)
The technique of ELISA as described by Voiler et al. [1978] and modified for 
the quantification of cytochrome P4504A1 by Sharma et al. [1988a] was utilised to 
quantify this protein in microsomal samples.
Microsomes were solubilised by the addition of Img cholate and 0.2mg emulgen 
911 per mg microsomal protein with stirring for 20 min on ice. The solubilised 
microsomes were suitably diluted with O.IM sodium bicarbonate/ carbonate buffer, 
pH 9.6, and 200/xl aliquots loaded onto microtitre plates on protein basis. The 
plates were left overnight at 4®C in a humid box. Subsequently, the plates were 
washed with phosphate buffered saline, pH 7.4, containing 0.1% (w/v) gelatin and 
0.05% Tween 20 (PBSGT). The antisera to cytochrome P450 4A1 or the pre- 
immune sera were diluted in PBSGT as required and applied to the microtitre plate 
at 200/il/ well.
The plates were incubated at 37®C for 2h, re-washed with PBSGT, and the 
donkey anti-sheep enzyme labelled conjugate, horseradish peroxidase (200/d/well) 
was applied and the remaining steps processed as outlined in Section 2.2.15(b). A 
calibration graph using electrophoretically homogeneous cytochrome P450 4A1 was 
constructed between 0 and 0.04 pmol of pure protein. The amount of cytochrome 
P450 4A1 in the microsomal samples was determined from the calibration curve 
after adjustment of the absorbances for non-specific binding (pre-immune sera 
values).
2.2.17 Western blot analysis
Western blotting involves the electrophoretic transfer of separated proteins from 
polyacrylamide gels to nitrocellulose sheets which are then subjected to 
immunological analysis. The methods employed were modifications of the basic 
procedures of Towbin et al., [1979], Burnette [1981] and reviewed by Bers and
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Garfin [19851.
a) Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
The method of Laemmli [1970] was routinely used to resolve the microsomal 
proteins. Electrophoresis was performed at room temperature using a vertical slab 
gel assembly (Hoefer Scientific Ltd) in which the gel was contained in a glass and 
perppex cassette.
All samples were diluted in sample solubilisation buffer, boiled for 2 min and 
subjected to a 10% (w/v) SDS-polyacrylamide gel electrophoresis. The following 
lypholised proteins of known molecular weights in a supplied kit (SDS-7B, Sigma, 
Poole Dorset) were routinely employed:
«2- Macroglobulin 180,000
B— Galactosidase 116,000
Fnictose-6-phosphate kinase 84,000
Pyruvate kinase 58,000
Fumarase 48,500
Lactate dehydrogenase 36,500
Triosephosphate isomerase 26,600
For cytochrome P450 4A1 Western blots, l.Opmol of purified cytochrome P450 
4A1 was loaded per tract as an authentic marker. Samples were in general loaded 
on equiprotein basis and a constant current of 40mA was maintained throughout 
electrophoresis. When electrophoresis was complete, the gels were either stained 
with coomassie R-250 dye for protein visualisation or subjected to immunoblotting 
analysis.
b) Electrophoretic transfer and immunochemical staining
The lower separating gel, having been removed firom the gel cassette, was 
immersed in transfer buffer (20mM Tris-HCl, 150mM glycine, 20% (v/v) 
methanol) for 45 min prior to transfer to nitrocellulose sheet. This was to allow the 
gel to shrink, thus avoiding distortion of the bands during transfer. The transfer
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process was achieved using an electrophoretic transfer apparatus (BIORAD) at room 
temperature and at a constant voltage of 30V overnight.
Following electrophoretic transfer the nitrocellulose sheet was washed in 
phosphate buffered saline containing 1% (w/v) bovine serum albumin and 0.2% 
(v/v) Triton X-100 (PBSBT) for 2h at room temperature. Subsequent washes were 
carried out at this temperature on a shaker. The PBSBT was then removed and 
replaced with fresh PBSBT containing anti-cytochrome P450 4A1 polyclonal 
antibody diluted 1:2000, in 50ml of PBSBT and incubation was left on for Ih. The 
primary antibody was then removed and the nitrocellulose sheet subjected to two 20 
min washes with PBSBT. Donkey anti-sheep enzyme label (horseradish peroxidase) 
was then applied to the filter in PBSBT while shaking for Ih. After further 2x20 
min washes, the nitrocellulose sheet was then developed in O.IM Tris-HCl, pH 7.5, 
containing 0.6 mg/ml 4-chloronaphthol and 1:5000 hydrogen peroxide (30vols). 
The reaction was terminated when judged appropriate by rinsing the filter several 
times with distilled water. This was to ensure that no substrate was left on the filter 
prior to storage. The developed blots were photographed for permanent record and 
quantified by using a CS-9000 Dual Wavelength Flying-spot Scanner (Shimadzu 
Corp, Japan).
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2.3 Results and Discussion
The purification protocol used is represented schematically in Figure 2.1 and a 
typical purification result presented in Table 2.2.
2.3.1 Sodium dodecyl sulphate polyacrylamide gel electrophoresis:
Following a step-wise gradient elution from DEAE-sephacel column, with 
potassium phosphate buffer, pH 7.7, five pools were obtained based on purity of 
individual fractions eluted. These pools were derived from elutions with 5, 10, 15, 
20 to 50, and 150mM concentrations of the buffer. Figure 2.2 shows the purity of 
some of the pools on a 10% SDS-PAGE gel and included two pools of the 15mM 
buffer elution fractions. Based on this information,, further purification steps 
utilised the 15mM pool that showed more homogeneity (track 6). This was loaded 
onto a hydroxylapatite chromatography column and eluted with a linear gradient 
system of the potassium phosphate buffer, pH 7.7, ranging from 5-KX) mM. Three 
main fractions were obtained designated fractions 1, 2, and 3 and their purities were 
checked on a calibrated 10% (w/v) SDS-PAGE gel (data not shown). Fraction 2 
was further processed on another hydroxylapatite column and eluted with 320mM 
phosphate buffer, pH 7.7. This last stage was carried out to minimise the emulgen 
content, a process referred to as desoaping. This final preparation and samples 
from the previous purification steps were separated on a calibrated 10% (w/v) SDS- 
PAGE gel as shown in Figure 2.3.
The purified rat hepatic cytochrome P450 was judged to have a molecular 
weight of approximately 51.5kDa, based on migration on a 10% (w/v) calibrated 
SDS PAGE gel. The homogeneity and extent of purity of this haemoprotein was 
indicated by the lack of protein staining bands elsewhere on the gel. The 
haemoprotein also exhibited electrophoretic mobility in a similar SDS- 
polyacrylamide gel, identical to cytochrome P450 4A1 previously isolated in our 
laboratory.
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5 mM -100 mM KPO4 (pH 7.7) Linear Gradient
Hydroxylapatite Column
5 mM Pool 10 mM Pool 15 mM Pool 20 - 50 mM Pool 150 mM Pool
Elution with 320 mM KPO4 (pH 7.7)
DEAE Sephacel Chromatography
Microsomes
8- Amino-Octyl-Sepharose 4B Chromatography
Solubilised Supernatant
Cytochrome P450 4A1 (P452)
Cytochrome P450
Fraction 1
Cytochrome P450
Fraction 2
Cytochrome P450
Fraction 3
Hydroxylapatite Column
 (Desoaping)______
Figure 2.1 Flow chart for the purification of cytochrome P450 4A1 isolated 
from the endoplasmic reticulum of clofibrate-induced rats
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180 K 
116K 
84K
58K
48-5K
30.5K 
20.0K
Figure 2.2 SDS-PAGE analysis on a 10% (w/v) gel of some pools obtained 
following DEAE sephacel chromatography of cytochrome P450 was performed as 
described in Materials and Methods. Track 1, prestained molecular weight markers 
(0.2jug); track 2, 5mM pool (1.5pmol); track 3, lOmM pool (1.5pmol); track 4, 
authentic cytochrome P450 4A1 (5jug); track 5, 15mM pool A (l.Spmol); and track 
6, 15mM pool B (l.Spmol).
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2,3.2 Spectral characteristics and catalytic activity.
Several spectral parameters have been used to delineate differences among 
purified isozymes of rat liver cytochrome P450s. The results from the present 
purification show that the absorbance maxima of the ferrous-CO complex of the 
haemoprotein occurred between 451 and 452nm, for three separate determinations 
(data not shown) and was quite similar to that at 451.5nm, previously reported in 
our laboratory. This preparation also had a specific content of 9.95nmol/mg protein 
which was almost a ten-fold increase over crude microsomal preparation.
Cytochrome P450 4A1 (P452) has previously been demonstrated by several 
workers (including our laboratory) to be induced following pretreatment of animals 
with the hypolipidaemic agent, clofibrate [Gibson et al., 1982, Tamburini et al., 
1984; Bains et al., 1985; Lake et al., 1984a, Sharma et al., 1989]. These workers 
also showed that induction resulted in significant and selective increases in one of 
the cytochrome P450 isozyme levels (P450 4A1) having a high activity towards 
hydroxylation of lauric (dodecanoic) acid at both the w— and (co—l)-positions, the 
former emerging as the predominant metabolite.
The catalytic activity of purified cytochrome P450 4A1 derived from clofibrate- 
induced rats was assessed by way of a reconstituted system. The reconstitution 
media usually contained saturating amounts of purified NADPH-cytochrome c 
reductase (previously prepared in our laboratories from phenobarbitone-induced 
microsomes) and optimal concentrations of dilaurylphosphatidylcholine. Results 
obtained from the reconstitution studies show that the cytochrome P450 4A1 
haemoprotein catalyses both œ— and (w—l)-hydroxylation of lauric acid, a marker 
substrate for this isozyme. The w—hydroxylated product was preferentially formed 
at a rate of 11.2 nmol/min/nmol P450 4A1 compared to 17.32 nmol/min/nmol 
P450 4A1, previously reported in our laboratory for similar purification procedures. 
The reason for such discrepancy was not very obvious, however, previous workers
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included cytochrome bg which has been demonstrated to stimulate lauric acid
hydroxylation mediated by cytochrome P450 4A1. Moreover, the preparation of 
NADPH cytochrome c reductase like that of cytochrome P450 4A1 contained trace 
amounts of emulgen 911 despite attempts of its removal on a hydroxylapatite 
column and this is well known to interfere with catalytic activity assays.
2.3.3 Polyclonal antibody production and inmiunochenncal reactivity
The sheep received a second boosting with lOO^g of purified cytochrome P450 
4A1 almost 24 months after it was last boosted, by which time the anti-cytochrome 
P450 4A1 concentration in the serum had returned to basal levels. The effect of a 
second boosting on the levels of anti-cytochrome P450 4A1 in sheep sera collected 
at two-week intervals is shown in Figure 2.4 and screened by an earlier established 
ELISA protocol [Sharma, 1988; Ph.D Thesis University of Surrey].
Generally, an immunisation programme will yield a number of antisera from 
which one or more must be selected for use in an assay. The criteria for this 
selection are specificity, affinity and titre all of which depend on the requirements 
of such an antiserum. The titre is defined as the reciprocal of the antiserum dilution 
giving half the maximum absorbance value when absorbance was plotted against the 
serial dilutions of the antiserum on a logarithmic scale. A typical antiserum curve 
obtained with bleed number 3 (two weeks after immunisation) is shown on Figure 
2.5A. From such information, the titre was estimated by extrapolation and 
corresponded to a titre value of approximately 1:25,000. This titre value was used 
in subsequent analyses.
An indication of the avidity of the antiserum to its specific antigen (in this 
instance, cytochrome P450 4A1 apoprotein), was demonstrated by constructing an 
antiserum displacement curve as shown in Figure 2.5B. This is a measure of the 
ability of the free antigen to compete with the same antigen bound to a microtitre
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Figure 2.4 Antibody levels in sheep bleeds following reboosting with a 
homogeneous preparation of cytochrome P450 4A1. The point of reboosting is 
indicated by an arrow and bleeds were collected every two-week interval and 
processed as described in Materials and Methods. The antiserum was used in a 
dilution of 1:25k and the enzyme label, 1:5k. The wells were coated with 0.02pmol 
cytochrome P450 4A1 each and values were corrected for non-specific binding with 
pre-immune sera.
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Figure 2.5 Titre and avidity assessments of cytochrome P450 4A1 polyclonal 
antibody levels in the reboosted sheep. The procedures used in obtaining these 
curves have been detailed in Section 2.2.15 of Materials and Methods.
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plate (possibly resulting in a slightly altered conformation), for binding sites in the 
IgG molecules present in the antiserum. The data presented clearly illustrates this 
point as the antiserum dilution curve is displaced to the left, thus indicating a good 
affinity of our prepared antiserum to its corresponding antigen, cytochrome P450 
4A1.
Moreover, the specificity must be the primary criterion; unless an antiserum has 
the appropriate specificity it will be of no value in the assay regardless of its affinity 
and titre. The specificity of the raised antibody was further investigated by Western 
blot analysis and quantification by densitometry (Figure 2.6). The data presented 
was derived from hepatic microsomes of, clofibrate-, phénobarbital-, isoniazid-, and 
3-methylcholanthrene- induced rat livers, representing members of the 4A, 2B, 2E 
and lA subfamily haemoproteins, respectively. The data demonstrates the binding 
of cytochrome P450 4A1 by reacting the antibody with various cytochrome P450 
isozymes as antigen. As would be expected, treatment with clofibrate led to 
several-fold increase in the level of immunodetectable cytochrome P450 4A1, 
whereas 3-methylcholanthrene and isoniazid treatments had the opposite effect in 
suppressing the P450 4A1 level, thus highlighting important changes occurring at 
the molecular level. Phénobarbital had a slight inductive effect but this was not 
significantly different from that of untreated rat.
The low levels of cross-reactivity seen with untreated, phénobarbital-, isoniazid- 
and 3-methylcholanthrene- induced microsomes may be as a result of a combination 
of contributions. Firstly it is highly likely that these microsomes possess low but 
immunochemically quantifiable constitutive levels of cytochrome P450 4A1 or 
secondly that the antibody recognises very similar epitopes to this haemoprotein. 
However, in a similar preparation, no cross-reactivity was noted between 
cytochrome P450 4A1 (P452) antibody and electrophoretically homogeneous 
preparations of P450b and P450c by immunodiffusion analysis [Tamburini et al., 
1984].
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Figure 2.6 Quantitation of cytochrome P450 4A1 in xenobiotic-induced liver 
microsomes by densitometry. A polyclonal sheep antibody (1:2000 dilution) to 
electrophoretically homogeneous rat liver cytochrome P450 4A1 was used in a 
Western blot procedure as described in Materials and Methods. Equivalent amounts 
of pooled microsomal protein (lOjLcg) derived from control- (CONT.), clofibrate- 
(CLOFIB.); phénobarbital- (PB); isoniazid- (INZ) and 3-methylcholanthrene- (3- 
MC) pretreated rat livers (n=3), were separated on a 7.5% SDS-PAGE gel 
electrophoresis. Using authentic cytochrome P450 4A1 as reference (l.Opmol), 
results are expressed as pmol P450 4A1/ mg protein. Data represents the average 
of 2 determinations.
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A typical calibration curve using the purified cytochrome P450 4A1 and raised 
polyclonal antibody, under optimised ELISA conditions, was constructed as 
depicted in Figure 2.7. It could be seen that there was a linear response up to about 
0.04pmol of the purified protein, indicating that very low amounts of this isozyme 
in various biological samples could be detected, as demonstrated in the subsequent 
chapters.
2,3.4 Immunopurification o f cytochrome P4S0 4A1 polyclonal 
antibody
When rat hepatic-derived microsomes was separated on a 7.5% SDS-PAGE gel, 
blotted with our polyclonal antibody to highly homogeneous cytochrome P450 4A1, 
two closely related bands that co-migrated were routinely obtained (Figure 2.8). 
The lower of the two bands, with relative molecular mass of approximately 
51.5kDa, corresponded to cytochrome P450 4A1 and the other band is believed to 
be a closely-related member of the same P450 4A subfamily.
By using immunoaffinity columns, an attempt was made to improve the 
specificity of this antibody reacting with each of these bands. The experiment 
utilizes IgG-enriched fractions eluted from an immunoaffinity column with pH's 
2.5, 4.0 and 5.5 used on Western blotting analysis. The results obtained (data not 
shown) do not appear to improve the specificity of the antibody to the P450 4A1 
apoprotein and therefore suggests that the other co-migrating band may be 
intimately related to this isozyme which presents similar epitopes to the anti­
cytochrome P450 4A1 polyclonal antibody.
In summary, the results presented for the above studies describe the purification 
and partial characterisation of highly homogeneous isoenzyme of the cytochrome 
P450 superfamily from hepatic microsomes of clofibrate-pretreated rats. Based on 
its molecular weight, spectral property (absorption maxima of the ferrous-CO
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Figure 2.7 Typical calibration graph with purified cytochrome P450 4A1 was 
constructed as described in Materials and Methods (section 2.2.16). Each data 
point represent triplicate determinations.
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Figure 2.8 Western blotting analysis on hepatic microsomes derived from 
untreated and clofibrate-induced rat liver was carried out as outlined in Materials 
and Methods. Track 1, authentic cytochrome P450 4A1 (O.Spmol); tracks 2, 
clofibrate-induced liver microsomes (20^g) and track 3, untreated rat liver 
microsomes (20jLtg).
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complex) and catalytic activity towards lauric acid, I believe this isoenzyme is 
cytochrome P450 4AI previously isolated in our laboratory. Other approaches used 
to confirm the identity of cytochrome P450 4A1 have been described elsewhere. 
This includes amongst those described above, uv - visible spectral properties for the 
spin state [Gibson et.al., 1982], peptide fragmentation pattern [Tamburini et al. y 
1984] and molecular properties such as cDNA nucleotide and amino acid sequences 
[Hardwick et aL, 1987; Eamshaw et a l. 1988].
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CHAPTER THREE
Stereochemico/ Specificity in the tnduction o f Cytochrome 
P450 4A t-Dependent Fotty Acid iiydroxyiotion and 
Peroxisome Proiiferation in the Pat
Stereochemical Specificity in the Induction of 
Cytochrome P450 4A1-Dependent Fatty Acid 
Hydroxylation and Peroxisome Proliferation in the Rat
3.1 Introduction
The administration of clofibrate and various other hypolipidaemic agents 
including non-therapeutic compounds such as the phthalate ester plasticizers, results 
in several characteristic hepatic changes in rodents. These induced hepatic 
responses include hepatomegaly, proliferation of smooth endoplasmic reticulum and 
induction of cytochrome P450 4A1-dependent fatty acid ùj—hydroxylase activity, 
peroxisome proliferation with associated changes in enzyme composition and 
alteration in mitochondrial number and structure with concomitant increases in 
certain enzyme levels [Orton and Higgins, 1979; Gibson et al. 1982; Reddy et al. 
1982b; Sharma et al. 1988a]. These subcellular changes are toxicologically 
important as sustained proliferation of peroxisomes in rodents is frequently 
associated with the development of hepatocellular carcinomas and this has led to the 
suggestion that peroxisome proliferators constitute a novel class of non-genotoxic 
hepatocarcinogens [Reddy et al. 1980; Reddy and Lalwani, 1983; Lalwani et al. 
1981].
In particular, the relationship between the xenobiotic-mediated induction of 
cytochrome P450 4A1 and peroxisome proliferation is at present stül not clear. 
Various suggestions have been proposed including the presence of a common or 
related organelle biogenesis [Zaar et al. 1987] or a cytosolic "receptor protein" 
[Lalwani et al. 1983]. The involvement of such a receptor in the induction 
phenomenon would, by its presence or absence, readily explain the well- 
documented tissue, sex and species differences in response to these agents, but the 
existence of this putative receptor still remains a matter of debate [Milton et al. 
1988].
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More recently, screening a mouse liver cDNA library using a probe derived 
from the combined nucleotide sequences of several nuclear hormone receptors, has 
led to the identification of four new members of the hormone receptor family 
[Issemann and Green, 1990, 1991]. Importantly, one of these receptors was shown 
to be activated by the addition of a variety of peroxisome proliferators including a 
number of the hypolipidaemic drugs investigated [Issemann and Green, 1990] and 
was termed the Peroxisome Proliferator Activated Receptor (PPAR). Data obtained 
by these workers suggested that the PPAR could mediate the biological effects of 
peroxisome proliferators as well as explaining the tissue-specific response to these 
compounds.
Other attempts have been made to explore any correlation between the induction 
of several enzymes related to both drug and lipid metabolism following treatment 
with structurally diverse peroxisome proliferators [Sharma et al. 1988a]. Results 
from such studies have led to the proposal that catalytically-competent cytochrome 
P450 4A1 is a necessary prerequisite for peroxisome proliferation by these 
xenobiotics, as verified by more recent studies [Milton et ah, 1990]. The proposed 
initial liver response is induction of microsomal cytochrome P450 4A1, which will 
generate increased cellular concentrations of long chain dicarboxylic acids. As 
these latter metabolites are preferentially degraded by B-oxidation in the peroxisome 
(as opposed to the mitochondrion), it has been proposed that dicarboxylic acids then 
form the proximal stimulus for peroxisome proliferation in an attempt by the cell to 
maintain Hpid homoeostasis [Sharma et al. 1988a].
Based on preliminary studies at ICI Pharmaceuticals (U.K) by Dr Brian 
Holloway, this chapter further examines the above hypothesis proposed by Sharma 
and co-workers, by comparing the relative abilities of optically-active enantiomers 
and the racemate of a clofibrate structural analogue to induce microsomal 
cytochrome P450 4A1 and/or peroxisome proliferation.
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3.2 Materials and Methods
3.2.1 Chemicals.
The optically pure R(-)-isomer, S(+)-isomer and the racemic mixture of a 
clofibrate analogue [2-[4-(4-chlorophenyl)benzyloxy]-2-phenylacetic acid], Figure 
3.1a, were kindly provided by ICI Pharmaceuticals (Macclesfield, U.K) and 
synthesised by Dr M.E. Edge. Lauric acid, NADPH and prestained molecular 
weight markers (stock No. SDS-7B) were purchased from the Sigma Chemical 
Co.(Poole, U.K.). [l-l4C]Lauric acid was supplied by the Radiochemical Centre 
(Amersham, U.K.)
Electrophoretically homogeneous cytochrome P450 4A1 and the corresponding 
anti-serum were prepared in our laboratories as outlined in Chapter Two. Anti­
trifunctional peroxisomal enzyme serum was a kind gift from Dr D. Cinti 
(University of Conneticut Health Centre, CT, U.S.A.). Donkey anti-sheep enzyme 
label, donkey anti-rabbit enzyme label, pre-immune sheep and pre-immune rabbit 
sera were kindly supplied by Guildhay Antisera Ltd (Guildford, U.K.).
3.2.2 Aniim is and Drug Pretreatment
Male Long Evans hooded rats (125-150 grams body weight. University of 
Surrey Breeders) were pretreated by gavage once daily for three consecutive days 
with each enantiomer or the racemic mixture at a dose level of 80mg/kg. 
Compounds were administered in gum tragacanth as vehicle and the control group 
received the same volume of vehicle only. All animals were sacrificed at the start 
of the fourth day, i.e. 24h after the last dose.
The livers, following excision, were rinsed and perfused with 0.9% (w/v) 
sodium chloride to remove contaminating blood, blotted dry and weighed. All 
subsequent steps were performed at 4®C. The livers were scissor-minced and
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a- [2-[4-(-chIorophenyl)benzyloxy]-2-phenylacetic acid
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F igure  3.1 Structures of the clofibrate analogue, 2-[4-(4-chlorophenyl)benzyloxyJ- 
2-phenylacetic acid (a), showing the chiral centre (*) and clofibric acid (b).
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homogenized in 0.25M sucrose using a Potter-Elvehjem glass-Teflon homogenizer. 
The liver homogenate was then adjusted to 25-33% (w/v) by the addition of 0.25M 
sucrose. Aliquots of homogenate were frozen at -80 for subsequent analysis.
The homogenates were then processed by the standard centrifugation procedures 
for preparing microsomal pellet as previously described in the Materials and 
Methods section of Chapter Two. The resuspended microsomal pellet was stored as 
1ml aliquots at -80®C and under these conditions the cytochrome P450 content and 
related enzyme activities remained stable for periods of up to several months.
3.2,3 Spectrophotometric Enzyme Assays
Total homogenate and microsomal protein contents, as well as total carbon 
monoxide-discernible cytochrome P450 were routinely determined by methods of 
Lowry et ah, [1951] and Omuia and Sato, [1964] respectively, as outlined in 
Materials and Methods, Chapter Two.
3.2.4 Determination o f Laurie Acid Hydroxylase Activity
The metabolism of lauric acid to (w—1)- and w—hydroxylated products was 
evaluated by reverse phase h.p.l.c analysis essentially as described by Parker and 
Orton [1980] and as detailed in Materials and Methods, Chapter Two.
3.2.5 Emynw-lJnked Immunosorbent Assay (ELISA)
The technique of ELISA as described by VoUer et al., [1978] and modified for 
cytochrome P450 4A1 was utilised to quantify this haemoprotein in microsomal 
samples, as outlined in Materials and Methods, Chapter Two.
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3.2.6 Western Blot Analysis
The methods employed were modifications of the basic procedures of Towbin et 
a l, [1979], Burnette [1981] and reviewed by Bers and Garfin [1985] which are 
detailed under Materials and Methods, Chapter Two.
3.2 .7  Estimation o f Cyanide-Insensitive Palmitoyl CoA llOxidation
The method utilised was that of Bronfman et ah, [1979]. The oxidation of 
palmitoyl CoA results in the reduction of FAD and NAD+. In mitochondria, these 
are re-oxidised by the cytochrome chain which can be blocked by the introduction 
of cyanide into the assay media. However, in peroxisomes, FADH is re-oxidised 
by molecular oxygen but the NADH accumulates and therefore an assay of NADH 
production in the presence of cyanide serves as a measure of the peroxisomal fatty 
acid oxidase system, as the palmitoyl CoA oxidase is the first and rate limiting 
enzyme in the system.
The assay medium containing, at a final concentration coenzyme A (75^M), 
FAD (180/xM), NAD+ (555/xM), nicotinamide (141mM), DTT (4.2/iM), KCN 
(3^M) and BSA (255;xg/ml) in 60mM Tris-HCl buffer (pH 8.3) was freshly 
prepared and stored on ice. Both sample and reference cuvettes each contained 25^1 
aliquots of rat liver homogenate solubilised with an equal volume of 60mM Tris- 
HCl buffer (pH 8.3) containing \% (w/v) Triton X-100 at 37®C for 2 minutes. To 
the solubilized homogenate was added 2ml of reaction mixture and 0.9ml of the 
above Tris-HCl buffer. The resultant incubation mix was allowed to equilibrate for 
a further period of 5 minutes at 37®C. The reaction was initiated by the addition of 
20fil palmitoyl CoA (75^M) and the change in absorbance at 340nm at 37°C was 
recorded using a Cary 219 spectrophotometer. Results were expressed as nmol 
NADH produced per minute per mg of protein, using the molar extinction 
coefficient of 6220 M"  ^ cm"l for NADH at 340nm.
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3.2.8 Measurement o f Carnitine Acetyl Transferase Activity
Total (peroxisomal and mitochondrial) carnitine acetyl transferase activity was 
measured by the method of Bieber et al., [1972] and Bock et al., [1980]. The assay 
is based on the measurement of free CoA formed during the acyl transfer from acyl- 
CoA to added carnitine; the free CoA being determined by the sulphydryl reagent, 
5,5' -dithio-bis-2-nitrobenzoic acid (DNB).
The 2ml incubation medium contained 200fil of diluted homogenate (1:5 in 
116mM Tris-HCl, pH 8.0 containing 2.5mM EDTA, 0.2% (w/v) Triton X-100); 
100/Lil of acetyl-CoA (2mM in distilled water) and 1.7ml of DNB (0.5mM in the 
above Tris-HCl buffer). The solution was mixed and centrifuged briefly at 
13,000rpm (MSE minicentrifuge). The incubation mixture was then divided 
between two 1ml quartz cuvettes and the reaction initiated by the addition of 10/zl of 
carnitine (l.OM in Tris-HCl buffer). The change in absorbance was recorded at 
412nm, 25°C, in a Cary 219 spectrophotometer. The rate of reaction was 
calculated using the molar extinction coefficient of the product at 412nm of 13,600 
M-^cm'l.
3.2.9 Immunological Detection o f Peroxisomal Trifunctional Protein
a) Enzyme-Linked Immunosorbent Assay (ELISA)
The method previously described for the quantification of cytochrome P450 4A1 
was adapted for the quantification of peroxisomal trifunctional protein.
Freeze-dried sera from rabbits immunised with trifunctional protein was 
reconstituted in phosphate buffered saline (PBS) prior to use. Homogenate samples 
were solubilised with an equal volume of 60mM Tris-HCl buffer (pH 8.3) 
containing 1% (w/v) triton X-100 at room temperature for Ih. The solubilised 
samples were then diluted as appropriate in sodium bicarbonate/ carbonate buffer 
(O.IM, pH 9.6) and loaded on a nanogram-protein basis in a total volume of 200/xl
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per well. A standard curve of solubilised homogenate from control rat liver was 
constructed from 0 to 2.0/xg protein (Figure 3.2).
b) Western Blot Analysis
The SDS-PAGE gel was cast as previously described except that the acrylamide 
and bis-acrylamide concentrations of the upper gel were 3% and 0.13% 
respectively. Samples were solubilised as before and loaded on an equiprotein basis 
(usually 30/xg in 10^1 total volume). The other difference with the protocol 
previously described, was the use of donkey anti-rabbit enzyme label (horseradish 
peroxidase) as the primary antibody was raised in the rabbit.
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Figure 3.2 Immunodetection of hepatic trifunctional protein of the B-oxidation 
spiral in total homogenate of untreated rat. A rabbit polyclonal antibody to this 
protein was used in the ELISA procedure as described in Materials and Methods at 
a dilution of 1:20,000. Linearity in the quantitation of the trifunctional protein was 
established. Each data point is derived from triplicate determinations.
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3.3 Results
The effect of administration of the pure enantiomers and racemic mixture of the 
clofibrate analogue on the liver/body weight ratio (a measure of hepatomegaly), 
total carbon monoxide-discernible cytochrome P450 and specific cytochrome P450 
4A1 isozyme levels are presented in Table 3.1.
Induction of specific cytochrome P450 4A1 was quantified by employing the 
enzyme-linked immunosorbent assay (Table 3.1). The cytochrome P450 4A1 
isozyme level in the control group was approximately 5% of the total cytochrome 
P450 population, and induction by the isomers and racemate led to 1.5-4-fold 
induction over this constitutive level. The highest fold increase in cytochrome P450 
4A1 was observed after treatment with the R(-)-enantiomer and corresponded to an 
eudismic ratio of approximately 3. Furthermore, the influence of treatment on 
cytochrome P450 4A1-dependent (w—1)- and w—hydroxylation of lauric acid, as 
determined by reverse phase h.p.l.c. analysis is shown in Figure 3.3. The data 
shows preferential induction of the w—hydroxylase activity with the highest fold 
increase of 4 produced by the R(-)-enantiomer and a 1.3-fold induction with the 
corresponding S(+)-antipode. Such a preferential induction of w—hydroxylase 
activity has been previously demonstrated with other peroxisome proliferators 
[Sharma et. al., 1989], and reflects the regioselectivity of the cytochrome P450 4A1 
isozyme for lauric acid w— hydroxylation [Gibson et al., 1982].
Western blotting analysis of hepatic microsomes derived Irom the various 
treatment groups was performed using a sheep polyclonal antibody raised against 
purified rat hepatic cytochrome P450 4A1 (Figure 3.4). In particular, the data 
presented demonstrates that the anti-cytochrome P450 4A1 serum recognises two 
proteins from both control and treatment groups. It appears that the lower of these 
two bands, which is preferentially induced, co-migrates with authentic hepatic 
cytochrome P450 4A1. Furthermore, following treatment (particularly with the R(-)
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F ig u re  3 .3  Stereochemical induction of lauric acid hydroxylation by rat liver 
microsomes. Rats (six animals in control and three in the test groups) were 
pretreated with the clofibrate structural analogues and both w- and (co-1)- laurate 
hydroxylase activities were determined by reverse phase h.p.l.c. as detailed in 
Materials and Methods. Each set of data points is generated from triplicate analyses.
*P< 0.01, **P< 0.005
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-enantiomer, the levels of hepatic cytochrome P450 4A1 as determined by ELISA, 
in addition to the induction of the cytochrome P450-dependent co—hydroxylation of 
lauric acid noted above, approximated more closely to the induction of the lower of 
the two bands. This data therefore lends further support to the conclusion that in 
the liver, the cytochrome P450 4A1 isozyme is represented by the lower molecular 
mass species, as previously observed [Sharma et al., 1989]. From the relative 
intensities of the protein bands judged by visual examination, the R(-)-isomer was 
again the more potent inducer of cytochrome P450 4A1 haemoprotein.
The effect of treatment on peroxisomal and mitochondrial lipid-metabolising 
enzymes is presented in Table 3.2. The data presented are for peroxisomal 
cyanide-insensitive palmitoyl-CoA oxidation (PCOA) and total (peroxisomal plus 
mitochondrial) carnitine acetyl transferase activity (CAT). The R(-)-enantiomer was 
more potent than the S(+)-isomer in inducing peroxisomal B-oxidation activity, the 
induction corresponding to an eudismic ratio of approximately 2.2. Similarly, 
carnitine acetyl transferase activity was also demonstrated to show stereoselectivity 
in the induction process. Although this latter enzyme, unlike palmitoyl CoA 
oxidase, is not a specific peroxisomal marker, much of the observed increase in 
enzyme activity may be ascribed to induction of peroxisomal rather than 
mitochondrial enzyme activity [Zaar et al., 1987]. An eudismic ratio of 
approximately the same magnitude as that for KCN-insensitive palmitoyl CoA 
oxidation was observed (Table 3.2).
The high sensitivity of an adapted ELISA method for the quantification of the 
trifunctional protein would be expected to highlight some differences which may 
otherwise escape detection during visual comparison of the Western blot analysis. 
A preliminary screening on the response of this protein, in the total homogenate 
from various treatments, to the antibody was carried out. The results obtained 
demonstrate a linear interaction was apparent up to approximately 5(X) nanograms 
for both the racemate and R(-)-isomer-treated groups (Figure 3.5) and about 1000
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Figure 3.5 Immunodetection of hepatic tri functional protein of the B-oxidation 
spiral in total homogenate of rats treated with either the R(-)-isomer or the racemic 
mixture of the clofibrate analogue. A rabbit polyclonal antibody to this protein was 
used in the ELISA procedure as described in Materials and Methods at a dilution of 
1:20,000. Linearity in the quantitation of the trifunctional protein was established. 
Each data point is derived from triplicate determinations.
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Table 3.2 Differential induction of palmitoyl CoA oxidase and carnitine acetyl- 
CoA transferase activities by stereoisomers of a clofibrate structural analogue.
Treatment
Palmitoyl CoA oxidation 
(nmol NADH/min/mg protein)
Carnitine acetyl transferase activity 
(nmol CoA/min/mg protein)
Control 4.42 ± 0.91 1.42 ± 0.44
R(-)-isomer 11.67 ± 2.66** 14.68 ± 4.90*
S(+)-isomer 5.20 ± 0.62 2.71 + 0.79*
Racemate 8.71 + 1.42** 6.01 ± 0.61**
R/S activity ratio 2.24 5.42
Values are for mean ± SEM of either six animals (control) or three animals in the 
test groups and treated as detailed in Materials and Methods.
P< 0.01, 0.005.
99
nanograms for the S( + )-isomer (data not shown). Based on this preliminary 
screening procedure, appropriate dilutions were then subjected to the ELISA 
protocol. Results for ELISA-based quantification of the trifunctional protein of the 
peroxisomal beta-oxidation spiral are presented in Figure 3.6, and demonstrates that 
the R(-)-isomer was more potent in inducing this protein (R/S activity ratio of 5.4). 
Further evidence lending support to this latter conclusion was obtained from 
Western blotting analysis using a polyclonal antibody to the trifunctional protein 
raised in the rabbit (Figure 3.7). Because of non-availability of the authentic 
trifunctional protein as a standard, this protein was identified by its co-migration 
with prestained molecular weight markers. The observed molecular weight of 
approximately SOkDa for this peroxisome associated polypeptide agreed with that of 
previous reports [Reddy et. a/. 1981]. Two lower molecular weight proteins were 
also recognized by the antibody to the tri functional protein, and are believed to be 
previously described proteolysis products [Nemali et. al. 1989j.
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Figure 3.6 Induction and immunochemical quantitation of peroxisomal 
trifunctional protein. ELISA determinations were carried out as described in 
Materials and Methods from pooled homogenates (six in control group, three in test 
groups). lOOng of protein were loaded per well from each of the R(-)- isomer and 
racemate-treated groups and 500ng from the S(+)-treatment group. Freeze-dried 
anti-trifunctional enzyme immune serum was reconstituted and diluted 1:20,(XX). 
Data are expressed as (units) mg control animal protein equivalents/ mg protein and
repesents mean ± SEM of 3 to 6 animals in each group. *P< 0.01, **P< 0.001.
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Figure 3.7 Induction and Western blot analysis of the peroxisomal trifunctional 
protein. Rats were pretreated with the R(-)- isomer, the S( + )- isomer or the 
racemate of the clofibrate analogue and Western blot analysis carried out as 
described in Materials and Methods. 30jug of total liver homogenate protein was 
loaded on each track (pooled from 3 to 6 animals) as follows. Track no. : 1 and 6, 
prestained molecular weight standards; 2, control homogenate; 3, R(-)-enantiomer 
pretreatment; 4, S( + )-enantiomer pretreatment; 5, racemate pretreatment.
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3.4 Discussion
It is well established that in vivo treatment with a number of structurally diverse 
hypolipidaemics to susceptible species such as the rat and mouse results in changes 
in liver biochemistry and morphology (Reddy et al., 1980; Bains et al., 1985; 
Sharma et al., 1988a). The results of the present study clearly demonstrates that 
there is a high degree of enantiomeric induction selectivity in lipid-metabolising 
enzymes and that the R(-)-isomer of a clofibrate analogue appears to be the more 
potent of the enantiomeric forms administered. My results also demonstrate the 
close relationship that exists between induction of the microsomal and peroxisomal 
lipid-metabolising enzymes following challenge with these xenobiotics. The 
following induction potency was obvious in all the parameters investigated in the 
present study: R(-)-isomer > racemate >  S(+)-isomer >  control. Moreover, the 
R(-)-enantiomer caused approximately double the inductive effects of the racemate 
suggesting that, at the dose levels administered and the duration of study, it is this 
enantiomeric form that mainly contributes to the observed changes in hepatic 
enzymes.
The induction of cytochrome P450 4A1 is mirrored by the concomitant parallel 
increase in lauric acid hydroxylase activity. Cytochrome P450 4A1 has previously 
been documented as the major hepatic isozyme of cytochrome P450 that exhibits a 
preferential regioselectivity for the w—hydroxylation of lauric acid in the rat 
[Gibson et al., 1982; Sharma et al., 1989], although more recent results have 
indicated that other members of the cytochrome P450 4A subfamily exhibit this 
substrate specificity [Nebert et al., 1991; Gibson and Lake, 1991]. Results 
obtained by reverse phase h.p.l.c. analysis (Figure 3.3), further substantiated the 
phenomenon of enantioselectivity in the induction process and again the R(-)-isomer 
was much more potent in inducing lauric acid w—hydroxylase activity. Very 
clearly, an eudismic ratio of approximately 3 is further evidence for 
enantioselectivity in this process. Hence, although the administration of these
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clofibrate analogues caused rather small increases in total microsomal cytochrome 
P450 content, the large increase in co—hydroxylase activity for lauric acid as 
exemplified with the R(-)-isomer, demonstrates that there are significant changes 
occurring among some constitutive forms present in the rat liver microsomes.
Further support for enantioselective induction is provided by Western blot data 
which demonstrates that both control and induced hepatic microsomes contained two 
cytochrome P450 4A1-related polypeptides that are recognized by the antibody 
(Figure 3.4). These two polypeptides are of unequal intensity with the lower 
molecular mass band predominating in all the various treatment groups. The 
molecular mass of the lower band is consistent with that of authentic rat hepatic 
cytochrome P450 4A1 (51.5 kDa) and the higher band estimated to be 52 kDa. At 
present, the precise nature of the 52 kDa polypeptide is unknown, but is believed to 
be a closely related member of the cytochrome P450 4A subfamily possibly 
cytochrome P450 4A3 [Kimura et al., 1989a]. This observation is based on the 
isolation of a novel P450 cDNA, designated Cyp4A3, isolated from a Xgtl 1 cDNA 
library from clofibrate-treated rat liver by screening with the lauric acid co— 
hydroxylase, 4A1, cDNA probe. Cytochromes P450 4A1 and 4A3 display 12% 
amino acid sequence similarity and are expressed in livers of rats treated with the 
hypolipidaemic drug, clofibrate [Kimura et al., 1989a]. These findings were 
further substantiated by the work carried out by Aoyama et al., [1990], who were 
able to demonstrate laurate hydroxylase catalytic activities for cytochromes P450 
4A1 and 4A3 by cDNA-directed expression using vaccinia virus.
Many critical features of the biological action of xenobiotics arise from their 
interaction with endogenous chiral molecules such as receptors or enzymes and it is 
therefore not surprising that the biological actions of chiral, pharmacologically 
active molecules reside predominantly in one enantiomer [Testa, 1988; Jenner and 
Testa, 1973; Simonyi et al., 1986; Ariens, 1983]. For example, the 2- 
arylpropionic acids, an important group of non-steroidal anti-inflammatory drugs
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(the profen series), contain a chiral centre and in vitro studies on inhibition of 
prostaglandin synthesis demonstrates that activity resides almost exclusively in the 
S(+)-isomer with a eudismic ratio of 160 [Adams et al., 1976]. However, in vitro, 
this activity ratio is dramatically reduced to 1.3, due to the unidirectional metabolic 
inversion of the chiral centre from the inactive R(-)-isomer to the S(+)-antipode 
[Caldwell et al., 1988]. Although the metabolic disposition and potential metabolic 
inversion of the enantiomeric clofibrate analogues described herein have not been 
investigated, it would appear unlikely that metabolic chiral inversion occurs in this 
case as may be deduced from the induction studies reported herein.
The stereospecificity of liver eiizyme induction noted in this study may be 
explained by differences in xenobiotic absorption, distribution or tissue uptake. 
Alternatively, enantiospecific selectivity may reside in the specific interaction of the 
inducer with a chiral intracellular macromolecule, which then initiates the induction 
process. This macromolecule is probably not a classical cytosolic protein receptor 
as was suggested by Lalwani et al., [1983] and subsequently disputed [Milton ef al., 
1988], but may be associated with the 5’-flanking regulatory segments of the 
cytochrome P450 4A1 and/or peroxisomal fatty acid beta-oxidation genes or the 
associated nuclear binding proteins, based on the fact that clofibrate induction of 
cytochrome P450 4A1 is by transcriptional activation of the corresponding gene 
[Hardwick et al., 1987], a concept that will be developed further in Chapter Six 
(Final discussion).
In conclusion, I have been able to demonstrate that there is stereochemical 
specificity in the induction of microsomal cytochrome P450 4A1-dependent fatty 
acid hydroxylase activity. These results identify the R(-)-enantiomer as the eutomer 
and its corresponding S(+)-antipode as the distomer, with the racemic mixture 
intermediary in inducing this enzyme activity. Also an identical enantiomeric 
selectivity was observed for the phenomenon of peroxisome proliferation by these 
compounds. Thus, taken collectively, the above findings are not inconsistent with
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the previously stated hypothesis 1 Sharma et al., 1988a] that cytochrome P450 4A1 
induction and peroxisome proliferation are intimately linked. Whether the observed 
stereochemical selectivity resides in xenobiotic recognition or disposition still 
remains to be determined.
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CHAPTER FOUR
Co-inducfion of Cytochrome P450 4A Subfami/y Proteins 
and Peroxisome Proiiferotion in the Rat and Guinea Pig by 
Perftuora-n-Decanaic Acid fPFDAj
Co-induction of Cytochrome P450 4A Subfamily 
Proteins and Peroxisome Proliferation in the Rat and 
Guinea Pig by Perfluoro-n-decanoic Acid [PFDA]
4.1 Introduction
The perfluoro-fatty acids are widely used in chemical industries as lubricants, 
surfactants, wetting agents and corrosion inhibitors [Olson and Andersen, 1983; 
Bryce, 1964; Shinoda and Nomura, 1980]. The choice of compound to be used for 
a specific purpose is largely dictated by economic factors, performance indices and 
their toxicity. The latter is an important consideration because of the potential 
occupational exposure to workers involved in the production and use of such 
products. Perfluorinated compounds have also been proposed for use as vascular 
replacement fluids and as contrast media in computer-assisted tomography, and as 
such, patients undergoing treatment designed to prevent heart attack are also at risk 
[Takagi ef af., 1991].
Perfluorinated compounds are generally considered to be metabolically inert 
[Clark et al., 1973]. However, recent studies involving the use of 
polychlorotrifluoroethylene (PCTFE), a perhalogenated chlorofluorocarbon, has 
shown that such compounds could be metabolized to carboxylic acid derivatives in 
rats which may be implicated in their toxicity [Brashear et al., 1992; Greene et al., 
1992] The relatively recent discovery that perfluoro-fatty acids also cause a number 
of hepatotoxic effects, raises some questions on their safety [Ikeda et ah, 1983; 
Pastoor et ah, 1987; Harrison et ah, 1988; Just et ah, 1989; Abdellatif et ah, 
1991; Vanden Heuvel et ah, 1991]. In particular, these halogenated hydrocarbons 
produce hepatomegaly (hyperplasia and hypertrophy), peroxisome proliferation and 
induction of smooth endoplasmic reticulum, the latter being accompanied by 
induction of a spectrum of enzymes including the cytochrome P450 superfamily of
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isoenzymes [Nebert et al., 1991]. This spectrum of biological responses is very 
similar to that extensively studied in our laboratory [Gibson et al., 1982; Bacher 
and Gibson, 1988; Sharma et al., 1988a,b; Milton et al., 1990; Chinje and Gibson, 
1991] in the safety assessment of phthalate ester plasticisers, chlorophenoxy acid 
herbicides and lipid-lowering drugs of the oxy-isobutyrate class, such as clofibrate 
and its analogues. Collectively, these chemicals are classified as peroxisome 
proliferators and concern has been expressed about their safety because they are 
non-genotoxic carcinogens in susceptible species, particularly rodents [Reddy and 
Lalwani, 1983], probably as a result of indirect DNA damage caused by oxidative 
stress mechanisms [Elliot et al., 1986; Takagi et al., 1990].
A number of bioassays have been used to assess the genotoxic potential of 
PFDA amongst other similar compounds [Godin et al., 1992] By utilising the 
chromosomal aberration assay, PFDA indicated positive only when conducted in the 
presence of S9 fraction and in an m vivo/ in vitro unscheduled DNA synthesis 
(UDS) assay, it induced S-phase synthesis 48h after dosing [Godin et al., 1992]. 
Although there are no available data on nephrotoxicity of the perfluoro-fatty acids, 
it has been suggested that PFOA has some effects on the kidney [Goldsworthy and 
Popp, 1987]. Generally, the biological effects appear to be of a persistent nature 
[Van Rafelghen et al., 1987] and exposure of rodents has been demonstrated to give 
rise to a peculiar "wasting syndrome" resulting in severe weight loss and 
hypothermia [Langley, 1990]. It has been reported that the body weights of rats 
provided with a diet containing PFDA ceased to increase, even though these animals 
consumed as much food as their control counterparts [Borges et al., 1990].
Much information on the hepatotoxicity of oxy-isobutyrate drugs is available, 
such as species differences in species response [Makowska et al., 1991], dose- 
response relationships [Sharma et al., 1988b] and molecular mechanisms of toxicity 
[Lock et al., 1989; Milton et al., 1990; Gibson, 1989], however, very little 
equivalent information is available for the perfluoro-fatty acids. Accordingly, this
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chapter is aimed at further investigating the biochemical liver and kidney changes 
elicited in response to a representative member of the perfluoro-fatty acids, PFDA, 
and by comparing the information obtained, with better characterised peroxisome 
proliferators, will provide the valuable biological information for their safety 
assessment and ultimately provide a valuable input to choice of product development 
and human exposure.
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4.2 Materials and Methods
4.2.1 Chenücats
Perfluoro-n-decanoic acid (PFDA reciystallised, approximately 99.5% pure), 
was kindly provided by Dr B. Jamot, of the Biochemistry Branch, Toxic Hazards 
Division, Wright-Patterson Air Force Base, Dayton, Ohio, U.S.A.
All other reagents and chemicals used were as previously described in Materials 
and Methods Section (Chapter Two).
4.2.2 Animals and Drug Ptetreatim nt
Male Wistar albino rats (150-200g body weight, University of Surrey Breeders) 
and male Dunkin Hartley guinea pigs (350-450g body weight, David Hall, Burton- 
On-Trent, Staffs.) were housed separately on wood chip bedding in a temperature 
controlled room with an 11-hour/13-hour light/dark cycle. The rats were fed a 
standard rat chow (LADl breeder) and the guinea pig, a diet supplemented with 
vitamin C (FDl breeder + stock). All diets used for feeding were supplied by 
Special Diets Services (Witham, Essex, England). All animals were provided water 
ad libitum through out the experiment.
In all experiments, PFDA treatment consisted of a single i.p administration of 
20 mg/kg body weight dissolved in a propylene glycol-water (l:l(v/v)) vehicle 
delivered in a volume of 1 ml/kg body weight. Weight-matched pair-fed controls 
were given the same vehicle in a volume of lml/1^  body weight and then pair-fed 
to the daily feed consumption record of the appropriate PFDA-treated animals. Ad 
Ubitum~fed control animals received the vehicle only. All the animals were killed at 
the start of the eighth day after commencement of treatment and the livers and 
kidneys were quickly removed. Microsomes were prepared from 33% (w/v) tissue 
homogenate in 0.25M sucrose, as previously described (Chapter Two, Section 
2.2.3).
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4.2.3 Total Protein Determination
Protein content in all instances, was determined according to the method of 
Lowry et al., [1951] and as outlined in Chapter 2, using crystalline bovine serum 
albumin as the standard.
4.2.4 Spectrophotometric Enzyme Assays
Total CO-discemible cytochrome P450 content, cytochrome b$ specific content
and NADPH-cytochrome c reductase activity were determined as outlined in 
Sections 2.2.9; 2.2.10 and 2.2.11, respectively of Chapter Two.
4.2.5 Determination of Lauric Acid Hydroxylation
The metabolism of [l-l'^C] lauric acid to (w—1)- and co—hydroxylated products 
was evaluated using h.p.l.c by employing the method described by Parker and 
Orton [1980] and as outlined in Section 2.2.14, Chapter Two.
4.2.6 Determination o f Alkoxyresorufin-O-Deethyiation
The 0-deethylation of ethoxyresorufin and pentoxyresorufin were determined 
spectrophotometrically, according to the method of Burke and Mayer [1974] and as 
outlined below.
The assay system composed of 2ml of O.IM Tris-HCl buffer (pH 7.8), either 
lOjLtl ethoxyresorufin (0.1 mM stock solution made in DMSG) or 5/d 
pentoxyresorufin (l.OmM stock in DMSG), and an appropriate volume of 
microsomes (equivalent to 0.5-2mg protein). The assay was performed in a 
fluorimeter cuvette placed in a thermostatically controlled cuvette housing of a 
Perkin-Elmer MPF-3 fluorimeter, set at an excitation wavelength of 510nm and an 
emission wavelength of 586nm with slit widths of 10 and 2.5nm respectively. After
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preincubation at 37®C for 2 minutes, a steady baseline with time was recorded. The 
reaction was initiated with lOjitl of 50mM NADPH (ImM final concentration) and 
the production of resorufin with time monitored as the increase in fluorescence at 
586nm. The fluorimeter response was calibrated with multiples of 2/il of resorufin 
standard (lOmM stock solution in DMSO).
4,2 .7  Measurement o f Peroxisomal and Mitochondrial Enzyme 
Activities
Whole liver and kidney homogenates were assayed for the activities of KCN- 
insensitive palmitoyl-CoA oxidation and carnitine acetyl-CoA transferase as outlined 
in sections 3.2.7 and 3.2.8, respectively, of Chapter Three.
4.2.8 Western Blotting Analysis
Western blotting procedures employing polyclonal antisera to cytochromes P450 
4A1 and lA l as well as the trifunctional protein of the peroxisomal 6-oxidation 
spiral, were conducted as previously described (Section 2.2.17, Chapter Two). 
Western blots were also quantified by densitometry using a CS-9(X)0 Dual 
Wavelength Flying-spot scanner (Shimadzu, Tokyo, Japan).
4.2.9 Statistical Analysis
The main effects of treatment (PFDA versus pair-fed) were analysed by two- 
way analysis of variance (ANOVA). Linear regression analysis was used to 
describe the relationship between cumulative feed intake and change in body weight 
at 7 days following treatment and statistical difference between PFDA-treated rats 
and those receiving vehicle was evaluated by simple Students’ f-test for small 
sample size (two-tailed). In all cases, significance levels were set at either 5% (P< 
0.05) or 1% (P< 0.01).
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4.3 Results
4.3.1 General Toxicity o f PFDA
At the dose level investigated (20 mg/kg body weight), PFDA did not show any 
significant variability in body weight change and feed intake over the 7-day period 
following dosing for any of the species studied. Rats receiving this dose of PFDA 
had a cumulative feed intake that was similar to the vehicle-treated group with 
unlimited access to feed (ad libitum-ïèd control). Moreover, these PFDA-treated 
rats did gain slightly more weight than either the ad libitum-^ or the pair-fed 
animals (Table 4.1), although this was not judged to be statistically significant (P> 
0.05). In contrast, male guinea pigs receiving the same dose of PFDA, showed a 
slight decrease in cumulative feed intake which was statistically significant when 
compared to the ad libitum-^  control group. However, these treated guinea pigs, 
like their pair-fed counterparts, did not gain as much weight as those receiving 
vehicle with unlimited feed intake (Table 4.1).
The relationship of cumulative feed intake (grams/ 7 days) to changes in body 
weight, with respect to day zero for the rat was further examined using linear 
regression analysis (Figure 4.1). Similar information was also obtained with the 
guinea pig treatment groups (Figure 4.2). As shown on the plots, the relationship 
was linear within aU the experimental groups.
4.3.2 Some Pathological Changes Associated with PFDA Dosing
The only striking pathological feature of PFDA toxicity in the rat but which 
was not seen in the guinea pig, was enlargement of the liver over the corresponding 
pair-fed group eight days post-dosing. The increase in relative liver weight 
(expressed as percentage of animal body weight) in this species, was about
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Table 4.1 Effects of single dose of PFDA on body weight and cumulative feed 
intake in the male rat and guinea pig
Species Treatment
Group
Initial Body 
Weight (g)
Final Body 
Weight (g)
Change in Body 
Weight (g)
Cumulative Feed 
Intake (g/ 7days)
AL 216.6 ± 19 272.9 ± 19 56.3 ± 1.8 163.1 ± 1.2
RAT PFDA 215.9 ± 14 277.6 ± 14 61.7 ± 1.8 163.8 ± 1.2
PF 225.3 ± 11 278.7 ± 11 53.5 ± 2.8 162.2 ± 0.6
AL 433.4 ± 26 532.7 ± 28 99.3 ± 4.6 299.2 ± 9.8
GUINEA PFDA 450.1 ± 6 517.2 ± 11 67.2 ± 8.4** 271.2 ± 12*
PIG
PF 453.7 ± 10 519.0 ± 13 65.3 ± 7.9** 267.1 ± 28*
Values are reported as the mean ± SEM for six animals per group. Final body weight was 
determined 7 days after treatment as outlined in Materials and Methods (i.e at the start of the 8^  day). 
AL = Ad libitum-kd; PFDA = perfluoro-n-decanoic acid-treated; PF = Pair-fed. *P< 0.05; 
**P< 0.01
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Figure 4.1 Relationship of cumulative feed intake in the rat to change in body 
weight in different treatment groups.
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Figure 4.2 Relationship of cumulative feed intake in the guinea pig to change in 
body weight in different treatment groups.
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1.4-fold over that of its pair-fed control partners (Figure 4.3). Concomitant with 
this effect in the rat, was a decrease in microsomal protein content expressed as mg/ 
gram wet liver tissue. Similarly, the data obtained for hepatomegaly in the guinea 
pig was also included in Figure 4.3 and showed a slight liver enlargement which 
was not statistically significant (P>0.05). No significant changes were observed in 
the relative kidney to body weight ratio expressed as a percentage in either of the 
species examined (Figure 4.4). In the present study, no macroscopical 
hepatocellular observations in these species were investigated, however, some 
swellings were noted in at least two of the PFDA-dosed rat livers and their precise 
nature was not determined.
4,3.3 Changes in Microsomal Enzymes
Table 4.2 summarises the induction of the mixed function monooxygenase
system in liver-derived microsomes from the rat and guinea pig. A similar
information obtained in kidney-derived microsomes, is presented in Table 4.3. In
rat liver, PFDA treatment resulted in statistically significant induction (P< 0.01) of
total cytochrome P450 specific content as weU as NADPH-cytochrome c reductase
activity when compared to the pair-fed controls. No spectral shifts were observed
for CO-cytochrome P450 adduct in any of the experimental group (data not shown)
In the guinea pig liver, PFDA-induced change in total cytochrome P450 content was
not statistically significant over the pair-fed group. In addition there was a slight
decrease in NADPH-cytochrome c reductase activity (P< 0.05). Determinations of 
cytochrome b$ in all the treatment groups of each species revealed no significant
differences (Table 4.2). In general, pair-feeding appeared to have minimal effects 
on the liver monooxygenase system when compared to ad libitum-ied controls. 
With the exception of NADPH-cytochrome P450 reductase activity in the guinea
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Figure 4,3 The effect of PFDA on guinea pig and rat liver sizes. Animals were 
treated as outlined in Materials and Methods and the values presented are the mean 
+ SEM from 6 animals per group. P values for results significantly differed between PFDA- 
dosed versus pair-fed and ad libitum-^  versus pair-fed. *P< 0.05.
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Figure 4.4 The effect of PFDA on guinea pig and rat kidney sizes. Animals 
were treated as outlined in Materials and Methods and the values presented are the 
mean + SEM from 6 animals per group.
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pig which was significantly inhibited (P<0.01), following PFDA treatment, the 
kidney was generally refractory to the above microsomal changes (Table 4.3).
Concomitant with PFDA-induced hepatomegaly in the rat, reverse phase h.p.l.c. 
analysis demonstrated that co—laurate hydroxylation was preferentially induced over 
(w — 1)-hydroxylation (Figure 4.5). This change is reflected by a relatively small 
increase (about 1.5-fold) in (w— l)-hydroxylase activity when compared to a 5 to 6- 
fold increase in the corresponding co—hydroxylase activity. Again, the effects of 
pair-feeding in the rats on laurate hydroxylation were minimal since no statistically 
significant changes were seen when compared to the ad libitum-iod group. Unlike 
in rats, the guinea pig liver was refractory to induction of lauric acid metabolism 
(marker substrate for cytochrome P450 4A1-mediated metabolism and other 
members of the cytochrome P450 4A subfamily), (Figure 4.5).
Similarly, reverse phase h.p.l.c. analysis of renal microsomal laurate 
hydroxylation in response to PFDA treatment exhibited differential response in 
both species (Figure 4.6). In rats, the level of total (i.e (co—l)- plus w— 
hydroxylation) lauric acid metabolism in control kidney microsomes, expressed as 
nmol/min/nmol P450, was 10-fold higher than the corresponding control value for 
liver microsomes, and about 2-fold higher in the PFDA treatment group. In the 
guinea pig, total laurate metabolism in untreated kidney was approximately twice 
that of the liver and the same ratio was maintained eight days after PFDA treatment 
suggestive of the refractory nature of this species.
The present study also showed that in the rat, marked increase in liver laurate 
hydroxylation activity (probably mediated by cytochrome P450 4A1 hydroxylase 
activity), was associated with a decrease in the dealkylation of ethoxyresonifin, 
marker substrate for cytochrome P450 lA l isoenzyme (EROD activity) (Table
4.4). This decrease was about 74% that of the corresponding pair-fed group. In 
contrast, pentoxyresorufin-O-deethylation (PROD) activity (marker enzyme for
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Figure 4.5 Modulation of hepatic 11- and 12- laurate hydroxylase activities in the 
rat and guinea pig by single dose of PFDA. Animals were treated as outlined in Materials 
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Figure  4 .6  Modulation of renal 11- and 12- laurate hydroxylase activities in the 
rat and guinea pig by single dose of PFDA. Animals were treated as outlined in Materials 
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cytochrome 2B1 isoenzyme) was slightly induced by approximately 1.3-fold over 
pair-fed animals. In the guinea pig liver microsomes, enzymatic activities were 
significantly reduced by 35 and 37% for EROD and PROD, respectively, over the 
pair-fed animals. Similar information obtained with the kidneys of both species is 
presented on Table 4.5. The results show both EROD and PROD activities were 
significantly lowered and more pronounced with PFDA-dosed guinea pigs.
Western blotting analysis of rat and guinea pig hepatic microsomes, by 
comparing the effects of various treatments on cytochrome P450 4A1 apoprotein 
levels, is shown in Figure 4.7. Immunoblotting involved the use of a polyclonal 
antibody raised against homogeneous rat cytochrome P450 4A1 (Chapter Two). 
The enhanced interaction between microsomes from PFDA-treated rat liver 
microsomes and the P450 4A1 polyclonal antibody was readily visualised and 
showed two intimately associated bands that co-migrate, the lower and more intense 
band being cytochrome P450 4A1. This induction was confirmed by scanning on a 
densitometer (data not shown) and showed an approximate 3-fold increase over its 
pair-fed counterparts. The difference between pair-fed and ad libitum-&d controls 
was not significant. Similar results with guinea pig-derived liver microsomes is 
included in Figure 4.7. The data also shows the rat polyclonal antibody to 
cytochrome P450 4A1 cross-reacts with, most likely, guinea pig orthologues. Two 
very distinct and well-resolved bands were obtained, with the lower band most 
likely representing the guinea pig cytochrome P450 orthologous form. Neither of 
the two bands was induced as assessed by densitometric analysis (data not shown). 
When the kidney-derived microsomes were investigated for interaction with the 
same rat liver polyclonal antibody to cytochrome P450 4A1, only the rat renal 
apoprotein indicated an enhanced interaction after eight days post-exposure to the 
single dose of PFDA (Figure 4.8). The response in the guinea pig kidney was very 
different and apart from showing only one major band, there was significant 
suppression of the cytochrome P450 4A1 orthologue apoprotein level.
126
ë<
i
î
ciC
I
I
I
I
I
<
g
tri
ri
i
I
I<
i
î
Q
î
I
Q
I
f
<i
!
c
1
I
S'
I
0  
2
1
"c
s
i
B
î
CL
S
I
l
o
2
I
Î
'g
'b
I
e
"c
e
e
CL
I
o o o CM 8 o VO
r<S o m d d
4-1 4-1 -H -H 4-1 4-1
IT) q m q O m
OV T t w-j Ov o v
«O T f VO m CM
* *
f "
*
*
O
O m O
O d d d d d
4-1 4-1 4-1 -H 44 4-1
O
8
o o o r -
» n q Ov o CM
v d VO t--' v d CM « n
* «
* * *
e n O * o v V>
O r " q O « d CM
d d T f OV I,
44 4 4 4-1 4 4 t "
<—1 q O O Os O
o d e n Ov r f e n
m 0 0 q VO i n
«
o « * «
O o o O O q «n
d d >n CM d
4 4 -H 44 4-1 -H 44
CM CM o O
VO q u n o o q
e n r - ' o v OC) e n f"-"
e n CM CM
i & <
M
i
O
S
<w
z
5o
Ë
i is g>p *c
CL cd
i;
0
K |
"a S
il o
o
CO
1 $  
i |
d)
■§ N «
l î
8 S  
S -
"O
:.g
5 1
VP4
I * -
O
<D
V
O*
Ë
g
I
ËC/5
i
127
I g
Figure 4,7 Western blot analysis of rat and guinea pig hepatic microsomes with 
anti-cytochrome P450 4A1 polyclonal antibody. Animals were pretreated as outlined in 
Materials and Methods. Pooled microsomes were loaded on protein basis (20/xg) as follows: track 1, 
a J  libitum-fed rat; track 2, pair-fed rat; track 3, PFDA-induced rat; track 4, ad libitum-fed guinea pig; 
track 5, pair-fed guinea pig; track 6, PFDA-induced guinea pig and track 7, authentic cytochrome 
P450 4A1 (O.Spmol). Ratios of PFDA/pair-fed and pair-fed/ad libitum-fed band intensities for the rat 
was evaluated by densitometry and this corresponded to 3 and 1.1 respectively.
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Figure 4.8 Western blot analysis of rat and guinea pig renal microsomes with 
anti-cytochrome P450 4A1 polyclonal antibody. Animals were pretreated as outlined in 
Materials and Methods. Pooled microsomes were loaded on protein basis (20/ig) as follows: tracks 1 
and 2, ad libitum-fed rat; tracks 3 and 4, PFDA-induced rat; tracks 5 and 6, pair-fed rat; tracks 7 and 
14, authentic cytochrome P450 4A1 (0.5pmol); tracks 8 and 9, ad libitum-fed guinea pig; tracks 10 
and 11, PFDA-induced guinea pig and tracks 12 and 13, pair-fed guinea pig.
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Significant inhibition of microsomal activity associated with the dééthylation of 
ethoxyresonifin (marker substrate for cytochrome P450 lA subfamily) was reported 
earlier (see Table 4.4). Attempts to quantify this response to PFDA exposure, was 
demonstrated by Western immunoblotting analysis employing a polyclonal antibody 
against the rat P450 lA subfamily (Figure 4.9). Microsomes derived from 3- 
methylcholanthrene-induced rats was also included as a positive control. Firstly, 
the results indicate a difference in migration of recognised apoproteins on a 10% 
SDS-PAGE gel, the guinea pig bands migrating slightly lower than the rat bands. 
Secondly, in the rat only one band (as opposed to two in the guinea pig) cross­
reacted with the antibody. Thirdly, in the guinea pig the upper of the two 
recognised bands showed less immunoreactivity and corresponded to the more 
intense rat bands, which in turn corresponded to the lower of the two (more or less 
equally intense) 3-MC-induced bands believed to be cytochrome P450 1A2. 
However, both the PFDA-exposed rat and guinea pig liver microsomes showed 
substantial decrease in the cytochrome P450 lA level over their pair-fed partners 
when quantified by densitometry, even though the changes seen with the latter 
species were very marginal. A similar trend of results was obtained with the 
kidneys but the low degree of cross-reactivity made quantification rather difficult 
(data not shown).
4.3,4 Peroxisomal and mitochondrial changes in response to PFDA 
treatment
PFDA resulted in differential induction profiles in liver and kidney whole 
homogenates of the two species. In rat liver, PFDA treatment resulted in 
significant increase in cyanide-insensitive palmitoyl-CoA oxidation (PCOA) activity 
of the peroxisomal B-oxidation spiral, with concomitant induction of total 
(mitochondrial and peroxisomal) carnitine acetyl-CoA transferase (CAT) activity 
(Figure 4.10). The latter enzyme is involved in the transfer of fatty acyl-CoA
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Figure 4,9 Interaction between rat and guinea pig liver-derived microsomes and 
anti-cytochrome P450 lA  polyclonal antibody. Western blotting technique was applied on 
pooled microsomal samples from various treatment groups as outlined in Materials and Methods. 
Samples were loaded on protein basis (20/rg/track) as follows: track 1, ad libitum-fed rat; track 2, 
PFDA-induced rat; track 3, pair-fed rat; track 4, ad libitum-fed guinea pig; track 5, PFDA-induced 
guinea pig; track 6, pair-fed guinea pig and track 7, 3-MC-induced rat microsomes (lO^ag).
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F igure  4.10 Influence of PFDA on the liver 6-oxidation system in the rat and 
guinea pig. KCN-insensitive PCOA and total CAT (mitochondrial and peroxisomal) were 
determined in whole liver homogenates derived from both species following different treatments as 
detailed in Materials and Methods. Data represents mean ± SEM of duplicate determinations from 6 
animals per group. The effect of treatment was evaluated by comparing PFDA-treated versus pair-fed 
and likewise ad Z/b/ft/m-ièd versus pair-fed. *P< 0.05; **P< 0.01.
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derivatives through the membranes of the mitochondria and in the peroxisomes it is 
mainly required for the outward movement. Guinea pig liver from PFDA-dosed 
animals did not show any significant difference from pair-fed and ad Ubitum-&d 
control animals (Figure 4.10). However, the CAT activity in untreated guinea pig 
Hver was at least four times that of untreated rat, whereas the PCOA activity was 
about the same.
The effect of PFDA treatment, eight days after administration, on renal PCOA 
and CAT activities in both species is presented in Figure 4.11. The results 
presented show a significant increase in rat PCOA activity over its corresponding 
pair-fed partners (about 1.5-fold, P<0.05), whereas the guinea pig again was 
refractory to the rat kidney changes. CAT activity did not reveal any significant 
changes in either species. Further evidence lending support to the peroxisome 
proliferation potency of PFDA treatment in rat liver was obtained from Western 
blotting analysis using a polyclonal antibody to the trifunctional protein of the 
peroxisomal 6-oxidation spiral (Figure 4.12). The observed molecular weight of 
approximately SOkDa for this peroxisome-associated polypeptide (PPA-80), agreed 
with that of previous reports [Reddy et aL, 1981; Osumi and Hoshimoto, 1979]. 
The two lower molecular weight proteins recognised by the antibody and which 
were not detectable in guinea pig hepatic microsomes are believed to represent 
proteolysis products as previously reported [Nemali et al., 1989]. In accordance 
with the enzyme data previously presented in this Chapter, the guinea pig showed 
little, if any response to the induction of this protein. The refractory nature of this 
protein in PFDA-treated guinea pig kidney was also reflected on Western blotting 
analysis (data not shown). Meanwhile, results from the different rat kidney groups 
demonstrated an increase in the PPA-80 level in PFDA-dosed group over its pair- 
fed controls (data not shown).
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Figure 4.11 Modulation of renal 6-oxidation system in the rat and guinea pig by 
a single dose of PFDA. KCN-insensitive PCOA and total CAT (mitochondrial and peroxisomal) 
were determined in whole liver homogenates derived from both species following different treatments 
as detailed in Materials and Methods. Data represents mean ± SEM of triphcate determinations from 
6 animals per group. The effect of treatment was evaluated by comparing PFDA-treated versus pair- 
fed and likewise ad Ubitum~Bd\eisüs pair-fed. *P< 0.05.
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Figure 4.12 Western blotting analysis of rat and guinea pig hepatic microsomes 
with antibody to the trifunctional protein. With the exception of track 7 (prestained 
molecular weight markers, see section 2.2.17 of Chapter Two), all tracks contained equal amounts of 
protein (30/xg) as follows; 1, ad libitum-fed rat; 2, PFDA-induced rat; 3, pair-fed rat; 4, ad libitum- 
IW guinea pig; 5, PFDA-induced guinea pig and 6, pair-fed guinea pig.
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4.3 Discussion
The results of this study have demonstrated various renal and hepatic enzyme 
changes (microsomal and peroxisomal), following administration of the perfluoro- 
fatty acid, PFDA to male rats and guinea pigs. In general there were quantitative 
and qualitative differences in liver and kidney responses within the two species. 
Unlike the rat, the guinea pig was refractory to most of the parameters investigated.
Administration of single intraperitoneal dose of PFDA (20mg/kg body weight) 
resulted in differential feed intake and body weight gain in both species. In the 
guinea pig, PFDA treatment resulted in an initial decrease in feed intake and body 
weight when compared to ad Hbitum-&d animals. This was followed by a slow and 
gradual increase from the day 2, the result being an overall decrease in body weight 
change and cumulative feed intake (Table 4.1 and Figure 4.2). A similar initial 
decrease seen in the pair-fed group may be accounted for as due to the restricted 
amount of feed provided. This may well suggest a more profound initial impact of
this compound in the guinea pig as opposed to the rat which showed a steady
1
increase in feed intake and body weight gain in all the groups (Table 4.1). When 
compared to its pair-fed counterparts receiving an equivalent amount of feed, 
PFDA-dosed rats did not show any statistically significant difference in cumulative 
feed intake, suggesting the dose level used in this study did not cause any 
observable alterations in energy balance. The influence of PFDA on energy 
metabolism, evaluated through the calculation of the feed intake needed for 
maintenance at zero change of body weight [Fischer and Canolty, 1983], was not 
addressed in the present investigation. The main areas of energy utilisation have 
been defined as: energy storage, cost of energy storage and cost of maintenance 
[Hill et al., 1984]. In the rat, measured feed intake throughout the duration of the 
study, was not different for PFDA (163.8 gram feed/ 7days) compared to the pair- 
fed (163.1 gram feed/ 7 days) or ad libituin-&d (163.1 gram feed/ 7days) treatment.
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Studies involving PFDA treatment at higher doses (>50 mg/kg body weight as 
compared to the 20 mg/kg dose level used in my study) have often resulted in a 
number of toxicity symptoms, the liver being the major target organ. This includes 
progressive reduction in body weight and feed intake, delayed lethalities, with 
deaths occurring in the second and third week post-treatment. However, in the 
present study, no such drastic changes were apparent 8 days after animals were 
exposed to PFDA even though there were significant changes occurring at the level 
of enzymatic activities, especially within the rat. Because of these reasons, we 
found it necessary to use this lower dose level to avoid complications of PFDA and 
metabolic changes, the latter can also change cytochrome P450 4A subfamily as in 
fatty acid diet studies
A striking response to PFDA treatment in rats but which was lacking in guinea 
pigs, was hepatomegaly with concomitant increases in total cytochrome P450 
specific content as well as NADPH-cytochrome P450 reductase activity (Table 4.2). 
The fact that liver enlargement was not very pronounced, if at all present, in the 
guinea pig may be related to the pharmacokinetics of PFDA in this species. It is 
known that the rate of elimination from the body is important in relation to the 
capacity of many substances to induce liver enlargement [Schulte-Hermann, 1974]. 
It may well be possible that a difference in the persistence of this compound in the 
two species studied may account partially for the difference in the degree of liver 
enlargement and associated enzyme changes.
In general, there is good indication that the fatty acid-metabolising enzyme 
complement in the kidney and liver are similar even although substantial 
quantitative tissue differences exist between control and induced states. Increased 
w—hydroxylation of lauric acid in rat liver and kidney following PFDA exposure, 
reflected changes occurring within the cytochrome P450 4A subfamily enzymes, the 
latter enzymes mediating the w—hydroxylation of this substrate. Rat kidney cortex 
has previously been shown to contain a cytochrome P450 monooxygenase with a
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preference for fatty acid hydroxylation [Parker and Orton, 1980] and medium chain 
saturated fatty acids, such as lauric acid, display a high affinity for kidney 
cytochrome P450. Subsequent studies by Sharma et ah, [1989] confirmed that 
cytochrome P450 4A1 (or a very closely related isoenzyme in the same gene family) 
is a major constitutive haemoprotein in rat kidney microsomes and actively 
supported w—hydroxylation of lauric acid as well as arachidonic acid. Similarly, 
the cloning and expression of three rabbit kidney cDNAs encoding lauric acid w- 
hydroxylases has been reported [Johnson et al., 1990]. This clearly indicates that 
the kidney cytochrome P450 4 family genes play a major role across various 
species.
By employing a polyclonal antibody against rat liver cytochrome P450 4A1 on 
Western blotting analysis (Figures 4.7 and 4.8), further evidence on the differential 
modulation of the cytochrome P450 apoprotein levels in the liver and kidney by 
PFDA was provided. Similar to previous reports by other workers [Sharma et al., 
1989, Hardwick et al., 1987], our polyclonal antibody recognised two bands in rat 
hepatic and renal microsomes, a major band characterised by a monomeric 
molecular mass of approximately 51.5kDa (similar to authentic homogeneous 
hepatic cytochrome P450 4A1) and a minor one at 52 kDa, most likely representing 
cytochrome P450 4A3 [Aoyama et al., 1990]. Levels of cytochromes P450 4A1, 
4A2 and 4A3 mRNA in untreated rat have been analysed in liver and kidney and 
were present at very low levels in the liver. These are coordinately induced in rats 
treated with clofibrate. In the kidney, cytochromes P450 4A1 and 4A3 mRNAs 
were present in low levels and were induced by clofibrate in a manner similar to 
that in liver. In contrast, the level of cytochrome P450 4A2 mRNA expression in 
the kidney of untreated rats was similar to that of the maximally induced 
cytochrome P450 4A2 mRNA in liver. A major cytochrome P450 from the kidney 
of untreated rats which was shown to catalyse the w— and (co—1)- hydroxylation of 
lauric acid had earlier been isolated, purified and N-terminal sequenced by two
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groups [Imaoka et al., 1990; Yoshimoto et al., 1986] and based on limited amino 
acid similarities appears to correspond to cytochrome P450 4A2.
The effect of PFDA on guinea pig renal and hepatic cytochrome P450 mediating 
the hydroxylation of lauric acid (marker substrate for cytochrome P450 4A1 and 
related isoforms) was also investigated. Because of the high refractory nature of 
this species to most peroxisome proliferators examined to date, it is often classified 
as a "non-responsive” rodent. My results showed liver and kidney microsomes 
were refractory to cytochrome P45Q 4Al-mediated co—hydroxylation of lauric acid 
when the PFDA-dosed group was compared to its corresponding pair-fed partners 
(Figures 4.5 and 4.6). However, when the constitutive levels in untreated hepatic 
microsomes derived from both species was compared, they were found to be 
approximately the same. This similar catalytic activity in liver-derived microsomes 
was not reflected in Western immunoblotting for the cytochrome P450 4A1 
apoprotein (Figure 4.8). Ad Ubitum-Bd rat liver microsomes produced a greater 
interaction with the P450 4A1 polyclonal antibody than with similar guinea pig 
liver-derived microsomes. Moreover, resolution of the two bands recognised by the 
antibody was much better with the lower major band most likely representing the 
guinea pig liver orthologue of the rat cytochrome P450 4A1. The upper minor band 
had a monomeric molecular mass slightly higher than that seen with the rat but may 
well still represent a member of the cytochrome P450 4A subfamily. None of the 
bands seen in the guinea pig liver was affected significantly by PFDA treatment and 
the precise nature of these (presumably) cytochrome P450 isoforms and their 
relationship to the rat enzymes awaits further characterisation and clarification.
Differential interaction between rat and guinea pig microsomes and the 
cytochrome P450 4A1 antibody was further highlighted with the response of kidney- 
derived microsomes. Whereas the induction of laurate hydroxylase activity seen in 
PFDA-treated rat kidney was reflected by a similar response on Western 
immunoblotting, the refractory response seen in the guinea pig kidney laurate
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hydroxylase activity was transformed to a very significant inhibition of the 
orthologous apoprotein (Figure 4.8). These results suggest that the kidney 
cytochrome P450 4A1 orthologue in both species is distinctively different from the 
well characterised liver form. This observation is supported by the studies carried 
out by Sharma and co-workers, [1989]. These workers were able to demonstrate 
that, although the kidney supported fatty acid w—hydroxylase activity, it was 
refractory to inhibition by a polyclonal antibody to liver cytochrome P450 4A1.
If the gene coding for guinea pig kidney cytochrome P450 4A1 orthologue is 
different from that in the rat, then modulation of its activity may also be different 
and it is plausible that PFDA administration could result in a gene switch-off 
phenomenon resulting in the expression of a different member of the cytochrome 
P450 4A subfamily hitherto unidentified. Measurement of specific isoenzyme 
changes using changes in the in vitro assessment of catalytic activities of 
cytochromes P450 2B1 and P450 lA l mediated O-deethylation of pentoxyresorufin 
(PROD) and ethoxyresorufin (EROD), respectively indicated in microsomes derived 
from the liver and kidney of both species, these activities were decreased to varying 
extents with similar trends in the liver and kidney (Tables 4.4 and 4.5). The 
decrease in ethoxyresorufin-related activity (mainly contributed by cytochrome P450 
1A2) was further confirmed by Western immunoblotting analysis on hepatic-derived 
nticrosomes (Figure 4.9). These results appear to indicate there is a specific gene 
"switch-on" for cytochrome P450 4A1 with concomitant gene "switch-off" for the 
lA subfamily.
Peroxisome proliferation and induction of hepatic peroxisomal fatty acyl-CoA 
oxidation are characteristic effects of several xenobiotics [Moody and Reddy, 1978; 
Cohen and Grasso, 1981; Moody et al., 1991]. The present study also examined 
any possible relationship between induction of hepatic and renal enzymes and the 
peroxisome proliferative potentials of PFDA. PFDA has previously been shown to 
affect hepatic lipid metabolism in rats by altering fatty acid profiles with increases
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in long-chain fatty acids such as palmitic and oleic acids [George and Andersen, 
1986], and the capacity of this class of compounds to induce peroxisomes in rats has 
recently been confirmed [Ikeda et al., 1985; Borges et al., 1992]. These effects on 
lipid metabolism are consistent with the substrate overload hypothesis of peroxisome 
proliferative response in the rat [Sharma et al., 1988a]. In rat liver, treatment with 
PFDA resulted in an obvious positive correlation between induction of cytochrome 
P450 4A subfamily protein(s) and peroxisome proliferation as evidenced by the 
enhanced laurate hydroxylase activity and the peroxisomal parameters investigated 
such as cyanide-insensitive palmitoyl Co A oxidation (Table 4.6) and Western 
immunoblotting of the "trifunctional protein of the 6-oxidation spiral (Figure 4.10).
The rat kidney produced a similar trend of results but with less dramatic 
changes (Table 4.7 and Figure 4.10). In contrast PFDA administration to the 
guinea pig did not lead to an induction in peroxisomal 6-oxidation parameters (an 
indirect assessment of peroxisome proliferation) in either tissue (Tables 4.4 and
4.5). Neither was there induction in total carnitine acetyl-CoA transferase (CAT) 
activities (localised in peroxisomal and mitochondrial subcellular fractions) in this 
species. This same activity was induced by PFDA treatment in the rat liver by 
approximately 15-fold over pair-fed controls. The mitochondrial fatty acid 6- 
oxidation system is dependent on this latter enzyme, as it functions as an 
intermediate carrier of acyl substrates into the mitochondrial matrix. The 
peroxisomal 6-oxidation system is not dependent on carnitine, but this transferase 
may play a role in the removal of end products of metabolism [Lazarow, 1982]. In 
untreated animals, the constitutive level of CAT was 3-4 fold higher in the guinea 
pig liver when compared to similar activity in the rat, whereas the levels in the 
kidney were about the same. It is possible that selective enzyme induction and 
tissue toxicity by peroxisome proliferators may be masked by the fact that specific 
cell types in the kidney are indeed very susceptible to peroxisome proliferation but
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are obscured by whole-tissue-homogenate activity analyses, a hypothesis that may 
be addressed by in situ hybridization studies with appropriate probes.
The above relatively refractory nature of rat kidney and guinea pig enzymatic 
parameters to modulation by PFDA treatment coupled with the low basal activities 
recorded, may have profound implications for the species/organ susceptibility to 
toxicity by this class of compounds and to the extrapolation of the information so 
obtained to humans. This problem is exacerbated by reports that peroxisome 
proliferation and induction of palmitoyl-CoA oxidation activity in the liver results in 
a dramatic increase in peroxisomal production of hydrogen peroxide, which may be 
responsible for the hepatocarcinogenicity of these xenobiotics in rodents [Reddy and 
Lalwani, 1983]. The lack of reported incidences of renal carcinomas, in direct 
contrast to the high susceptibility to toxicity of mouse and rat liver, may be related 
to the poor respondent nature of this tissue or may be due to low levels of the 
recently identified peroxisome proliferator-activated receptor [Green, 1992].
In conclusion, I have examined the effect of a single i.p dose of PFDA (7 days 
post-administration) in male rats and guinea pigs. The findings of the present study 
indicate there are differential pleiotropic responses in both species. In all the 
parameters examined, the rat proved very responsive and the guinea pig either 
weakly responsive or non-responsive. As exemplified by the rat, there is very good 
agreement between PFDA-induction reflected in PCOA, peroxisome proliferation 
and cytochrome P450 4A1 activities, suggesting both processes may be activated 
through a common mechanism [Sharma et al., 1988a]. Association of PFDA 
exposure and hepatocarcinogenesis must be proven as a preliminary step to 
extrapolating the risk implications of this class of compounds to the human 
population. Also a deeper understanding of PPAR in a non-responsive species such 
as the guinea pig may help in better understanding its modulation in humans, if it is 
expressed at all.
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CHAPTER FIVE
Cfioroctensafion o f Human Liver Cytochrome P450 4A
Sub family Proteins.
Characterisation of Human Liver Cytochrome P450 4A 
Suhfamily Proteins
5.1 Introduction.
The cytochrome P450-mediated mixed-function monooxygenases of liver 
microsomal membranes are of central importance in the metabolism of steroid 
hormones and xenobiotics, including many drugs, environmental pollutants as well 
as many carcinogens [Coon et al. 1980]. Marked species differences in xenobiotic 
metabolism in the liver seriously limit the extrapolations from animals to man and 
therefore necessitates metabolic studies with human liver. Such studies are sparse in 
the literature and in general, apart from limited access to human tissues, the 
material used in such studies is often not completely characterized with respect to 
the morphology, homogenisation, fractionation, and storage procedures. Tissue 
from diseased patients or from livers probably having marked post-mortem changes 
has also been used making it difficult to satisfactorily preserve a range of drug 
metabolism activities in man. In one such study cytochrome P450 in human liver 
decreased to undetectable levels within 5h of death [Schenkman et al. 1969] and 
other qualitative modifications have been reported [Barker, 1974].
Of about twenty-seven cytochrome P450 gene families so far described, ten exist 
in all mammals, which comprise eighteen subfamilies of which sixteen have been 
mapped in the human genome [Nebert et al. 1991]. Individual human variations are 
well known in the metabolism of some foreign compounds such as therapeutic drugs 
[Conney, 1982]. This metabolic variability may be due, in part, to genetically 
determined factors relating to the structure and expression of cytochrome P450 
isozymes. The existence of multiple forms of cytochrome P450 in humans has been 
directly demonstrated by the isolation, from tissues, of several cytochrome P450 
isozymes that vary in their catalytic activity towards drugs and carcinogens [Wang
143
et al. 1983; Nhamburo et al., 1989; Johnson et al., 1990; Stromstedt et al., 1990; 
YokoXam et al., 1991].
The role and function of w— and (oj—l)-oxidation of fatty acid metabolism has 
received considerable attention [Kupfer, 1982; Sharma et al., 1989]. It is well 
documented that prostaglandins and leukotrienes can serve as substrates for such a 
reaction, suggesting that this may represent a pathway for the further metabolism of 
these physiologically important compounds [Okita et al., 1981; Feinmark et al., 
1981; Tanaka et al., 1990]. Similarly, the finding that lauric acid and more 
importantly yet another endogenous substrate, arachidonic acid are w— and (w—1)- 
oxidised by liver microsomal cytochrome P450 4A subfamily proteins, raises the 
question of whether therapy with agents of the fibric acid type, such as clofibrate 
(an inducer of some of the cytochrome P450 4A subfamily isozymes) can perturb 
the in vivo steady-state levels of these eicosanoids. Evidently, any such changes 
may have pronounced effects on cellular homoeostasis and may contribute to the 
hypolipidaemic functions of these types of drugs. Arachidonic acid is a starting 
material in the in vivo synthesis of potent bioactive substances such as 
prostaglandins and leukotrienes, and their metabolism in the renal tissues may 
contribute to kidney function.
Recently, it was reported that some of the metabolites of arachidonic acid are 
biologically active with several roles, including those of a vasodilator [Carroll et. 
al., 1987], an inhibitor of ion transport in the collecting tubules of rabbit kidney 
and a Na“*“/ K+-ATPase inhibitor [Jacobson et. al., 1984; Schwartzman et. al., 
1985]. Furthermore, the w—hydroxyeicosatetraenoic acid (20-HETE) metabolite 
produced by the kidney is a potent vasoconstrictor, which may affect renal vascular 
resistance and contribute to the pathogenesis of hypertension, and the corresponding 
(co—l)-hydroxyeicosatetraenoic acid (19-HETE) metabolite, a stimulator of Na“*“/ 
K+-ATPase [Escalante et al., 1989; Schwartzman et. ah, 1989,1990]. Thus by 
manipulating Na"^/ K’^ '-ATPase activity, dilating and/or constricting vascular
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smooth muscles, these metabolites may influence renal function and contribute to 
the development of a pathological state such as hypertension.
In the present chapter, I have examined the existence/ similarity of cytochrome 
P450 4A1 reported in other animal models to that which may exist in human liver 
tissue. It is hoped the results obtained would serve as a prelude in the assessment of 
human risks following exposure to hypolipidaemics.
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5.2 Materials and Methods
5.2.1 Chemicals
The chemicals used in the present study were essentially as listed in Materials 
Section (Chapter 2), but with a few additions: [l-^^C]-arachidonic acid and [1- 
l^C]- sodium arachidonate were purchased from the Radiochemical Centre 
(Amersham, U.K.) and Sigma Chemical Co. (Poole, Dorset, U.K.) respectively,
5.2.2 Human Liver sam ple
Liver tissue samples were kindly provided by Drs Mike Tarbit and Alan Boobis 
of Glaxo Group Research and the Royal Postgraduate Medical School, London, 
respectively, and ethical permission for cytochrome P450 characterisation was 
previously obtained by these workers. The samples were transported in dry ice and 
once received, they were immediately stored at -80®C until processed. For most of 
the samples, extensive case histories were not available. The limited information 
available is presented in Table 5.1.
5.2.3 Animals and Drug Pretreatment
Isozymes of cytochrome P450 corresponding to the lA, 2B and 4A subfamilies 
were also assessed in the panel of human livers and were compared with similar 
forms in the rat . Rats were dosed intraperitoneally as follows: 80mg/kg of
phenobarbitone followed by 0.1% in drinking water for 3 days; 20mg/kg 3- 
methylcholanthrene for three consecutive days; clofibrate at 250mg/kg body weight 
also for three consecutive days and the control group received 0.9% (w/v) saline for 
three consecutive days. The rats were all killed by cervical dislocation 24h after the 
last injection and microsomes were prepared by standard centrifugation procedures 
as previously described in Materials and Methods, Chapter Two.
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T ab le  5.1 Available Clinical Data on Human Liver Samples^
Code Sexl) Age Date obtained Case history Drug history 
by original
investigators
HLM-1 F 45 22-12-88 moderate smoker Temazepam 
obstructive jaundice Thiopentone
HLM-2 M 10 - 11-88
HLM-3 F 31 08-03-89 liver resection
HLM-4 F 33 29-03-89
HLM-5 M 16-08-89
HLM-6 04-11-89
HLM-7 01-11-89
HLM-8
Information not available 
b M = male, F= female
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5.2.4 Preparation o f Human Liver Microsomes
Human liver, especially that of older patients, contains connective tissue, which 
makes homogenisation difficult. Microsomes were therefore prepared by a slight 
modification of the procedure used for the rat. All manipulations were performed at 
4°C. Frozen liver pieces were partially thawed out in 0.9% (w/v) sodium chloride, 
diced with scissors, washed O.OIM Tris, pH 7.4, containing 1.15% (w/v) KCl and a 
25-33% (w/v) homogenate prepared in a buffer containing 0.25M sucrose, O.IM 
Tris HCl and ImM EDTA, pH 7.4 using initially an ultra-Turrax for 10-20s and 
further homogenisation with a motor-driven Potter-Elvehjem device. The 
homogenate was successively centrifuged at 12,500g for 30 min after which the 
supernatant was further centrifuged at 105,000g for Ih to isolate the pelleted 
microsomal fraction. The microsomal pellet was washed with lOOmM sodium 
pyrophosphate, pH 7.5, to eliminate as much of the contaminating haemoglobin as 
possible. The microsomes were then resuspended in 50mM phosphate buffer, pH
7.4, containing 20% (v/v) glycerol, and stored at -80®C until required. The 
cytochrome P450-dependent enzymatic activities were verified not to decrease under 
these storage conditions for at least a few months.
5.2.5 Spectrophotometric Assays
Total microsomal protein content, total carbon monoxide-discernible cytochrome 
P450, cytochrome b^ and NADPH-cytochrome P450 (cytochrome c) reductase were
determined as previously described in Materials and Methods (Chapter Two).
5.2.6 Determination o f Alkoxyresorufin O-deaikylase Activities in 
Human Liver Microsomes
The O-dealkylation of ethoxy- and pentoxy- resorufins, was determined 
spectrophotometrically according to the method of Burke and Mayer, [1974] by 
using the difference in fluorescent properties of ethoxyresorufin and
148
pentoxyresorufin (excitation wavelength at 456nm, emission wavelength at 560nm) 
and the product resorufin (excitation wavelength at 510nm, emission wavelength at 
586nm). Details of the procedures is outlined in Materials and Methods (Chapter 
Four).
5.2 .7  Enzyme-Linked Lmmunosorbent Assay (ELISA)
Human hepatic microsomal cytochrome P450 4Al-related material was 
quantified by the ELISA protocol as described in Materials and Methods (Chapter 
Two).
5.2.8 Detennination o f Lauric A dd Metabolism
This was carried out as described under Section 2.2.14 (Chapter Two). 2mg of 
human microsomal protein was used per incubation for 20 minutes. Reaction rates 
were initially verified to be linear as a function of incubation time.
5.2.9 Arachidonic Acid Metabolism
The method used in the determination of arachidonic acid metabolism was 
essentially that described by Capdevila et al. [1985]. The products of arachidonic 
acid metabolism were isolated from a constantly stirred incubation mixture 
containing either human liver microsomes (2mg/ml), control rat microsomes 
(Img/ml) or clofibrate-treated microsomes (Img/ml), lOmM magnesium chloride, 
and 50mM Tris-HCl buffer, pH 7.5.
After temperature equilibration at 25®C for 5 min with constant stirring, [1- 
^^C] sodium arachidonate (0.6mCi/ mmol) was added to a final concentration of 
O.lmM. NADPH (ImM final concentration) was then added to initiate the 
reaction. The reaction mixture was then transferred to a 37®C shaking water bath. 
The reaction was allowed to proceed for 20 min and then terminated by the addition
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of 2ml ethyl acetate containing 0.05ml of IM HCl and 0.1% (w/v) butylated 
hydroxytoluene (BHT) as anti-oxidant. Following two further extractions with ethyl 
acetate (2ml), the combined extracts were dried over anhydrous sodium sulphate, 
filtered and evaporated to dryness under a stream of nitrogen. About 95% of the 
radioactivity added was reported to be recovered in the organic extracts under these 
procedures [Capdevila et al., 1985], and therefore no correction for recoveries was 
applied to my data.
The dried ethyl acetate extracts were reconstituted in 150fil of starting solvent 
(water ; acetonitrile, 70:30 containing 0.1% (v/v) acetic acid). The metabolites 
were separated by reverse phase h.p.l.c. on a Cjg Ultrasphere ODS 5mm column
(4.6mm x 25cm, Beckman Instruments, Inc., CA, U.S.A.), using a shallow elution 
gradient ranging from the starting solvent to 100% acetonitrile (containing 0.1% 
(v/v) acetic acid), at a flow rate of Iml/min for 50 min. The elution profile of the 
radioactive products was monitored using a Berthold LB 506 C-1 Radioactivity 
monitor (Lab Impex, Twickenham, UK) containing a 150^1 flow cell and interfaced 
with a microprocessor. This was linked to a PC-IV 286 AT-compact computer 
(Opus Technology Pic, Redhill, UK) enabling quantitative analysis of the 
arachidonic acid metabolites, essentially as described for lauric acid metabolites 
quantification (Section 2.2.14, Chapter Two).
5.2.10 Antibody Inhibition o f Microsomal Laurate Metabolism
Inhibition of w— and (w—1)- laurate and arachidonate hydroxylase activities in 
human liver microsomes was studied using cytochrome P450 4A1 and pre-immune 
IgG antibody-enriched fractions, prepared as previously described (Section 2.2.15, 
Chapter Two). Human liver microsomes (2mg/ml) and control rat microsomes 
(Img/ml) were each separately preincubated with 5 and 10 mg/nmol P450 of the 
pre-immune and immune IgG fractions at 25°C for 10 min. The reaction mixture
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was then maintained at 4^0 and the remaining components for lauric acid 
metabolism assay added. The w— and (oj—l)-hydroxylated products of lauric acid 
were quantified on reverse phase h.p.l.c. chromatography, as previously described 
under Materials and Methods (Chapter Two).
5.2.11 Western Blotting Analysis
Human hepatic cytochromes P450 1A1-, 2B1- and 4A1- related materials were 
analysed using specific rat antibodies to these isoforms, essentially as was 
previously described in Materials and Methods (Chapter Two).
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5.3 Results
Only a single microsomal preparation was made from each human liver sample
of which the results are discussed in this chapter. Liver tissue wedges from eight
individuals with little available clinical history were investigated. A summary of
the results obtained for the monooxygenase components in these samples is
presented in Table 5.2. The values obtained for total CO-discemible cytochrome 
P450 and cytochrome b$ are quite similar to those published by other workers
[Darby et al. 1970, Nelson et al. 1971, Beaune et al. 1986; Distelrath and
Guengerich, 1988]. Mean specific contents of 0.36 ± 0.19 and 0.32 ± 0.06
nmol/mg microsomal protein were obtained for total cytochrome P450 and 
cytochrome b$ respectively. The average value for cytochrome P450 was less than
that obtained with control rat microsomes (0.56 + 0.06 nmol/mg). The absorption 
maxima of the cytochrome P450 CO-adduct ranged between 450-452nm. Some of 
the microsomal preparations also showed a peak at 420nm which was due to 
haemoglobin contamination even though this was minimised by washing the 
microsomes during preparation with sodium pyrophosphate.
The NADPH-cytochrome P450 reductase activity recorded for all eight human 
samples is also included in Table 5.2. The values ranged between 13.6 and 
75.2nmol product formed/min/mg of microsomal protein with a mean activity of 
51.34 + 16.9nmol product formed/min/mg microsomal protein. The corresponding 
rat activity was 85.4 ± 2.9 nmol product formed/min/mg protein. The lowest 
activity was obtained with HLM-1 and the highest with HLM-4. In general, these 
values were slightly lower than those cited in literature for human autopsy samples 
that ranged between 70-193nmol reductase/min/mg protein [von Bahr et al. 1980, 
Beaune ef a/. 1986].
Figure 5.1 shows the SDS-PAGE analysis of human and rat liver microsomes. 
By examining this data very closely, it was obvious that some significant differences
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Figure 5.1 SDS-PAGE patterns of human liver microsomes (HLM).
Electrophoresis was carried out by using a 1mm thick 10% (w/v) gel as described in Materials and 
Methods. All tracks contained 20jwg of protein loaded as follows: 1 and 12, clofibrate-induced rat; 2 
and 13, untreated rat; 3, HLM-1; 4, HLM-2; 5, HLM-3; 6, HLM-4; 7, HLM-5; 8, prestained 
molecular weight markers (see Section 2.2.17, Chapter 2); 9, HLM-6; 10, HLM-7; 11, HLM-8. Rat 
cytochrome P450 4A1 is indicated by an arrow.
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appeared between the panel of human liver microsomes and that of the rat, as 
evidenced by the intensities of some of the protein bands. A few of the bands were 
peculiar only in rat microsomes tracks (1 and 2). Similarly, some of the protein 
bands were very prominent only in human microsomes. It is probable that some of 
these bands may correspond to species specific cytochrome P450 types, thus 
providing a possible explanation for some of the differences in enzyme activities 
observed with the various monooxygenase components. Of major significance in 
each human liver-derived microsomal preparation, was the presence of a detectable 
protein band that co-migrated with that of cytochrome P450 4A1 in clofibrate- 
induced microsomes (Figure 5.1). Except for HLM-1 (track 3), these bands 
showed similar intensities to that of untreated rat microsomes and may well 
represent the orthologous human form of the cytochrome P450 4A1 or other 
closely-related member(s) of the cytochrome P450 4A subfamily proteins. Figure 
5.1 also demonstrates that microsomes prepared from one of the human samples 
(HLM-1, track 3) showed significant difference in band intensities and this is 
reflected in its much lower enzymatic activities (see later).
In order to estimate the amount of orthologous human liver microsomal form of 
cytochrome P450 4A1 that cross reacts with the rat polyclonal antibody by an 
ELISA technique, it was necessary to establish an antigen-antibody response with 
increasing amounts of the antigen. A typical protein calibration graph obtained 
with one of the human liver samples (HLM-3) is depicted in Figure 5.2 and this 
demonstrates that there is linearity with such a technique within the range of protein 
concentrations examined (r= 0.925). Similar response was shown for all the other 
human liver samples with the maximum concentration for linearity ranging between 
0.4jtig and 0.6ptg of solubilised microsomal protein /well (data not shown). Based 
on these findings 0.2/ig and 0.4/iig protein of each sample were then used together 
with a rat P450 4A1 standard for ELISA quantification. The results are presented 
in Table 5.3 and shows that the orthologous human cytochrome P450 4A1 isozyme
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Figure 5.2 Linearity of orthologous cytochrome P450 4A1 determination in 
human liver microsomes. A polyclonal sheep antibody (1:20k dilution) to electrophoretically 
homogeneous rat Uver cytochrome P450 4A1 was used in an ELISA procedure as described in 
Materials and Methods. Each data point was derived from triphcate determinations with HLM-3 
microsomes.
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Table 5.3 Immunoquantitation of Orthologous Cytochrome P450 4AI Apoprotein 
in Human Liver Microsomes
Sample Orthologous cytochrome P450 4A1 
specific content (pmol/ mg protein)
Percentage of total 
cytochrome P450
HLM-1 3.50 ± 0.71 2.01 ± 0.33
HLM-2 17.75 ± 0.50 4.79 ± 0 .13
HLM-3 23.01 ± 1.56 4.18 ± 0.27
HLM-4 36.70 ± 2.60 5.78 ± 0.40
HLM-5 23.90 ± 3.20 4.15 ± 0.54
HLM-6 20.50 ± 3.54 7.54 ± 1.40
HLM-7 25.10 ±  1.06 11.63 ± 0.52
HLM-8 24.20 ± 2.76 9.66 ± 1.09
Mean 21.80 ± 8.6* 6.22 ±  2.98
Untreated rat 35.20 ±  1.7 6.41 ± 0.67
Results are the mean ±  SEM of tripicate determinations for each sample. Difference in mean 
cytochrome P450 4A1 specific content in human livers (n=8) and untreated rats (n=3) was
significant at *P< 0.05.
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levels estimated ranged between 2-12% of the total cytochrome P450 population. 
The data obtained was of the same order of magnitude as that determined for 
untreated rat (about 6% of the total cytochrome P450 population).
Lauric acid has been used previously as a specific substrate for the cytochrome 
P450 4A subfamily proteins in the rat [Gibson et al. 1982]. It was therefore 
relevant to investigate the metabolic capabilities of the different human liver 
microsomes towards lauric acid as a substrate. Catalytic activity in human liver 
samples was determined under conditions in which metabolism was proportional to 
time of incubation (Figure 5.3) and the results obtained for the human samples 
presented in Figure 5.4. The information presented shows that the liver 
microsomes derived from different human subjects display significant activity 
toward w— and (w — 1 )-hydroxylation of lauric acid, except for HLM-1 whose 
activity was barely detected and was close to the limits of sensitivity of our assay 
procedures (approximately 0.02nmol product/min/nmol P450). The mean activities 
for human w— and (w-1)- hydroxylation of laurate were 3.23 + 1.51 and 1.59 + 
0.99nmol product/min/nmol total cytochrome P450, respectively, corresponding to 
a ratio of w— to (w-l)-hydroxylase activities of about 2.0. These values are very 
comparable to that demonstrated with rat liver microsomes for w— and (w—1)- 
laurate hydroxylases at 4.92 and 2.96nmol product/min/nmol P450 respectively. 
However, unlike the rat liver cytochrome P450 4A1 isozyme which is well 
characterised and shown to exhibit regioselectivity for w—laurate hydroxylation 
[Gibson et al. 1982], the equivalent detailed information on the cytochrome P450 
4A subfamily-related enzymes is only now beginning to emerge. Of relevance to 
this, were the findings of separate experiments, in which lauric acid hydroxylation 
by human hepatic microsomes was carried out under the following conditions (i) in 
the absence of NADPH (ii) using carbon monoxide as an inhibitor to cytochrome 
P450-mediated metabolism and (iii) in an atmosphere of nitrogen (data not shown). 
Collectively, these simple experiments were indicative that in human liver
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Figure 5.3 Typical lauric acid metabolism time-course study with a human liver 
microsomal sample. .Determination of the rate of formation w - and (w-l)-hydroxylated 
products by HLM-3 microsomes was assessed by reverse phase h.p.l.c. analysis and as detailed in 
Materials and Methods. Each data point represents the mean of triplicate determinations.
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Figure 5.4 Lauric acid metabolism by human hepatic microsomes.
Reverse phase h.p.l.c. analysis of laurate metabolites following incubations of human (2mg/ml) and 
rat (Img/ml) microsomal protein, was conducted as described in Materials and Methods. Triplicate 
analysis was performed for each sample. Control rat values were 4.92 ± 0.51 and 2.96 ± 0.10 nmol 
product/min/nmol P450 for w— and (co-l)-hydroxylase activities, respectively.
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microsomes, lauric acid hydroxylation is most probably cytochrome P450-mediated 
since no metabolites were detected under these conditions (data not shown).
The results of immune complex inhibition (using an antibody to rat P450 4A1) 
of lauric acid metabolism by one of the human liver microsomes that showed 
highest activity towards this substrate is presented in Figure 5.5. The objective of 
such an experiment was to investigate the influence of the rat antibody to 
cytochrome P450 4A1 as a potential inhibitor of laurate biotransformation by human 
liver microsomes and therefore indicative of which cytochrome P450 species might 
be involved in laurate hydroxylation. The higher concentration of the immune IgG 
fraction used in this study was such that it caused approximately 50% inhibition of 
the rat w—hydroxylase activity. The data presented was also normalized by taking 
into account any non-specific inhibition by non-immune IgG fraction. From figure
5.5, it could clearly be seen that lOmg immune IgG/nmol P450, that caused 
approximately 50% inhibition of w—hydroxylase activity in the rat, was also very 
potent towards similar activity in the human liver causing up to 70% inhibition. By 
lowering the concentration of immune IgG used to 5 mg/nmol P450, the human 
catalytic activity also reduced to about 55% inhibition whereas that for the rat was 
just below 20%. The picture for (w— l)-hydroxylation was different since by 
doubling the IgG concentration from 5 to lOmg, the inhibition percentage of the 
human activity did not change at about 80% whereas that for the rat decreased from 
about 40% to about 20%, suggesting more of stimulation. Attempts to use 20mg 
immune IgG/nmol P450 totally inhibited the human activity beyond detection (data 
not shown). The effect of pre-immune IgG at 20 mg/nmol P450 was not 
investigated.
When [1-1 ^ C] -arachidonic acid is incubated with rat and human liver 
microsomes under conditions that support metabolism, i.e. in the presence of 
NADPH and molecular oxygen, and the organic soluble products isolated and 
analysed by reverse-phase high performance liquid chromatography analysis, a
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F igu re  5 .5  Inhibition of ll-(w—1) and 12-(co) hydroxylation of lauric acid 
biotransformation in human liver microsomes by an antibody against rat P450 4A1.
Human liver microsomes (HLM-3, 2mg/ ml) and control rat microsomes (Img/ml) were each 
separately preincubated wifli the pre-immune and immune IgG fractions (5 and lOmg IgG/nmol
cytochrome P450) at 37°C for 10 minutes. The reaction mixture was then placed on ice and lauric 
acid hydroxylase activity determined as described under Materials and Methods. Values for the rate 
of formation of (w-1)- hydroxylated products by human and rat in the presence of pre-immune sera 
were 1.12 and 1.45 nmol/min/nmol P450 respectively and for their corresponding co-hydroxylated 
products, 2.12 and 4.28 nmol/min/nmol P450, for human and rat, respectively.
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complex pattern of metabolites is formed. Figure 5.6 shows HPLC chromatograms 
obtained for such studies with liver microsomal fractions derived from livers of 
either untreated male rats, clofibrate-induced rats, or human. The formation of 
these metabolites would appear to be cytochrome P450-dependent, as separate 
incubations where NADPH was omitted resulted in no apparent metabolism (Figure 
5.7). All the human liver microsomal preparations examined (n=5) showed the 
same qualitative metabolic pattern as that depicted in figure 5.6, except that the rate 
of formation of the individual peaks was different. Extensive characterisation and 
identification of these peaks was not possible due to the lack of authentic standards 
and was not addressed in the current study. However based on previous 
experiments carried out in our laboratories and reports from studies reported by 
other workers [Capdevila et ah, 1985], some tentative qualitative and quantitative 
analyses were made, even though the metabolic profiles were not exactly the same. 
Five major peaks stood out and were common in all the chromatograms. These 
were designated as peaks 1, 11, 111, IV and V with retention times of approximately 
25.2, 26.4, 27.3, 28.1, 29.2 and 30.1 minutes respectively.
Figure 5.8 represents chromatograms derived from combined incubation 
mixture extracts derived from either human plus untreated rat liver microsomes (A) 
or human plus clofibrate-induced rat liver microsomes (B). This data lends support 
to the observation that similar peaks were present in all the microsomal preparations 
and the metabolites are very similar to each other. Table 5.4 shows the rate of 
formation of these peaks expressed as pmol. product formed/min/nmol P450 for 
each hepatic microsomal preparation. The unmetabolised arachidonic acid substrate 
was eluted at approximately 45.4 min in all the chromatograms. Notably, the 
overall rate of arachidonic acid metabolism was nearly the same for all the human 
samples and averaged 2.10 + 0.22 nmol/min/nmol P450 (n=5). The values 
obtained for untreated and clofibrate-induced male rats were 2.39 ± 0.02 and 3.89 
+ 0.02 nmol/min/nmol P450 respectively. Comparison of the rates of formation of
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Figure 5.6 Metabolite profiles generated by NADPH-dependent oxygenation of
I l-^'^C)-arachidonate by different liver microsomal preparations. Incubation and 
metabolite analyses were as described under Materials and Methods. The chromatograms shown were 
obtained using microsomes from untreated rat (A, 1 mg/ml), clofibrate-induced rat (B, 1 mg/ml), and 
human (HLM-3) (C, 2mg/ml) livers. Incubation times were 10 and 20 minutes for rat and human 
microsomes, respectively. The specific contents of microsomal cytochrome P450 were 0.57, 0.87 
and 0.53 nmol/ mg protein for untreated, clofibrate-induced and human microsomes, respectively.
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Figure 5.7 Lack of arachidonic acid metabolites formation in rat and human 
liver microsomes in the absence of NADPH. Microsomes derived from untreated rat (A), 
clofibrate-induced (B), and human (C) livers were subjected to the same procedures as in Figure 5.6 
and as detailed under Materials and Methods except for the omission of NADPH. AA = arachidonic 
acid
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Figure 5.8 Reverse-phase chromatograms of the metabolites formed during the 
NADPH-dependent metabolism of arachidonic acid catalysed by combinations of 
microsomal preparations: Untreated rat (U) (Img protein/ml) + Human (H) (2mg protein/ml) 
liver microsomes (A) and Clofibrate-treated rat (CF) (0.5mg protein/ml) + Human (2mg protein/ml) 
liver microsomes (B). All incubations were carried out for 10 minutes. The experimental conditions 
were essentially as described under Materials and Methods. The specific contents of microsomal 
cytochrome P450 determined for tliese combinations were 0.51 (U+H) and 0.63 (CF+H) nmol/mg 
protein for chromatograms A and B, respectively.
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Table 5.4 Comparison of the Rate of Formation of Some Arachidonate 
Metabolite Peaks by Rat and Human Hepatic Microsomes
Peak name Retention time 
(minutes)
pmol product formed/ min/ nmol P450
Control rat Clofibrate-induced
rat
Human
1 24-25 266.1 ± 8 . 8 367.5 ± 14.5 420.9 ± 18.9
11 25 - 26 451.8 ± 16.1 251.0 ± 17.0 230.2 ± 14.3
III 26-27 191.5 ± 17.3 578.5 ± 8.5 104.6 ± 17.8
IV 29-30 178.4 ± 15.9 943.5 ± 25.5 235.0 ± 36.7
V 30-31 106.7 ± 14.4 288.0 ± 20.0 108.7 ± 35.1
Total metabolism* 2.4 ±  0.02 3.9 ±  0.03 2.1 ±  0.22
This represents the overall rate of formation of all the metabolites after NADPH-
dependent metabolism of [ 1 -  ^^ C]-Arachidonic acid by microsomes derived from 
untreated and clofibrate-treated rats and human livers. Data presented for humans is 
the mean obtained with all the microsomal samples.
Units are: nmol product formed/ min/ nmol P450.
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individual metabolites revealed major differences. Whereas the predominant 
metabolite, when untreated rat microsomes was used, eluted at about 26.4 min 
(Peak II), those for all the individual human microsomal preparations eluted at 
approximately 25.2 min (Peak I).
Clofibrate is a hypolipidaemic agent which has been unequivocally demonstrated 
as a potent inducer of the cytochrome P450 isozyme mediating w— and (w—1)- 
hydroxylation of arachidonic acid [Gibson et al., 1982; Sharma et al., 1989]. In 
my studies, pretreatment of rats with this drug resulted in a significant increase in 
the rate of formation of a peak with retention time of approximately 29.2 min (Peak 
IV) (Figure 5.6). This peak together with that eluted at approximately 30.1 min 
(Peak V) were reduced with concomitant increase in the other peaks (data not 
shown). Based on these findings and those of other workers [Capdevila et al., 
1985; Sharma et al., 1989], peaks IV and V were tentatively identified as the w— 
and (co—l)-hydroxyarachidonic acid metabolites. According to our current 
knowledge, the oj—hydroxylation of arachidonic acid represents a reaction pathway 
catalysed by cytochrome P450 4A1 [Sharma et al., 1989]. The results presented 
here show that the rate of formation of peak IV in clofibrate-induced rat liver 
microsomes was approximately 8-fold over that of untreated rat microsomes and 
between 6 to 50-fold over those of human liver microsomes. The rate of formation 
of individual metabolite peaks by individual human liver microsomes is presented in 
Table 5.5. Similarly, a summary of the rate of formation of the tentatively 
identified (co—1) and w—hydroxyeicosatetraenoic acid metabolites, by these human 
liver microsomes compared to that generated with rat liver microsomes, is presented 
in Table 5.6.
Western blot analysis of hepatic microsomes derived from each human liver 
sample was performed using a sheep polyclonal antibody raised against the 
electrophoretically homogeneous rat hepatic cytochrome P450 4A1 (Figure 5.9). 
Of major significance, was the observation that the anti-cytochrome P450 4A1 
serum recognised only one major band in all the human liver samples examined, as
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Table 5.6 Rates of formation of tentatively identified arachidonic acid metabolites 
by rat and human liver microsomal samples
Rate of metabolite formation (pmol/min/nmol P450)
Metabolite untreated rat 
microsomes
clofibrate-treated 
rat microsomes
human liver 
microsomes
20-HETE 178.4 ± 16 943.5 ± 26 255.0 ± 37
19-HETE 106.7 ± 15 288.0 ± 20 108.7 ± 35
Ratio (co/oj-l) 1.7 3.3 2.4
Abbreviations: 20-HETE, 20(w)-hydroxyeicosatetraenoic acid; 19-HETE, 19(w-l)-hydroxy- 
eicosatetraenoic acid.
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opposed to two bands seen with rat liver microsomes. Moreover, this human liver 
microsomal protein did not co-migrate to the same position as seen with either the 
authentic P450 4A1 apoprotein or the lower of the two rat bands representing the rat 
P450 4A1 isoform [Tamburini et ah, 1984; Sharma et al., 1988a; Chinje and 
Gibson, 1991). The molecular mass of the human liver orthologous form was 
estimated on a 7.5% SDS-PAGE gel at about 51kDa, approximately 500 daltons 
lower than the rat P450 4A1 isoform. Linear regression analysis was used to 
describe the relationship between Western blotting data (band intensities) and 
ELISA-determined levels of human liver cytochrome P450 4A1 orthologue. A 
correlation coefficient (R) of 0.694 was found not to be statistically significant at 
5% level of significance. The difference in molecular weights between the rat and 
human cytochrome P450 4A1 orthologues became more apparent when rat authentic 
cytochrome P450 4A1 was spiked with human microsomes (Figure 5.10). As 
shown in this figure, the human species has a slightly lower molecular mass 
compared to that of the rat.
In order to further characterise the panel of human liver samples, 
alkoxyresorufin-O-dealkylase activities associated with the cytochromes P450 lA l 
and 2B1 isozymes were determined and the results are presented in Figure 5.11. 
The average ethoxyresorufin-O-deethylase (EROD) activity in the human samples 
examined (n= 8) was 54 + 34 pmol product formed/min/nmol P450. The rather 
large standard deviation suggested interindividual variation within the samples 
investigated and were comparable in magnitude to that of the male rat (n=3), 
estimated at 56.9 ± 2 . 0  pmol product formed/min/nmol P450. HLM-1 showed 
least ethoxyresorufin-related activity when compared to the other samples. The data 
for pentoxyresorufin-related activity (PROD), representing cytochrome P450 2B1 is 
also shown in Figure 5.11. The mean rate of production of resorufin from the 
substrate pentoxyresorufm in human liver was 2.58 ± 1.24 pmol/min/nmol P450 
(n=8) and was not very different when compared to that of the rat (n=3) measured
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Figure  5.10 Difference in molecular weights between rat and human cytochrome 
P450 4A1 species. Western blotting analysis was carried out using a rat cytochrome 
P450 4A1 polyclonal antibody at a dilution of 1:20k, as described in Materials and 
Methods. Tracks were loaded as follows: track 1, HLM-3 (30/.ig); track 2, HLM-6 
(30jLtg); track 3, homogeneous cytochrome P450 4A1 (0.5pmol spiked with 20jLtg 
HLM-6); track 4, authentic cytochrome P450 4A1 standard (O.Spmol); track 5, 
untreated rat microsomes (20/xg).
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Figure 5.11 Alkoxyresorufîn-0-dealkylase Activities in Human and Rat Liver 
Microsomes. Each bar represents the mean ± SEM of triphcate determinations for individually 
processed microsomal preparations. Human liver samples are numbered from 1 to 8 for HLM-1 to 
HLM-8 and possess a mean activities of 54.5 and 114.2pmol product formed/min/nmol P450 for 
EROD (A) and PROD (B), respectively. Mean values for untreated rat (n=3) were 56.9 ± 1.3 and 
3.6 ± 0.2 pmol/min/nmol P450, for EROD and PROD activities, respectively.
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at 3.55 ± 0.98 pmol/min/nmol P450. Attempts to immunochemically substantiate 
the variation recorded in EROD catalytic data by Western blotting analysis, which 
included positive control microsomes from 3-MC-induced rat liver (data not 
shown), was not quite successful as very little cross reactivity was detected between 
the rat cytochrome P450 lA l antisera and the orthologous human protein.
A relationship was established between the tentatively identified P450 4A- 
mediated œ— and (w-1 )-hydroxylation products of arachidonic acid and lauric acid 
based on regression analysis (r= 0.740, P >  0.05) (Figure 5.12). Likewise, an 
attempt was made to identify any significant correlations within the rest of the data 
presented in this chapter and a correlation matrix table was constructed as depicted 
in Table 5.7.
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Figure 5.12 Relationship between cytochrome P450 4A-mediated laurate and 
arachidonate hydroxylase activities in human liver microsomes (n= 4). Metabolites 
were quantified by reverse phase h.p.l.c. analysis as outlined under Materials and 
Methods. Each data point was from duplicate determinations.
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5.4 Discussion
The variations often seen in drug-metabolising activities of the livers of patients 
probably reflects variability of a normal population clinically observed as variation 
in plasma concentrations of drugs [Sjoqvist and von Bahr, 1973]. In general, the 
values I have obtained for total cytochrome P450 specific content (0.07-0.64 
nmol/mg protein) are quite similar to those published by other workers, ranging 
between 0.13-0.49 nmol/mg protein [Darby et al. 1970, Nelson et al. 1971, Beaune 
et al. 1986], and are somewhat lower than that in the rat. One of the samples 
examined (HLM-1) reflected a very low cytochrome P450 specific content, believed 
to be due to the presence of cytochrome P420, which may have arisen due to post­
mortem changes, possibly arising as a result of poor handling of obtained tissue 
prior to proper storage for subsequent analyses. The difficulty in perfusing such 
tissues also renders haemoglobin a source of contamination in microsomal 
preparations thereby interfering with spectrophotometric determination of 
cytochrome P450. No information about the immediate processing of the tissues 
after death of the patients in my study was readily available. It is well established 
that storage of tissues under the appropriate conditions at -8CPC for several months 
does not alter monooxygenase activity.
To have an insight into the probable causes of the variations between rat and 
man liver monooxygenase activities, it was important to consider the relative 
cytochrome b^/P450 and NADPH-cytochrome c reductase/P450 ratios in both
species. The reason for such comparison was made obvious because of the
importance of NADPH-cytochrome c reductase in metabolism and the role of 
cytochrome b$ in stimulating cytochrome P450 4A1-mediated hydroxylation of fatty
acids. The ratio cytochrome b^/ P450 in untreated rats was 0.64, whereas a similar
ratio in man ranged between 0.47-3.29, the highest recording being for HLM-1 
which incidentally showed the least enzymatic activity. However, this ratio did not 
correlate with any of the catalytic activities measured (data not shown). For
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instance, HLM-6 showed the second highest ratio of 2.1, but resulted in the highest 
laurate hydroxylase activity which was similar to that obtained with untreated rat 
liver microsomes. Likewise, NADPH-cytochrome c reductase/P450 ratios 
determined did not correlate with any of the enzymatic activities examined (data not 
shown).
Sex difference, in the tissues used, was not reflected in the total cytochrome
P450 specific contents and may not have been obvious because of the relatively
small sample size used in my study. This pattern of result was repeated with the 
determination of cytochrome b^ specific contents and NADPH-cytochrome P450 (c)
reductase activities. The measured NADPH-cytochrome c reductase activities were 
slightly lower than that reported for biopsy samples (between 70-193nmol 
reductase/min/mg protein), which are often considered to be fresh and more 
accurate in reflecting in vivo activities [von Bahr et al. 1980]. NADPH-cytochrome 
P450 reductase activity has been reported to be fairly labile and therefore decreases 
relatively rapidly after death [Marzella and Glaumann, 1976; Wang et al. 1980]. 
The results I have obtained with these samples may either be a true reflection of the 
in vivo situation or an alternative explanation for apparent lower values recorded 
being as a result of post-mortem changes.
ELISA-based quantification of the human orthologous form of cytochrome P450 
4A1, using the rat polyclonal antibody, show that this represents about 7% (n=8) of 
total cytochrome P450 determined spectrally. It is important to bear in mind when 
interpreting such data that, by immunological methods, it is the apoprotein that is 
measured whereas spectrally, only the haem-linked cytochrome P450 is measured. 
However, until the corresponding human protein to rat cytochrome P450 4A1 is 
purified to homogeneity and its antibody produced, the rat antibody described and 
used herein serves as a useful tool in the study of the expression of the cytochrome 
P450 4A subfamily proteins in human liver. My results suggest that a human
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orthologous form(s) to the rat cytochrome P450 4A1 protein is/are expressed in the 
human liver samples examined.
Further evidence lending support to the existence of the P450 4A subfamily
proteins in humans came from the results obtained by Western blotting analysis.
My results show our polyclonal antibody recognised only one major band on
analysis and this had a slightly lower molecular mass when compared to that of rat
liver microsomes and the corresponding authentic P450 4A1. A similar experiment
employing human liver microsomal preparations has been reported elsewhere
[Efirven et. al., 1991]. However, in addition to the strong reacting band observed 
in my studies (M^of approximately .51 kDa), these workers also detected a weaker-
reacting band with a higher relative molecular weight, estimated at 56.5kDa, in 
most of the samples. The absence of such an additional reacting band, in the studies 
reported herein, goes to show some of the interindividual variations that might exist 
when dealing with human samples and more specifically with the liver.
The difference in molecular weights between the rat and human enzymes 
became more apparent when authentic rat P450 4A1 was spiked with human 
microsomes (Figure 5.10). It was possible with such an experiment to establish 
with some degree of certainty that a slight difference in molecular mass exists 
between the rat and human liver microsomal specimens examined. The observation 
that the rat antibody cross-reacted with a single protein band in the human liver 
microsomes is further evidence of the existence of cytochrome P450 4A1 or a close 
relative. The varying intensities of the bands after scanning by densitometry did not 
correlate well with the ELISA quantification data (r=0.69, Figure 5.10). This 
inconsistency may well be attributed to the difficulties in establishing linearity with 
Western blot analysis, a technique which is best suited for qualitative studies.
The absence in human hepatic microsomes of an upper protein band of about 
52kDa as seen in the rat, raises some questions regarding the measured catalytic
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activity with lauric acid as substrate. In rats, apart from the clofibrate-inducible 
P450 4A1, cytochrome P450 4A3 has also been demonstrated to catalyse the w— 
and (oj—l)-hydroxylation of lauric acid, the latter possibly a 52kDa protein 
[Aoyama et al. 1990]. The implications of these observations may be interpreted as 
suggesting that fewer human P450 isozymes of the P450 4A subfamily are involved 
in generating fatty acid metabolites as compared to rat liver. The exact number of 
P450 isoforms involved in human liver fatty acid hydroxylation still remains to be 
determined but it is clear that in all the human samples examined, there is a 
preferential hydroxylation of lauric acid at the w—position. It is also worthwhile 
mentioning that quite recently, a cytochrome P450 has been purified to homogeneity 
from human kidney microsomes (termed P450Hkco) which catalysed the o j —  and
(co—l)-hydroxylation of fatty acids with no activity for prostaglandins or
xenobiotics such as benzphetamine and 7-ethoxycoumarin [Kawashima et a l, 
1992]. It was therefore suggested by these workers that cytochrome P450hjc^ is a
member of the P450 4A gene subfamily. The physiological significance of this 
fatty acid w-hydroxylase is not known but predominates over other forms of 
cytochrome P450 in human kidney cortex microsomes [Jakobsson et al., 1973; 
Okita etal., 1979; Imaoka et al., 1990b].
Unlike the rat, where regioselectivity has been firmly established, such 
conclusion could not be drawn with certainty in the case of human hepatic 
microsomes. For instance, there were a few anomalies encountered in this 
investigation as was seen in the case of HLM-1 which had barely detectable 
catalytic activity towards laurate metabolism even although quite an appreciable 
amount of P450 4A1 apoprotein equivalent was immunodetectable by Western 
blotting and quantified by ELISA. As earlier mentioned, there is a possibility that 
this may be as a result of post-mortem changes occurring in the tissues after death. 
Moreover HLM-1 was reported as a moderate smoker, suffering from obstructive 
jaundice and died of hepatocellular carcinoma. This subject was also taking
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temazepam and thiopentone, and taken collectively probably had an important 
impact on the cytochrome P450 isozyme complement.
I have also investigated the role of the cytochrome P450 4A subfamily proteins 
in the metabolism of arachidonic acid by using liver microsomes derived from 
untreated and clofibrate-induced rats as well as human liver. Liver microsomal 
cytochrome P450 haemoproteins catalyse essentially three main reactions during 
arachidonic acid metabolism, namely: olefin epoxidation reactions or formation of 
epoxyeicosatrienoic acids (EETs), allylic oxidation or formation of hydroxy- 
eicosatetraenoic acids (HETEs) and oxidation of an unactivated sp^ carbon leading 
to the formation of 20(w)- and 19(co—l)-hydroxyeicosatetraenoic acids. The peaks 
observed in all the h.p.l.c chromatograms represent metabolites resulting from an 
interplay of these pathways, however, their identification and full characterisation 
was not addressed in the present study.
Studies carried out elsewhere, involving the pretreatment of rats with the 
hypolipidaemic drug, ciprofibrate, resulted in a dramatic change in oxygenation 
regiospecificity catalysed by the microsomal fraction [Capdevila et a l, 1985]. 
These workers observed that metabolites, with retention times corresponding to 
those of authentic w— and (w—l)-alcohol standards, were the predominant feature 
of the reaction catalysed by ciprofibrate-induced microsomal fractions, concomitant 
with a marked decrease in the ability of the liver microsomal suspension to catalyse 
both olefin epoxidation and allylic oxidations. In a similar experiment where I used 
clofibrate to induce rat liver microsomes, there was a significant enhancement of the 
tentatively identified w— and (oj-l)-oxidation products, however, contrary to the 
results reported by Capdevila and co-workers, other unidentified metabolites were 
still detected although with a net decrease in their formation rates, possibly the 
HETEs and EETs. The observed differences may be explained by considering some 
of the factors that affect drug disposition. First of all, different rat strains were 
used in each of the above studies even though it is an unlikely reason. Secondly,
182
the inducer employed in my study was different to that used by these workers, and 
thirdly, the use of 1,2, epoxy-3,3,3,-trichloropropane as an epoxide hydrolase 
inhibitor, was omitted in my studies. The absence of this inhibitor would result in 
the formation of secondary metabolites which may also be enhanced by the slightly 
longer incubation periods used in my studies (20 min) compared to 5 min used by 
these workers. The enhanced formation of secondary metabolites (mainly polar) as 
a result of longer incubation periods of up to 60 min, has been investigated by using 
12(j^-hydroxyeicosatetraenoic acid in the presence of NADPH [Jajoo et al., 1992]. 
These workers used rat liver microsomes and established linearity in product 
formation up to 40 min, the two major metabolites being dihydroxyeicosatetraenoic 
acids (DHETEs) generated by w/(w—1) hydroxylation.
Controversy surrounds the uniqueness of a single cytochrome P450 capable of 
catalysing both the w— and (w-1 )-hydroxylation reactions [Tamburini et al., 1984; 
Bjorkhem and Danielsson, 1970]. However, the results of the findings described 
above and those reported elsewhere strongly lends support to the idea of a unique 
species of haemoprotein for the catalysis of this reaction [Sharma et al., 1989]. I 
have tentatively identified two peaks present in the h.p.l.c. chromatograms 
generated after perturbation by clofibrate, which is a classical inducer of the 
cytochrome P450 (P450 4A1) mediating such reactions and labelled them as 19(w— 
1) and 20(w)-hydroxylated products of arachidonic acid. These peaks were amongst 
others not positively identified, but were all very likely cytochrome P450-mediated 
and required the presence of NADPH. The positive correlation between the overall 
rate of formation of co— and (co—l)-metabolites (Peaks IV and V) of arachidonic 
acid and those with lauric acid as substrate (r=0.74, n=5) further supports the 
hypothesis that these metabolites are derived from a closely related member(s) of 
the cytochrome P450 4A subfamily.
Specific antibodies can be used to inhibit P450-mediated reactions in 
microsomes. In principle, the degree of immunoinhibition indicates what species
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are involved in the metabolic pathway under investigation [Thomas et al. 1977]. 
Obviously the interpretation of immunoinhibition experiments depends upon the 
specificity of the antibodies, especially as in some cases cytochrome P450s within a 
family are likely to have considerable similarity such that distinguishing individual 
forms may be quite a difficult task [Guengerich and Shimada, 1991]. The situation 
can be rendered more complicated as in humans where a complete account of the 
multiplicity within the gene superfamily and/ or even the CYP4 gene family is not 
available.
The influence of rat anti-P450 4A1 antibody as a potential inhibitor to laurate 
biotransformation was investigated and the results obtained were not very conclusive 
as to which species is/ are involved. The observation that even the immunopurified 
IgG fractions from normal sheep serum showed a certain extent of inhibitory action 
at concentrations that had little or no effect on the rat activity, cast some doubts as 
to the interpretation of these results. However, some valuable information could be 
obtained when control experiments were normalised using pre-immune IgG 
fractions from the same animal. At a concentration of 5mg immune IgG/nmol P450 
used, the rat o j — laurate hydroxylase activity was inhibited by almost 50% whereas 
in the humans about 80% of similar activity was lost. No immunoselectivity in 
inhibition pattern of w— and (w— l)-hydroxylation products formation was apparent. 
The degree of potency exerted by the rat cytochrome P450 4A1 antibody on human 
liver microsomal laurate hydroxylation meant there was adequate access of the 
antibodies to the membrane-bound enzyme(s) involved in this metabolic pathway. 
Since the human liver isozyme(s) responsible for fatty acid hydroxylation is yet to 
be purified to homogeneity, it is impracticable to carry out direct inhibitory 
experiments with antibodies directed against the human isoform of interest.
As discussed above, I can only postulate within the limitations of the present 
findings that there are some indications as to the existence and close similarity of a 
member(s) of the cytochrome P450 4A subfamily proteins in the human hepatic
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microsomes examined to those well documented in the rat and it is still premature at 
this stage to pin-point cytochrome P450 4A1 as the sole isoform involved.
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C H A P T E R  S I X
Genera/ Discussion
General Discussion
6.1 Structural and functional comparison between human 
and rat liver cytochrome P4S0 4A subfamily proteins
One of the questions that was not clear prior to the initiation of the studies 
described in this thesis, was whether there was similar multiplicity in the 
cytochrome P450 4 gene family in human liver as previously observed for the well 
characterised rat isoform(s). The extraordinary broad substrate specificity of the 
cytochrome P450 system results from the multiplicity of distinct molecular forms 
which have different, but overlapping substrate specificities [Lu and West, 1980; 
Nebert and Negishi, 1982]. Many different cytochrome P450 isoenzymes have 
been purified from human liver [Wang et al., 1983; Guengerich, 1988a], their 
corresponding cDNAs cloned and classified into families and subfamilies based on 
their DNA and amino acid sequence similarity [Nebert et al., 1991]. These families 
are mainly involved in steroid biosynthetic processes as well as catalysing the 
oxidation of fatty acids, drugs and carcinogens [Guengerich, 1991]. Specifically 
with families 1,2,3 and 4, it appears that a tremendous variability exists between 
species in the number of cytochrome P450 genes and the substrate specificities of 
individual isoenzymes [Nebert et ah, 1991; Souçek and Gut, 1992]. On the basis 
of these findings, it is difficult, in many instances, to extrapolate toxicological and 
carcinogenicity studies from rodents to man. Thus, species differences underscore 
the necessity to directly study human cytochrome P450s. Only limited data are 
available on the cytochrome P450 4 family in human liver as opposed to the 
relatively well-documented data on the corresponding rat proteins.
In view of the diverse function of cytochrome P450s, individuality in isoenzyme 
expression can have severe implications in the risk assessment of xenobiotic 
exposure. Much of the structural comparison data described herein was based on 
enzyme-linked immunosorbent assay (ELISA) and Western blotting employing anti-
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rat cytochrome P450 4A1 polyclonal antibody (Chapter 5). My results revealed that
in the panel of eight human liver samples, hepatic microsomes apparently expressed
only one protein that cross-reacted with our rat polyclonal antibody. This protein
band was slightly lower in molecular weight (approximately 51kDa) when compared
to rat authentic cytochrome P450 4A1 (estimated at 51.5kDa). This result was
consistent with those of other workers who observed a similar protein band that
immunoreacted with rat anti-cytochrome P450 4A1 antibody [Dirven et al. 1991;
Forrester et al., 1992]. Moreover, in addition to the 51kDa protein expressed in
human liver microsomes, Forrester and co-workers found two additional prominent 
cross-reacting protein at about Mj- 51.5 and 60kDa in their panel of 12 human
livers, which were subject to 30-fold and 15-fold induction variations, respectively.
An intriguing correlation in the data presented by Forrester and co-workers was 
in the level of expression of the Mj- 50 and 51.5kDa proteins. Such co-ordinate
regulation would be consistent with the findings in the rat with regard to 
cytochromes P450 4A1 and 4A3 [Kimura et al., 1989b]. It is worth mentioning 
here that our polyclonal antibody recognised similar proteins in untreated and 
clofibrate-induced rat liver-derived microsomes even after attempts to immunopurify 
the antibody (Chapter 2). Similar co-ordinate regulation was seen in the rat after 
treatment with stereoisomers of a clofibrate analogue (Chapter 3). There are many 
examples in rodents where the levels of cytochrome P450 isoenzymes from distinct 
gene families or subfamilies are regulated by the same foreign compound inducing 
agents. An example of this phenomenon was seen in Chapter 4, where two 
proteins, cytochromes P450 lA l and 1A2, were shown to be regulated by the same 
inducer (3-methylcholanthrene in this instance) in the rat. On Western blot analysis 
only one cytochrome lA protein could be identified, and the evidence indicated that 
this was cytochrome 1A2. This phenomenon, which to a degree represents co­
ordinate regulation, appears to be subject to some species and strain variation, and it
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is therefore of central importance to identify which enzymes are co-ordinately 
regulated in man.
One basis of variation in humans is genetic polymorphism, classically defined as 
affecting less than 1 % of the population. First of all it is plausible that there may 
be some generic polymorphism in the expression of the cytochrome P450 4A 
subfamily proteins in human liver. This assumption is based on the tremendous 
variation in Western blotting studies carried out in three laboratories (including the 
work described herein. Chapter 5). Alternatively it is plausible that the antibody 
may be recognising similar epitopes in proteins that may be structurally unrelated to 
cytochrome P450 4A1. The second possibility is highly unlikely since the fatty acid 
hydroxylase activity associated with these proteins could be inhibited in human liver 
microsomes by the rat antibody.
My studies did not address Northern blotting analysis for mRNA levels in our 
panel of human livers but results by other workers showed no correlation between 
the mRNA levels and the level of protein detected by Western blot analysis 
[Forrester et al., 1992]. This finding suggests that the rate of translation and 
protein turnover may be important in determining human hepatic cytochrome P450 
levels. However, it should be noted, that when analysing human cytochrome P450 
4A enzymes by using an antibody raised against rat hepatic cytochrome P450 4A1, 
the human cytochrome P450 4A levels may be incorrectly estimated due to lack of 
specificity of the antibody for the human orthologue. Another aspect that may be 
responsible for the inter-individual variation seen on Western blot and ELISA data 
may be variation due to enzyme induction. However, it is not trivial to establish 
that a particular compound is inducing a specific cytochrome P450 isoenzyme in 
humans. Studies with animal models indicate that a pleiotropic response is often 
seen with a single chemical and that altered protein levels may have their basis in 
any of several modes of regulation, including transcriptional activation, mRNA or
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protein stabilisation, or even translational enhancement [Porter and Coon, 1991; 
Nebert ef aA, 1991].
Preliminary investigation into the possible number of GYP 4A genes in human 
genomic DNA by Southern blotting analysis, appears to suggest that there is only 
one member of this gene family [Hood et al., 1992]. These workers screened a 
human genomic DNA library (after digestion with the restriction endonuclease, 
BanMl) with a 2.1 kb rat GYP 4A1 cDNA probe [Eamshaw et al., 1988] and 
obtained a single positive clone. This 1.4kb clone was in the region of exons 8-10 
which showed strong sequence homology to several cytochrome P450 4 family 
genes. Similarly, genomic DNAs from a panel of human livers were digested with 
the same restriction endonuclease as used in the digestion of the human genomic 
library. These were then subjected to Southern blotting analyses using the above 
human 1.4kb clone as a probe. The result was the recognition of a single band of 
the same size as the probe which suggested strong similarity to the rat GYP 4A1. 
This result was confirmed by employing another restriction endonuclease (iScoRl) in 
digesting the genomic DNA and the single gene obtained when probed was of the 
predicted size [Hood, personal communication]. It should be borne in mind that 
studies using either oligonucleotide or partial cDNA probes are capable of 
determining only the presence of mRNA encoding a protein and not whether the 
protein itself is being expressed. Nonetheless, this information lends support to the 
data presented in this thesis (Ghapter 5) in which, a single protein in our panel of 
human liver-derived microsomes, immunoreacted with the rat anti-cytochrome P450 
4A1 polyclonal antibody.
Gomparisons of the relative levels of cytochrome P450 isoenzymes in our panel 
of human livers with activity towards model substrates in vitro is essential in order 
to define the toxicological consequences of the inter-individual variation in the 
expression of these proteins in the liver. A few aspects of catalytic specificity are 
often worth considering with human cytochrome P450 enzymes. With some
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reactions, there can be considerable overlap of the different cytochrome P450 
enzymes in their efficiency for catalysis. In other circumstances, a single enzyme 
may be responsible for most of the activity, either because of its intrinsic rate of 
catalysis or because other isoenzymes showing similar rates are not very well 
expressed. My studies employed arachidonate and laurate (marker substrates for 
members of the cytochrome P450 4A subfamily, including P450 4A1) in the 
characterisation of the human liver orthologous cytochrome P450 4A1. Both 
substrates were w—hydroxylated by all the human liver microsomes at rates 
comparable in magnitude to the rat isoform even though my data showed indications 
of small interindividual variations (about 2.5-fold). My initial observations were 
investigated further by antibody inhibition studies with lauric acid as substrate and 
the results suggested the involvement of member(s) of the cytochrome P450 4A 
subfamily. The single protein band obtained on Western blot analysis of our panel 
of human liver suggests that this protein may be responsible for most of the 
measurable functional activities in mediating (w-1) and co-hydroxylase metabolism of 
the above fatty acids. Correlation between the arachidonate and laurate hydroxylase 
activities was positive but not statistically significant at 95% confidence interval 
(r=0.74), thus highlighting the debate on whether both activities are mediated by 
the same enzyme in human liver. However, it is difficult to infer from such results 
because of the constraints imposed by limited sample size. We must also await the 
isolation and purification of the human cytochrome P450 4A orthologue which 
could be useful in reconstitution studies.
My observation on the lack of correlation between Western blot and lauric acid 
hydroxylation data is in agreement with those of other workers [Dirven et aL, 
1991], who were unable to find any observable relation between the staining 
intensities of the 51kDa protein band and the rate of lauric acid co-hydroxylation. 
Other researchers have identified a clofibrate-inducible cytochrome P450 that is not 
a lauric acid hydroxylase and does not appear to be a member of the cytochrome
190
P450 4A subfamily [Swinney et al., 1991]. This highlights possible problems that 
may be encountered when interpreting catalytic activities due to specific cytochrome 
P450 inducers. The effects of age, sex or drug history of patients on the 
cytochrome P450 4A subfamily is not known.
6.2 Rationalisation of structural diversity of cytochrome P450 
4A inducers and peroxisome proliferatois
Many structurally diverse chemicals are capable of inducing hepatomegaly 
which is characterised by pronounced proliferation of cellular organelles, including 
peroxisomes and the smooth endoplasmic reticulum [Hawkins et al., 1987], and 
some of these compounds, termed peroxisome proliferators, have been associated 
with an increased incidence of hepatocellular carcinomas in susceptible rodent 
species [Reddy and Lalwani, 1983]. Concomitant with these xenobiotic-dependent 
subcellular changes, is an induction of several proteins and associated enzyme 
activities including the enzymes of the peroxisomal and mitochondrial 6-oxidation 
system and an isozyme of cytochrome P450, termed cytochrome P450 4A1 [Sharma 
et al., 1988]. Similarly, there is elevation in the expression of the hepatic fatty- 
acid-binding protein (FABP) [Appelkvist and Dallner, 1980; Kawashima et al., 
1983; Bass et al., 1985]. Results from my studies on the relative cytochrome P450 
4A1 and peroxisome proliferating induction potencies of the S(+)- and R(-)- 
isomers of a structural analogue of clofibrate, (2-[4-(4-chlorophenyl) benzyloxy]-2- 
phenylacetic acid (Chapter 3), in the rat, as well as a fatty acid analogue, perfluoro- 
n-decanoic acid (Chapter 4) in a susceptible species (the rat) and a non-responsive 
species (the guinea pig), further suggested that both peroxisome proliferation and 
cytochrome P450 4A1 induction are intimately related phenomena. Taken 
collectively, the above information tends to indicate that the microsomal- 
peroxisomal-mitochondrial axis plays a prominent and major role in the onset of 
peroxisome proliferation.
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Although these peroxisome proliferator inducers possess clearly different 
physico-chemical properties, most of them contain a carboxyl group in their 
structures (or may be metabolized to one) which may play an important role in 
induction. This observation is related to the findings of other workers [Bronfman et 
a l,  1986, 1989; Aarsland et al., 1990] who suggested that the acyl-CoA thioesters 
of compounds like the hypolipidaemic drug, ciprofibrate, which are formed in vitro 
and in vivo might be the pharmacologically active species of the drugs. The 
formation of these acyl-CoA derivatives may be responsible for CoA sequestration 
and subsequent perturbation of lipid metabolism and homoeostasis triggering 
peroxisome proliferation [Sharma et al., 1988a]. In agreement with this view, 
Bronfman et al. [1989] showed that the acyl-CoA thioesters of several of these 
compounds potentiated the activity of protein kinase C (Ca^+-activated 
phospholipid dependent protein kinase; pkC), while the fi*ee drugs were inactive. 
PkC is a key enzyme involved in a number of cellular processes, including receptor 
function, cellular differentiation and carcinogenesis [Nishizuka, 1986; Berridge, 
1987].
The presence of the carboxylate moiety in peroxisome proliferators does not
appear to be the only requirement in the induction of cytochrome P450 4A1 and
peroxisome proliferation and this should argue against the CoA-thioester-formation
theory put forward by Bronfmann and co-workers. This observation is drawn from
the fact that there exists a number of such compounds which do not have a carboxyl
group in their structure nor can they be metabolized to one. Typical examples of
such compounds include the N-methylsulphonyl-2-nitrobenzamide derivative,
Fomesafen [Elcombe, 1986] and many tetrazole-substituted acetophenone 
derivatives such as that of the leukotriene D4 antagonist (LY171883), 2-hydroxy-3-
propyl-4-[6-(tetrazol-5-yl)-hexyloxy]acetophenone (4-THA) and other structural 
analogues [Cannon and Eacho, 1991; Eacho et al., 1986, 1989; Foxworthy and 
Eacho, 1988]. The structures of some of the latter compounds are presented in
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Figure 6.1. The ability of this class of compounds to elicit peroxisome 
proliferation with concomitant elevation of the expression of the hepatic fatty-acid- 
binding protein (FABP) was also reported by these workers. FABP, a 14kDa 
cytosolic protein binds endogenous fatty acids [Appelkvist and Dallner, 1980], 
including arachidonic acid and some of its metabohtes. This protein is also thought 
to be involved in the uptake and intracellular transport of fatty acids [Peeters et al., 
1989]. It is therefore plausible that the potencies of these compounds, like other 
peroxisome proliferators, may be related to their ability to bind to FABP, thereby 
displacing an endogenous ligand from its binding site (which may sequester CoA as 
observed by Bronfmann and other workers) thus leading to perturbation of lipid 
homoeostasis and hence development of the pleiotropic response of peroxisome 
proliferation.
The potency of some of the tetrazole-substituted acetophenone compounds (as 
well as other known hypolipidaemics, including clofibric acid) in eliciting 
peroxisome proliferation was assessed by their ability to displace a known ligand (in 
this case oleic acid), which bounds specifically and saturably to purified FABP 
[Cannon and Eacho, 1991]. Based on this information, the order of potency was: 
clofibric acid> LY171883> LY 189585>>> LY213768 and LY163443 ( both 
inactive). LY163443 differs from LY189585 only in the position of the methylene 
tetrazole on the phenyl ring {para and meta substitutions, respectively. Figure 6.1) 
and this slight structural difference has a major effect on the in vivo and in vitro 
peroxisome-proliferating activity of these compounds. Whereas the former has 
strong peroxisome proliferation activity, the latter is devoid of any such activity 
[Eacho et al., 1989] and this difference may be attributed to the tertiary 
conformations of the molecules [Foxworthy et al., 1990a; Eacho et al., 1989]. 
However, it should be noted that members of this class of compounds eliciting 
peroxisome prohferation do have a non-carboxylate acidic functional group and it 
may be that this general structural feature (together with the energetically favourable
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Figure 6.1 Chemical structures of some tetrazole-substituted acetophenone 
derivatives.
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tertiary conformations of the molecules) is more essential for ligand binding and 
receptor activation. LY213768, an analogue of LY 171883 in which the acidic 
nitrogen of the tetrazole is blocked with a methyl group, does not elicit peroxisome 
proliferation in vivo and in vitro [Eacho et a l, 1989]. Molecular graphic plots of 
clofibric acid and LY171883 using the COSMIC package [Lake et al., 1988] is 
shown in Figure 6.2 and illustrates the structural similarities of these compounds 
which may well rationalise why both compounds elicit similar pleiotropic response 
of peroxisome proliferation.
Any consideration of the biological effects of peroxisome proliferators must take 
into account the structural diversity of the chemicals. The fact that many 
functionally diverse genes are regulated by peroxisome proliferators would indicate 
the existence of a receptor or receptor-related events that would explain most of the 
pleiotrophic responses following the administration of such compounds. The report 
of a peroxisome proliferator binding protein of AÇ 70 kDa in rat liver [Lalwani et
al., 1983, 1987] together with the known ability of peroxisome proliferators to 
modulate specific gene transcription rapidly [Hardwick et al., 1987; Eamshaw et 
al., 1988], led Issemann and Green [1990] to suggest that peroxisome proliferators 
could act by a mechanism similar to that of steroid hormones. Indeed a peroxisome 
proliferator-activated receptor (PPAR) was recently isolated fi*om the mouse, cloned 
and sequenced [Issemann and Green, 1990, 1991; Green, 1992]. This receptor 
constitutes a novel member of the steroid hormone receptor superfamily activated by
peroxisome proliferators and contains both DNA-binding and ligand-binding
domains. These workers argued that PPAR could mediate the action of peroxisome 
proliferators and therefore proposed that it should recognise peroxisome
proliferation response element(s) (PPRE) in the 5’ flanking sequence of those genes
that are regulated by peroxisome proliferators. This observation prompted 
Tug wood and co-workers [1992] to demonstrate that PPAR does indeed recognise 
such PPRE located upstream of the rat acyl-CoA oxidase gene and that the presence
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Figure 6.2 Molecular graphic plots of LY 171883 (LY) and Clofibric acid (CL) 
either apart (A) or overlaid (B) to illustrate their structural similarities.
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of the receptor is essential for mediating the effects of the peroxisome proliferator, 
Wy-14,643. The pattern of expression of this latter receptor mirrors the tissue- 
specific responses to peroxisome proliferators earlier reported [Nemali et al., 1988]. 
Coincidentally, there is increased transcription of genes required for the 
peroxisomal 6-oxidation of long chain fatty acids [Reddy et al., 1986] as well as 
genes of the cytochrome P450 4A subfamily [Hardwick et al. , 1987; Eamshaw et 
al., 1988; Kimura et al., 1989a,b; Sharma et al., 1989]. Based on the above 
observation on the co-induction of cytochrome P450 4A1 and peroxisome 
proliferation together with the ample evidence presented in this thesis (chapters 3 
and 4), it may well be that cytochrome P450 4A1 induction is also mediated via this 
receptor in a similar manner to that suggested for rabbit kidney CYP 4A6 gene 
[Muerhoff et al., 1992], a concept that is not inconsistent with molecular modelling 
studies involving the PPAR [Lewis and Lake, 1992,]. Such modelling studies 
would be useful in discerning some of the more general structural features of 
peroxisome proliferators and should provide an insight into aspects of peroxisome 
proliferator binding and activation of the receptor.
The mouse PPAR consists of two domains, a DNA-binding domain of 
approximately 70 amino acids that interacts with responsive genes and a ligand- 
binding domain of approximately 200-250 amino acid residues that binds the 
inducer and may additionally be involved in transcriptional gene activation. It has 
been possible to generate computer-derived models of the ligand binding domain 
based on a prediction of secondary and tertiary configuration by using standard 
protein folding packages such as the Sybyl molecular modelling package (Tripos 
Associates, St Louis, MO) [Lewis and Lake, 1992]. This model identifies tyrosine 
residues in the helical structure which possibly ring-overlap with the ring systems in 
inducers such as clofibrate. It would appear that the more potent cytochrome P450 
4A1 inducers and peroxisome proliferators such as methylclofenepate [Lock et al.,
1989] have two phenyl rings in their structure and this apparently provides for better
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binding via the aromatic rings. More crucially, the g-amino group of a lysine 
residue in the ligand binding domain may play a significant role in binding the 
carboxyl function of peroxisome proliferators containing this moiety (or may be 
metabolized to one or contain a chemical grouping which is bioisosteric to this 
functional group). This feature was present in all the peroxisome proliferators 
investigated in my studies (see Figures 1.3 and 3.1 earlier). A general inspection of 
the computer-modelled PPAR ligand-binding domain reveals a likely binding site 
containing amino acid residues in the appropriate orientation and complementary 
with key groups of known peroxisome proliferators [Lewis and Lake, 1992]. 
Therefore, it would appear as if the carboxyl group requirement for both 
cytochrome P450 4A1 induction (and co-induction of peroxisomal fatty acid 6- 
oxidation) may well be rationalised by the above interactions with basic amino acid 
residues in the PPAR.
My results from studies on the inductive potencies of the S(+) and R(-) isomers 
of a structural analogue of clofibrate on cytochrome P450 4A1 and peroxisome 
proliferation (Chapter 3) demonstrated that the R(-)- isomer was a more potent 
inducer of both cytochrome P450 4A1 and peroxisome proliferation than the 
corresponding S(+)- isomer at the dose level administered. The fact that there was 
a notable stereoselectivity in induction implies that it is reasonably likely that the 
induction processes are probably receptor-mediated. More support to this 
hypothesis is derived from the fact that the more potent R(-)- isomer interacts with 
the PPAR much better than its antipode (Figure 6.3), as reflected in the AG values 
of -16.9kcal mol“^  and -12.0kcal mol"^ respectively. Additionally, difference in 
potency elicited by these isomers may be linked with the rate of formation of the 
corresponding acyl-CoA thioesters which in turn may be linked to the phenomenon 
of signal transduction via interaction with pkC [Bronfman et al., 1989]. It is 
conceivable that the most favoured configuration adopted by the R(-)- isomer would 
have a higher rate of formation of the acyl-CoA thioester than its corresponding
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Figure 6.3 Possible interaction of the S(+)-{A,purple} and R(-)- 
{B,green}isomers of (2-[4-(4-chlorophenyl)benzyloxy]-2-phenylacetic acid with the 
peroxisome proliferator-activated receptor (critical residues in binding site are 
shown in yellow).
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antipode thus, underscoring the pivotal role of the acyl-CoA synthetase(s) in 
mediating this process. Differences in peroxisome proliferation potency by 
stereoisomers of 2-arylpropionic acid and derivatives have often been associated 
with chiral inversion of one of the enantiomers and usually mediated via formation 
of the thioester intermediate [Porubek et al., 1991]. Similarly, the degree to which 
a particular 2-arylpropionate inhibits the 6-oxidation of fatty acids may be governed 
by the efficiency with which it is transformed to its CoA thioester [Freneaux et al.,
1990]. Work would have to be carried out with authentic specimens of the CoA 
conjugates of these drugs to substantiate the implication of thioesters as key 
intermediates in this process.
In chapter 4 we also demonstrated that the phenomenon of cytochrome P450 
4A1 induction by the perfluorocarboxylic acid, PFDA, in susceptible species such 
as the rat was invariably associated with peroxisome proliferation. The interaction 
of this compound with the modelled binding site of PPAR is depicted in Figure 6.4. 
Its theoretically calculated free energy of interaction with the PPAR (AG) was 
evaluated at -15.3kcal mol"^(compared to -28.4kcal moT  ^ for clofibrate). It is 
generally accepted that there is a complementarity between a ligand and its receptor 
site and this comprises a mutual molding of the ligand and receptor macromolecule 
to take maximum advantage of steric and electronic effects. Under optimal 
conditions, the energies liberated in binding (AG) may be indicative of the affinity 
of the ligand to the receptor which may also be related to the biological potency of 
the peroxisome proliferator in question.
It was intriguing, however, that PFDA (20mg/kg, single i.p. dose for 7 days) 
and clofibrate (250mg/kg, daily for three days) showed about the same biological 
potency (in inducing cytochrome P450 4Al-mediated fatty acid hydroxylase activity 
and other enzymes of the peroxisome proliferation domain) and yet their calculated 
AG values were significantly different. This discrepancy may be explained as a 
result of some of the assumptions made in their calculations. First of all hydrogen
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Figure 6.4 Postulated interaction of perfluoro-n-decanoic acid (green) and the 
peroxisome proliferator-activated receptor (critical residues in the binding site are 
shown in yellow).
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atoms were excluded from the modelled binding site of the PPAR molecule as well 
as the ligand to simplify the calculations and because of their relatively negligible 
mass effect. However, in the case of PFDA, fluorine atoms were present (surrogate 
atoms for hydrogen) and these were considered in AG calculations. Moreover, 
none of the calculated AG values fully took into account the solvation energies due 
to entropy changes as a result of receptor-ligand interaction. This aspect may be 
well appreciated when one considers the likely high solvation energy of the 
fluorinated compound due to the presence of extensive hydrogen bonding, which 
would probably give rise to large entropy changes during binding..
A scheme proposed to explain the relationship between cytochrome P450 4A1 
and peroxisome proliferation requires that cytochrome P450 4A1 induction precedes 
that of peroxisomal 6-oxidation enzymes [Sharma et aL, 1988a; Lock et al., 1989]. 
This scheme proposes that peroxisome proliferators are taken up by the dual 
mechanism of inhibition of carnitine acyl-transferase in the mitochondrion [Lock et 
al., 1989] or sequestration of essential CoA by the peroxisome proliferator itself, 
the result possibly being the accumulation, within the liver cell, of medium and 
long-chain fatty acids. These preceding events are then judged to be responsible for 
triggering the induction of cytochrome P450 4Al-fatty acid hydroxylase, in an 
attempt to maintain cellular lipid homoeostasis. The latter enzyme then enhances 
the formation of long-chain dicarboxyhc acids [Sharma et al., 1988a]. Because the 
resulting long-chain dicarboxylic acids are the preferred substrate for peroxisomal 6- 
oxidation system, it is proposed that this leads to induction of other elements of the 
peroxisome proliferator domain, in an attempt to cope with the substrate overload 
and hence the observed pleiotropic response in peroxisome proliferation.
By contrast, the above sequential mechanism may not be dependent on 
cytochrome P450 4A1 induction of peroxisomal 6-oxidation. As depicted in Figure 
6.5, an alternative regulatory scheme is possible whereby the commonality is related 
to structurally similar regulatory elements in the 5’ upstream flanking regions of the
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cytochrome P450 4A1 and acyl-CoA oxidase genes. Thus the peroxisomal 
proliferator may directly interact with the common regulatory sequences or 
indirectly modulate gene expression by lipids derived as a direct result of inhibition 
of mitochondrial fatty acid 6-oxidation [Elcombe et al,, 1986; Eacho and 
Foxworthy, 1988] or derived from lipids displaced from the fatty acid binding 
proteins [Cannon and Eacho, 1991]. This commonality of gene expression may 
also rationalise why so many proteins are induced by peroxisome proliferators and 
the so-called peroxisome proliferator domain may simple reflect the existence of 
common regulatory elements in what would appear to be functionally unconnected 
proteins. Although the regulatory elements of the CYP 4A1 gene have yet to be 
characterised, the corresponding regions of the acyl-CoA oxidase gene are 
beginning to be elucidated [Osumi et al., 1991] and the preliminary indications are 
of a complex pattern of regulation.
CODING
LIPIDS LIPIDS
BINDING PROTEINS
FATTY ACID
PERTURBATION
METABOLISM
OF LIPID
PEROXISOM E PROLIFERATOR
REGULATORY ELEMENTS OF 
P4504AI AND Acyl-CoA OXIDASE GENES
SEQUENCE
Figure 6.5 A scheme postulating a common regulatory mechanism of the 
cytochrome P450 4A1 and the peroxisomal 6-oxidation spiral acyl-CoA oxidase 
genes.
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Thus, the scheme shown in Figure 6.5 may serve as a useful paradigm for 
further experimentation in both the acyl-CoA oxidase and CYP P450 4A1 genes. In 
addition the above scheme may rationalise why there are so many structurally 
diverse inducers of cytochrome P450 4A1 and acyl-CoA oxidase, in that the 
peroxisome proliferators may not all directly interact with the inducible genes but 
indirectly act by influencing lipid disposition or a common perturbation of lipid 
biotransformation. However, it remains uncertain if peroxisomal 6-oxidation 
crucially depends on cytochrome P450 4A1 induction as described previously 
[Sharma et al., 1988a] or if the above commonality of regulation of gene expression 
plays a more important role. It is hoped that the isolation and characterisation of 
the 5’ flanking regulatory sequences in the CYP 4A1 gene will identify the putative 
regulatory elements which could then be compared to the equivalent regions in the 
better characterised acyl-CoA oxidase gene. It is worth mentioning a recent report 
which indicated sequence similarities between the 5' flanking regulatory sequences 
in rabbit CYP 4A6 and the corresponding region in the acyl-CoA oxidase gene 
[Muerhoff, 1992, personal communication].
It is plausible that accumulation of metabolites resulting from lipid perturbation 
could be the natural constitutive ligand(s) for cytochrome P450 4A1 and the acyl- 
CoA oxidase genes. In general, natural ligands or physiologically occurring 
activators have been identified for only a few of the steroid hormone receptors 
[Evans, 1988]. It is also possible that the species differences in response to PFDA 
seen in the rat and guinea pig (Chapter 4) may be related to either differences in 
lipid disposition and biotransformation or differential expression of PPAR or even a 
combination of these factors. Transactivation studies using chimeric proteins 
consisting of a cDNA encoding the putative ligand-binding and the amino-terminal 
and DNA-binding domains of known steroid hormone receptors such as the PPARs 
have been used to demonstrate their activation by peroxisome proliferators and some 
intermediates in lipid metabolism [Issemann and Green, 1990; Gottlicher et al.,
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1992]. Screening compounds related to lipid metabolism revealed that fatty acids 
such as linoleic (Cig.2), arachidonic (€20:4), or lauric acid (Ci2;o)» but not
dehydroepiandrosterone (DHEA), cholesterol or its 25-hydroxy-metabolite, 
activated the reporter gene expressing the chimeric receptor [Gottlicher et al., 
1992]. The findings of these workers, in principle, demonstrates that fatty acids 
can regulate gene expression by activating a member of the nuclear receptor 
superfamily.
6.3 MultijAicity of PPAR expression and Us biological 
implications
If peroxisome proliferation is mediated by PPAR, then such species differences, 
as reported in this thesis and by many other researchers, could reflect either 
variation in PPAR or in the gene networks that are regulated by PPAR. Support for 
such possibilities comes from the cloning of PPARs from species such as the mouse 
[Issemann and Green, 1990; Green, 1992], rat [Gottlicher et al., 1992] and 
Xenopus laevis [Dreyer et al., 1992] which may account for differences in response 
to a peroxisome proliferator across species. Differential response within the same 
species by structurally diverse peroxisome proliferators may also suggest 
multiplicity in PPAR expression as shown by the cloning of three PPARs fi'om 
Xenopus laevis [Dreyer et al., 1992]. This discovery raises a number of pertinent 
questions such as: does each of these PPARs exert a specific function, and are there 
different PPAR signalling pathways within the cell?. If these receptors have the 
same DNA recognition specificity, then they would be expected to recognise similar 
elements in the acyl-CoA promoter gene and this appears to be so. It would also be 
interesting to see if there is any differences in ligand specificity of these PPARs 
when assessed by their response to well known peroxisome proliferators with 
differing potencies.
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Taken collectively, the information presented in this thesis supports a model 
where PPAR(s) plays a key role in mediating the action of peroxisome proliferators 
and it is tempting to speculate that this receptor(s), the peroxisome proliferator- 
inducible and fatty acid-metabolizing cytochrome P450 4A subfamily together with 
the peroxisomal 6-oxidation pathway might constitute an autoregulatory loop in lipid 
or fatty acid homoeostasis [Elcombe and Mitchel, 1986]. Given both the key role 
of acyl-CoA oxidase in the 6-oxidation spiral and its peroxisome proliferator- 
dependent stimulation, activated PPARs may represent an essential and obligatory 
step in the action of diverse peroxisome proliferators. Furthermore, examination of 
the expression and function of PPAR in humans could have important implications 
in assessing the hazard that peroxisome proliferators may pose to humans. To this 
end, it is worth mentioning a transfection experiment carried out to identify putative 
regulatory DNA elements within the isolated human 4A gene [Hood et al., 1992] in 
the absence/ presence of mouse PPAR. Preliminary results suggested that there is 
probably no peroxisome proliferator responsive element to PPAR in the first 6kb of 
5' flanking sequence of the human CYP 4A gene [S. Hood, personal 
communication].
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6.4 Suggestions for future woik
1) It has previously been suggested that the acyl-CoA thioesters of most 
peroxisome proliferators, which are formed both in vivo and in vitro, might be the 
pharmacologically active species of these compounds in eliciting the observed 
pleiotropic responses. This is apparently because several of these compounds 
potentiate the activity of protein kinase C, a key enzyme involved in cellular 
differentiation and carcinogenesis. I demonstrated in Chapter 3 that there was 
differential inducing potencies of two enantiomers of a clofibrate structural analogue 
which may be related to the rate of formation of their corresponding thioester 
conjugates. It would therefore be interesting to investigate the effect of 
administering authentic specimens of the CoA conjugates of these drugs on signal 
transduction mechanisms.
2) My results in Chapter 4 suggested PFDA exhibits a similar potency to clofibrate 
induced rats. Clofibrate has also been shown to activate a chimera of the rat and 
mouse PPARs. It would therefore be interesting to see if a similar pattern of result 
is obtained when repeated with PFDA. The information so-derived would help in 
the overall classification of PFDA and other structurally-related analogues in 
relation to other well-characterised peroxisome proliferators. Obviously this 
information is necessary for evaluation of the ultimate risks posed by using such 
chemicals which have a valuable input in the aerospace and many other chemical 
industries.
3) It would also be of interest if the peroxisome proliferator-activated receptor 
could be isolated, purified and used in binding studies with various ligands or 
peroxisome proliferators.
4) Finally, the results presented in Chapter 5 suggest a close similarity between the 
rat cytochrome P450 4A1 and the corresponding human orthologue. This issue
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could be better addressed by isolation and sequence analysis of cDNA clones coding 
for human cytochrome P450 4A1 and comparing it to the well characterised rat 
form. This should provide a vital contribution to the understanding of the structure, 
diversity and risk assessment of peroxisome proliferators on humans. Similarly 
catalytic activities associated with the human orthologous enzyme could be better 
assessed by the ultimate isolation and purification of the human liver cytochrome 
P450 4A1 which will be useful in reconstitution studies.
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